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ABSTRACT 
 
Evidence of Y Chromosome Long Non-Coding RNAs involved in the Radiation Response 
of Male Non-Small Cell Lung Cancer Cells 
 
Tayvia Brownmiller 
 
  
   Non-small cell lung cancer (NSCLC) is the number one cause of cancer related mortality 
in the United States and worldwide. Advanced and therapeutically resistant lung tumors contribute 
to the high rate of mortality from NSCLC, therefore there is a need for new methods of diagnosing 
and treating this disease. Long non-coding RNAs (lncRNAs) have been shown to be a crucial 
component of human molecular biology, regulating nearly every cellular pathway from chromatin 
condensation to transcription and translation. Furthermore, many lncRNAs have been classified as 
oncogenes or tumor suppressors, highlighting the various molecular mechanisms they are involved 
in regarding the formation and progression of cancer and their use as prognostic and diagnostic 
biomarkers has been proposed in numerous cancers, including NSCLC. 
 
 Our group has discovered, for the first time, a three member family of Y chromosome 
lncRNAs (linc-SPRY3-2, lin-SPRY3-3, and linc-SPRY3-4) which regulate NSCLC cell response 
to ionizing radiation (IR). Briefly, the linc-SPRY3 family demonstrated a dose dependent 
induction of expression following exposure to IR in male radiosensitive NSCLC cell lines, but not 
in male radioresistant cell lines. This difference was revealed to be due to loss of the Y 
chromosome in the radioresistant cell lines. Using gain-of-function and loss-of-function 
experiments, we demonstrated statistically significant changes in cell viability and apoptosis in 
vitro. Furthermore, in vivo tumor growth delay assays showed a more radioresistant phenotype in 
tumors with knockdown of the linc-SPRY3 RNAs versus control tumors. We hypothesize linc-
SPRY3-2/3/4 mediate their tumor suppressive effect via sequestration of the RNA binding protein 
IGF2BP3 demonstrated by CLIP and RNA degradation assays. Moreover, DNA FISH and 
bioinformatic analysis revealed a trending negative correlation in patient survival between loss of 
the Y chromosome and linc-SPRY3-2/3/4. These findings suggest that the linc-SPRY3 RNAs 
function as tumor suppressors by promoting cell death following IR through interactions with 
IGF2BP3, and could have potential as biomarkers in male NSCLC. 
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CHAPTER 1 
 
INTRODUCTION AND LITERATURE REVIEW 
 
I. Non-coding RNA  
 
 The accepted central dogma of biology that has been taught to us has been as follows: DNA 
is transcribed to RNA, which is then translated to protein, and proteins have long been considered 
the primary functional units of cellular and molecular biology. However, over the past several 
decades, we have learned that RNA plays a much larger role in the cell than previously thought 
(Fig. 1). There is actually an immense universe of non-coding RNA (ncRNA), RNA that do not 
code for a protein, which carry out regulatory roles once attributed to proteins (1). The two earliest 
examples of ncRNAs are transfer RNAs (tRNAs) and ribosomal RNAs, both of which are 
extremely important in translation. Transfer RNAs (tRNAs) are carriers for amino acids that are 
incorporated into a peptide. Ribosomal RNAs (rRNAs) make up the ribosome, including the 
ribozyme, an enzymatic RNA which is responsible for processing other RNA molecules such as 
the tRNA or splicing of nuclear pre-mRNA (2). While these types of RNAs have been extensively 
studied, they are only a small part of an expansive RNA world. Thanks to the continuing 
advancement of sequencing technologies and completion of The Human Genome Project followed 
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by the Encyclopedia of DNA Elements (ENCODE), we have learned that roughly 70-80% of 
human genome is transcribed, but less than 2% of that RNA is translated to protein. This 
means that nearly 98% of the transcripts produced in a human cell are ncRNA. Originally, this 
98% of RNA was considered “junk” or transcriptional noise, with no function and therefore was 
considered unimportant, but we now have a much better understanding of this “dark matter” of the 
genome (3,4).  
 
Interestingly, they offer the connection to organism complexity that was once unknown. 
What we know now is that the more complex the organism, the larger the noncoding RNA content 
of that organism, with the human genome harboring the largest percentage of noncoding 
information compared to other genomes (5). We also know that ncRNAs are invoved in nearly 
every facet of cellular biology, and are categorized in numerous ways, beginning with regulatory 
or housekeeping ncRNAs. Housekeeping ncRNAs are those important for translation, such as 
tRNAs and rRNAs. The rest are grouped into regulatory ncRNAs, a much larger group which is 
categorized first by size. NcRNAs larger than 200 nucleotides are classified as long non-coding 
RNAs (lncRNAs), which have wide ranging functions. Any ncRNAs smaller than 200 nucleotides 
are classified as small 
ncRNAs encompassing 
microRNAs (miRNAs), small 
nucleolar RNAs (snoRNAs), 
small interferring RNAs 
(siRNAs), small nuclear 
RNAs (snRNAs), and PIWI-
interacting RNAs (piRNAs), 
each of which have their own 
specific functions (Fig. 2) (6). 
 
 As previsouly mentioned, ncRNAs function in a myriad of ways which are important for 
every cellular process. Because they are so intricately woven into our basic biological functions, 
their dysregulation leads to the development of disease, including cancer (7). While the roles of 
 3 
 
the small RNAs, especially miRNAs, have been relatively well studied in regards to cancer cell 
biology, lncRNAs remain poorly characterized in comparison. 
 
II. Long Non-coding RNA 
 
A. Overview 
Long non-coding RNAs (lncRNAs) are those RNAs greater than 200 nucleotides long and 
lack an open reading frame, and due to their emergence over the past 15 years, there has been a 
fundamental shift in the landscape of molecular genetics (8). LncRNAs are comprised of intergenic 
transcripts, enhancer RNAs, and sense or antisense transcripts that overlap coding genes and can 
function in cis or trans. They also show incredible cell type and tissue specificity. Those that have 
been functionally characterized have revealed a myriad of roles, many of which are dictated 
primarily by sequence and/or cellular localization (9). As it stands, there are currently over 120,000 
identified lncRNAs in the human genome (10). Unfortunately, only a handful of these have been 
functionally characterized leaving hundreds of thousands left to be studied. 
 
B. Characterization 
 Through advancements in RNA sequencing technologies, we have learned that lncRNAs 
are abundant and extremely diverse. In general, a non-coding RNA (ncRNA) is classified as a 
lncRNA if they are larger than 200 nucleotides, but their sizes are very heterogeneous ranging 
from a few hundred to even larger than a few thousand nucleotides. Furthermore, they originate 
from nearly every part of the human genome, can be found in virtually every cellular compartment, 
and carry out numerous functions (8,11). Unfortunately, all of these factors combined with a 
limited understanding of lncRNAs has resulted in poorly defined system for classification.  
 
LncRNA – Separating non-coding from coding transcripts 
 The major defining factor for any ncRNA is its lack of coding potential, or its inability to 
be translated into a protein, but quantitatively determining this characteristic is not an easy task. 
Moreover, lncRNAs have begun to emerge as a gray area in terms of coding potential, as many 
lncRNAs have been found to contain small open reading frames (smORF) which could produce 
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micropeptides. It is also important to note that some mRNAs could have non-coding functions 
(12). 
 
The primary method for determining coding 
potential of a RNA is ribosome profiling followed by deep 
sequencing (RiboSeq). Ribosomes are the cornerstone of 
protein translation. Briefly, when ribosomes associate with 
an RNA during translation (protein synthesis), they also 
protect that piece of RNA from digestion by exonucleases. 
That protected RNA can be recovered and then be used for 
deep sequencing and the sequencing data can be aligned to 
a genome which determines the translational profile of a 
given RNA (Fig. 3) (13). LncRNAs typically have no to low 
enrichment of ribosome occupancy and therefore are 
classified as non-coding (14). However, as sequencing 
technologies advance and become more sensitive, we are 
able to better detect and identify small ORFs such as those 
attributed to micropeptide encoding lncRNAs (15).  
 
There are also computational methods that can be 
utilized. A few of the more popular pipelines are 
phylogenetic analysis of codon substitution frequencies 
based on sequence alignment (PhyloCSF) scoring, sORF 
finder, coding region identification tool invoking 
comparative analysis (CRITICA), and micro-peptide detection pipeline (micPDP) (16–19). It is 
important to note that some controversy still surrounds this grey area as micropeptide potential is 
a very new field in the realm of lncRNAs. Furthermore, just because a lncRNA contains a small 
ORF and can produce a micropeptide, does not mean its primary function isn’t that of a non-coding 
RNA.  
 
Biogenesis 
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 In general, lncRNAs are very similar to messenger RNAs (mRNAs). Their promoters 
display similar epigenetic markers, they are transcribed via Pol II, undergo splicing, and can 
include both a 5’ cap and a Poly A tail. However, that is where the similarities end (20). Every 
gene is controlled first by epigenetic markers such as histone methylation and acetylation, 
essentially signaling if a RNA should be transcribed. Both mRNAs and lncRNAs are controlled 
by promoter enrichment of trimethylation of lysine 4 on histone 3 (H3K4me3), but lncRNAs 
typically show much higher enrichment of acetylation of lysine 27 of histone 3 (H3K27ac), with 
more recruitment of transcriptional regulators like Swr1, Isw2, Rsc, and Ino80 resulting in 
repression (21). This would explain the relatively low expression of most lncRNAs across human 
tissues.  
  
 As previously mentioned, lncRNAs are primarily transcribed by Pol II, and processed 
similarly as mRNAs by splicing and 3’ polyadenylation. However, there are some mechanisms of 
post-transcriptional regulation that affect lncRNAs and not mRNAs. For example, the lncRNA 
NEAT1 can be processed like a mRNA to produce what is known as its short form, but 
alternatively its long form contains a pre-tRNA like structure on its 3’ end which is recognized 
and cleaved by the ribonucleoprotein complex RNaseP (responsible for processing mature 
tRNAs). The resulting free end then forms a triple helix structure, stabilizing the lncRNA strand 
(22). Some other forms of alternative RNA processing that affect lncRNAs includes splicing 
events that result in the formation of circular RNAs (circRNAs). This includes products from 
canonical splicing called lariat loops, formed by a 2’,5’-phosphodiester bond, or the non-sequential 
splicing of introns, otherwise known as backsplicing. The difference between the two being that 
circRNAs formed from backsplicing are typically more stable since there are no free ends for 
exonucleases to recognize and degrade (20,23).  
 
Complexities of Classification 
 Due to the ever-growing field of lncRNA biology, there is no one unified way to classify a 
lncRNA other than the basic attributes that they are longer than 200 nucleotides and lack an open 
reading frame. This cutoff of length is an arbitrary number, set to separate lncRNAs from their 
short ncRNA counterparts (miRNA, snoRNA, piRNA, etc.). Other than this, there are a number 
of subclasses of lncRNAs which divides them based on characteristics such as genomic location, 
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association with DNA elements, tandem repeat content, sequence or structure conservation, 
cellular localization, and function, just to name a few (24). This has led to some confusion in 
regards to lncRNA characterization, classification, and even naming. However, as the field of 
lncRNA biology advances one thing is constant. This species of complex RNAs is extremely 
important and nearly all aspects of cellular and molecular biology. 
 
Genomic Location 
The most commonly used method of classification is based on the genomic location relative 
to a protein coding gene (8). LncRNAs can be classified as sense or antisense, intronic, divergent 
(bidirectional), or intergenic (Fig. 4). Sense lncRNAs are transcribed in the same direction of a 
protein coding gene 
and contain one or 
more exons, and 
sometimes overlap or 
cover an entire 
sequence of a protein 
coding gene. These 
overlapping lncRNAs 
are considered non-
coding transcript variants of the protein coding gene as they originate from the same promoter but 
lack an open reading frame. Antisense lncRNAs are transcribed in the opposite direction of a 
protein coding gene, usually initiate inside or downstream of a protein coding gene, and include at 
least one exon from the protein coding gene. Their expression typically correlates with an mRNA 
of the same promoter and have been shown to be very important in cancer, usually regulating the 
expression of tumor suppressor or oncogenic proteins (25). Intronic lncRNAs, as the name 
suggests, are lncRNAs that initiate from an intron, are composed entirely of introns and can be 
transcribed in either direction of a protein coding gene. These intronic transcripts have not been 
well studied, but have been implicated in regulating RNA splicing and stability (26,27). Divergent, 
or bidirectional, lncRNAs are transcripts that initiate in the opposite direction as its protein coding 
gene counterpart, typically around a few hundred bases to 1 kilobase from a neighboring protein 
coding gene promoter (11,28). Finally, intergenic lncRNAs (lincRNAs) are transcripts that 
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originate from their own transcriptional unit which is found between protein coding units. 
LincRNAs are by far the most studied among the above listed classes. They have been shown to 
function in both cis and trans, affecting transcription, translation and splicing. They have also 
shown high conservation between species (28,29). 
 
Cellular Localization 
LncRNAs can also be classified by their cellular localization. The two main methods 
primarily used to identify a lncRNA’s primary compartment are cellular fractionation and RNA 
fluorescent in situ hybridization (FISH). Cellular fractionation involves lysing cells and separating 
the nuclear fraction from the cytoplasmic fraction, primarily by multiple centrifugation steps, 
followed by methods like quantitative reverse transcriptase PCR (qRT-PCR) or even RNA-seq 
(30). RNA FISH is a method in which a fluorescent probe complementary to an RNA of interest 
is designed and incubated with cells or tissue of interest. The probe should hybridize to its target 
RNA and this can be imaged via fluorescent microscopy (31). 
 
Identifying a perspective lncRNA’s compartment is a very important part of characterizing 
a lncRNA, as it narrows the potential functions inside a cell. Unlike mRNAs, the vast majority of 
lncRNAs are localized to the nucleus due to a number of factors such as inefficient splicing and 
polyadenylation. Many lncRNAs essentially retained to the nucleus due to their interactions with 
nuclear structures and proteins. Nuclear lncRNAs typically regulate epigenetic markers, chromatin 
structure, transcription, and post-transcriptional processing (32,33). To a much lesser extent, there 
are some lncRNAs which localize to the cytoplasm. Cytoplasmic lncRNAs have been shown to 
regulate translation, post-translational processing and interact directly with other regulators in the 
cytosol like microRNAs (miRNAs) and even other mRNAs. Furthermore, a few cytoplasmic 
lncRNAs have been shown to produce micropeptides, though this function needs more study to 
fully understand its role in the cell (33,34). 
 
Biological Functions 
Unlike proteins, the extent of possible lncRNA functions has yet to be elucidated, 
nonetheless it has emerged as a way to classify a lncRNA. Those handful of lncRNAs that have 
been well characterized have revealed a number of important functions, nearly all of which are 
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regulatory. As mentioned before, a lncRNA’s function is highly determined by the cell 
compartment in which they are found. Furthermore, their functions can be categorized as cis, those 
that directly regulate neighboring genes, or as trans, those that translocate to another part of the 
cell to perform its function. The main classifications have been previously described in four major 
groups: signals, decoys, guides, and scaffolds (Fig. 5). However, 
these four groups are much more complex and a single lncRNA 
can have multiple functions within the cell (Fig. 6) (35–37). 
 
eRNA: Enhancer lncRNAs (eRNAs) are a type of nuclear lncRNA which can enhance 
target gene expression, and can be considered both scaffold and signal lncRNAs (Fig. 6A). They 
can originate from enhancer regions of DNA and stand apart from most “traditional” lncRNAs as 
they can be transcribed in either direction and most do not undergo maturation such as splicing 
and polyadenylation. Most importantly, eRNAs function by regulating transcription by recruiting 
transcription factors and acting as a bridge to bring two genes close together, one of which is 
usually an enhancer region, primarily by intrachromosomal interactions via chromosome looping 
or alternatively by interchromosomal interactions by bringing two different chromosomes together 
(Fig. 6D) (38). An example of an eRNA is the lncRNA HOTTIP (HOXA distal transcript antisense 
RNA). HOTTIP functions in cis and facilitates chromosome looping which brings itself into 
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proximity with the HOXA gene cluster. From there, it recruits WDR5 and the MLL complex which 
triggers deposition of H3K4me3 to activate transcription of HOXA genes (39).  
 
 Chromatin modifiers: One of the better characterized lncRNA functions is their role in 
chromatin modification and remodeling (Fig. 6B). They can be categorized as scaffolding or guide 
lncRNAs, are nuclear, can act in either cis or trans, and can recruit chromatin modifiers that can 
either promote transcription or repress it (40). One of the most well studied examples is the 
lncRNA Xist (X-inactive specific transcript). Xist’s primary function is the silencing of one of the 
two X chromosomes in female cells (X chromosome inactivation). Xist coats the inactive X 
chromosome with multiple copies of itself which recruits transcriptional repressors such as the 
polycomb repressive complex 2 (PRC2) triggering accumulation of H3K27me3 (41). 
 
 Transcriptional regulators: A number of lncRNAs have been shown to directly interact 
with protein binding partners and thereby affect gene expression by regulating transcription (Fig. 
C). Their roles in transcription can happen in cis or trans, and can be activating or repressive. 
ANRIL is an antisense lncRNA clustered with the genes CDKN2A and CDKN2B and represses 
them in cis by recruiting both PRC1 and PCR2 to the gene loci (42). In contrast, the lncRNA Evf-
2 (DLX6-AS1) acts as a transcriptional cofactor and forms a complex with DLX2 to activate 
transcription of genes located at the DLX5/6 locus (43). LncRNAs can also affect transcription by 
acting as decoys to sequester transcription factors which can inhibit or promote transcription of 
target genes (44).  
 
 Regulation of mRNA splicing, stability, and translation: Alongside regulating 
transcription, lncRNAs can also function post-transcriptionally by affecting the maturation, 
translation, and degradation of mRNAs (Fig. 6E-H). For example, MIAT (myocardial infarction 
associated transcript) sequesters splicing factor 1 (SF1) to inhibit formation of the spliceosome 
complex during splicing (45). Another example is the famous lncRNA MALAT1, which can bind 
SR splicing factor [serine-arginine (SR)-rich splicing factor] and affect its distribution, 
downregulating splicing (46). In terms of affecting mRNA stability, some lncRNAs have been 
shown to directly interact with mRNAs, either to stabilize the mRNA strand itself (e.g. BACE1-
AS) or to act as a guide for proteins necessary to stabilize an mRNA (e.g. TINCR) (47,48). 
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Similarly but in contrast, lncRNAs can destabilize mRNA strands and downregulate protein 
expression by inducing degradation of a target mRNA (e.g. 1/2sbsRNAs) (49). Additionally, 
lncRNAs can influence (e.g. lincRNA-p21) translation of target mRNAs (50). LncRNAs can also 
function as competing endogenous RNAs (ceRNAs) and act as molecular sponges, not just for 
proteins but also for miRNAs. miRNAs regulate protein expression by binding the 3’ UTR of a 
target mRNA and inhibiting translation or triggering mRNA degradation. LncRNAs can “sponge” 
miRNAs, preventing them from targeting an mRNA, which allows that mRNA to be translated 
(51). 
 
 Micropeptide encoding lncRNAs: One of the most recent discoveries in lncRNA biology 
is the capacity for some lncRNAs to contain small open reading frames (smORFs) which can be 
translated into functional micropeptides (usually <100 amino acids). These lncRNAs could be their 
own transcript, or a non-coding variant transcript from a protein coding gene and typically localize 
to the cytoplasm of the cell (Fig. 6I). Computational analysis has predicted numerous smORFs, 
but studies have suggested that only around 17% of predicted smORF containing lncRNAs are 
translated. Moreover, these micropeptides are expressed at very low levels and are typically 
unstable (12,15,52). However, there are some examples of functional micropeptides derived from 
putative lncRNAs. DWORF is a muscle specific micropeptide (34 amino acids) which originates 
from the human lncRNA LOC100507537 and functions by displacing SERCA (sarco/endoplasmic 
reticulum Ca2+-ATPase) membrane pump inhibitory proteins which allows increased calcium 
uptake and myocyte contractility (53).  
  
 Overall, it can be easily determined that lncRNAs are extremely vital to cellular and 
molecular biology and offer an explanation for organism complexity that scientists have sought 
for decades. It is important to note that, while we have made great strides in characterizing 
lncRNAs, we have barely scratched the surface of their importance and potential and given their 
broad range of functions we should look to them for answers regarding numerous pathologies, 
including cancer. 
 
C. LncRNAs and Cancer 
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 LncRNAs have emerged as one of the most important and diverse regulators in the human 
cell. Considering their widespread involvement in nearly every biological process, it is easy to 
assume that their dysregulation can lead to the 
development of disease including cancer. 
Cancer is a collection of diseases, but nearly all 
have one or more disruptions in the molecular 
pathways of what cancer researchers call “the 
hallmarks of cancer”(54). We now know that 
lncRNAs are just as intricately involved in these 
processes as proteins and act as tumor 
suppressors or oncogenes. However, it is 
important to note that a tumor suppressive or 
oncogenic role is highly dictated by the cancer 
type in which a lncRNA is dysregulated (Fig. 7) 
(55). 
 
Tumor Suppressor LncRNAs 
Tumor suppressor genes, as their name suggests, are those genes necessary to suppress 
carcinogenesis (56). There are a number of tumor suppressor proteins (p53, Rb, BRCA, etc.) and 
the same can be said for lncRNAs, where their dysregulation via loss or downregulation of their 
expression results in the promotion of a malignant phenotype. One of the most well characterized 
tumor suppressive lncRNAs is MEG3. Downregulated in multiple cancer types (renal, liver, lung, 
and brain) its primary function is regulating the tumor suppressor p53 (57). MEG3 downregulates 
MDM2 expression, an E3 ubiquitin ligase responsible for targeting p53 for degradation. This 
allows p53, a transcription factor, to function properly and regulate its target genes which are 
important in a number of cellular processes such as cell cycle and apoptosis (58). Another well-
known example is the lncRNA GAS5 (growth arrest specific transcript 5). It has also been 
associated with numerous cancer types (breast, renal, prostate, and endometrial) and it is an 
important regulator of cell metabolism (among other mechanisms) which binds glucocorticoid 
receptor (GR), inhibiting the activation of GR dependent genes. This leads to metabolic stress and 
eventually cell death (59,60). There are even lncRNAs that are important for regulating telomeres, 
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the ribonucleoprotein structures at the end of chromosomes. In healthy cells, telomeres shorten 
every time a cell divides. Once they reach a certain size, the cell is signaled to stop dividing, either 
undergoing apoptosis or permanent cell growth arrest. One component of telomeres is a group of 
lncRNAs called telomeric repeat-containing RNAs or TERRA (61). While the complete 
mechanisms of TERRA have yet to be elucidated, they have been shown to interact with and inhibit 
telomerase, an enzyme hijacked by cancer cells to maintain telomeres and essentially mediate 
immortality (62). Additionally, TERRA transcripts are commonly downregulated in cancer, 
further supporting their role as tumor suppressors in human cells (55,63). 
  
Oncogenic LncRNAs 
 Oncogenes are those genes that give rise to proteins or lncRNAs that promote 
tumorigenesis, and upregulation or activation of oncogenic factors results in phenotypes that are 
beneficial to cancer (56). Some well-known oncogenic proteins include members of the RAS 
family (KRAS, NRAS, and HRAS), Myc, and numerous receptor tyrosine kinases (RTKs, e.g. 
EGFR, VEGF, and RET).  These proteins stimulate tumor formation via promoting proliferation, 
resisting apoptosis, and even reprogramming cancer cell metabolism (64). Not surprisingly, there 
are lncRNAs that have been shown to promote the same oncogenic phenotypes. One example of a 
fairly well studied oncogenic lncRNA found upregulated in multiple tumor types is HOX transcript 
antisense RNA (HOTAIR). It’s been associated with many different signaling pathways 
(proliferation, apoptosis, and invasiveness) across numerous cancers including lung, breast, 
pancreatic and ovarian cancer. It’s a wildly promiscuous lncRNA that can regulate the PI3K/Akt 
pathway by suppressing the expression of the tumor suppressor PTEN, affect cell adhesion and 
cancer cell epithelial-to-mesenchymal transition via inhibiting expression of proteins such as Wnt 
inhibitory factor-1 (WIF-1), and also promote metastasis by silencing of specific genes through 
PRC2 (63,65). Another example is the lncRNA PCAT1 (prostate cancer-associated transcript 1), 
which is named for the caner in which it was originally identified. While it is mostly prominent in 
prostate cancer cell biology, we now know that it is upregulated in other cancer types and functions 
primarily by upregulating cell proliferation by post-transcriptionally stabilizing the oncogenic 
protein c-Myc. Furthermore, it essentially forms a positive feedback loop with c-Myc since c-Myc 
is the transcription factor that controls the expression of PCAT1 (66–68).  
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Clinical Relevance 
 Given their dysregulation in cancer and higher tissue specificity relative to their protein 
counterparts, lncRNAs have become attractive candidates as potential biomarkers (69).  One of 
the best examples is PCA3, a prostate specific lncRNA that is undetectable in healthy tissue, 
overexpressed in >90% of prostate cancers and can be detected in the urine of patients (70). In 
2012, it became the first lncRNA approved by the US Food and Drug Administration for biomarker 
use and is now considered more reliable than the standard prostate-specific antigen (PSA) level 
test since it’s use is more accurate for prostate cancer diagnosis (71). A recent search of 
ClinicalTrials.gov revealed 5 ongoing biomarker studies looking at lncRNAs including specific 
trials investigating HOTAIR for use in thyroid cancer (NCT03469544) and CCAT1 for use in 
colorectal cancer (NCT04269746). Though their clinical use is slowly emerging, the list of 
potential biomarker lncRNAs is continuously growing, and with the advancements of less invasive 
techniques such as the liquid biopsy, it is only a matter of time before more lncRNAs are proven 
as effective diagnostic and prognostic indicators.  
 
 LncRNAs have also been investigated as targets for cancer therapeutics. As mentioned 
before, lncRNAs are highly tissue and/or cancer specific which makes them ideal candidates as 
druggable targets. Current methods in development include RNAi (siRNA, miRNA), antisense 
oligonucleotides (ASOs), and small molecules, however none have yet to enter clinical trials. 
There a multiple examples of these methods effectiveness in vitro and in vivo, however the lack of 
an efficient systemic delivery method has proven challenging for use in humans. The alternative 
option to directly targeting a perspective lncRNA is identifying novel binding partners or 
downstream effectors and targeting them instead (69). Considering the multitude of functions 
attributed to lncRNAs, these strategies could one day prove useful in treating cancers. 
 
III. LncRNAs and Non-Small Cell Lung Cancer (NSCLC) 
 
A. Lung Cancer Overview 
 In the U.S., lung cancer is the number one cause of cancer related mortality, and is the 
second most commonly diagnosed cancer amongst both men and women. Currently, the average 
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overall 5 year survival rate is 18.6%, which can be attributed to the fact that more than half of lung 
cancer cases are diagnosed at late stages (72).  
 
Lung cancer is typically divided into two major types, small cell lung cancer (SCLC), 
which makes up ~20% of cases, and non-small cell lung cancer (NSCLC), which makes up ~80% 
of cases. NSCLC is then further divided into three histological subtypes, lung adenocarcinoma 
(LUAD), lung squamous cell carcinoma (LUSC), and large cell carcinoma (LCC). Of these 
subtypes, LUAD is the most common, followed by LUSC and then LCC. Interestingly, the subtype 
most found in non-smokers is LUAD, while LUSC is mostly found in those who currently smoke 
or have a history of smoking. While most cases can be linked to smoking, other causes also include 
genetic changes and carcinogenic environmental factors such as asbestos or radon gas (73). 
Regardless of the cause, genetic alterations such as activation or overexpression of oncogenes 
and/or down regulation or loss of tumor suppressors and their affected pathways are crucial in the 
development of lung cancer. With advancements in genomics and proteomics, there have been 
over two dozen alterations identified that can be classified as “driver mutations.” These are 
mutations which occur typically in a tumor suppressor gene or oncogene. For NSCLC, the most 
common are changes in TP53, KRAS, EGFR, and CDK2NA. Alterations in these genes results in 
drastic consequences, leading to changes in multiple cellular processes such as cell cycle 
regulation, DNA damage response, growth signaling and even metabolic reprogramming, leading 
to tumorigenesis (74,75). Additionally, like changes in protein coding genes, changes in lncRNAs 
can also wreak havoc in the cell. 
 
B. Roles of LncRNAs in NSCLC 
 Numerous lncRNAs have been found to affect all the major hallmarks of cancer, and thanks 
to the continuing advancements in RNA sequencing technologies, more and more are being 
discovered. In NSCLC specifically, there have been a number of dysregulated lncRNAs 
(oncogenic and/or tumor suppressive) characterized to affect nearly all major hallmark pathways 
involved in carcinogenesis including epithelial-to-mesenchymal transition (EMT), apoptotic 
resistance, migration and metastasis, and therapy resistance (76,77).  
 
MALAT1 
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Arguably one of the most studied lncRNAs associated with not only lung cancer but 
numerous cancers is the oncogenic Metastasis-Associated Lung Adenocarcinoma Transcript 1 
(MALAT1). As its name suggests, it was first characterized in lung adenocarcinoma as a mediator 
of metastasis (78), but further studies revealed it is actually one of the most abundantly expressed 
lncRNAs in normal human tissues. Only when is it dysregulated, usually overexpressed, does it 
become oncogenic (79). Since its discovery, MALAT1 has been shown to carry out multiple 
functions in NSCLC. The most common functions typically involve regulation of RNA splicing 
and are associated with pathways that promote invasion and metastasis.  Moreover, studies using 
NSCLC cell lines have shown that depletion of MALAT1 leads to a decrease in migration, 
invasiveness and metastatic potential (80). Interestingly, MALAT1 can also act as a competing 
endogenous RNA (ceRNA) by sponging miRNA. One study describes an ERβ/MALAT1/miR-
145-5p/NEDD9 axis that promotes the phenomenon vasculogenic mimicry (the ability for cancer 
cells to trans-differentiate into endothelial like cells) and NSCLC invasion. Briefly, estrogen 
receptor β (ERβ) signaling upregulates the expression of MALAT1, which in turn sequesters miR-
145, allowing NEDD9 to be expressed and promote cell invasiveness (81). Another mechanism 
involving sponging of miR-145 promotes resistance to the chemotherapeutic agent cisplatin in 
NSCLC cell lines. Sequestration of miR-145 lead to an increase in Kruppel-like factor 4 (KLF4), 
a factor known to regulate stemness in cancer cells and promote resistance to chemotherapeutics 
(82). MALAT1 has also been shown to promote cisplatin resistance through STAT3 activation 
which upregulates MDR1 and MRP1, known mediators of drug resistance (83). Additionally, 
numerous studies have proposed MALAT1 as a prognostic marker for NSCLC. Overall, high 
expression correlates with worse overall survival and high metastatic potential in NSCLC patients 
(84,85). 
 
HOTAIR 
The lncRNA HOX Transcript Antisense RNA (HOTAIR) is another well studied and 
characterized oncogenic lncRNA found in numerous cancers. In lung cancer, it has been shown to 
be important in cell proliferation, invasion, and therapeutic response, typically when 
overexpressed compared to normal tissue (86). One study found that the tumor suppressor p53 
negatively regulates HOTAIR expression by directly binding to and occupying its promoter. 
Furthermore, overexpression of HOTAIR resulted in downregulation of p53 via recruitment of 
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PRC2 to the p53 promoter, revealing a feedback loop between HOTAIR and p53 that causes 
changes in cell proliferation and invasiveness (87). Another study revealed that hypoxia is a major 
regulator of HOTAIR expression in NSCLC. Briefly, hypoxia turns on expression of the 
transcription factor HIF-1α, a major regulator of cellular hypoxia response, which binds to hypoxia 
response elements within the HOTAIR promoter. The upregulation in HOTAIR expression 
resulted in enhanced cell proliferation, migration, and invasion under hypoxic conditions (88). 
HOTAIR can also function as a ceRNA to influence tumorigenesis. For example, one study 
showed that HOTAIR can sponge the miRNA miR-217 which prevents downregulation of 
dachshund homolog 1 (DACH1), a cell fate determination factor favorable for tumorigenesis (89). 
Additionally, HOTAIR has been shown to influence cellular response to chemotherapeutics such 
as Crizotinib, a tyrosine kinase inhibitor, via promoting autophagy in NSCLC cell lines (90). 
Lastly, increased expression of HOTAIR is negatively correlated with NSCLC patient outcomes 
(91,92). 
  
MEG3 
MEG3 (maternally expressed gene 3) is one of only a handful of characterized tumor 
suppressor lncRNAs. It is found expressed in many normal tissues, and its loss is associated with 
numerous cancer types (57). Furthermore, one of the primary roles of MEG3 is activation and 
accumulation of the tumor suppressor protein p53. It is suggested that it stabilizes the p53 protein 
which promotes increased activity of the protein and proper regulation of p53 target genes which 
control cell cycle and apoptosis (58). In NSCLC, the loss of MEG3 is attributed to apoptotic 
resistance and increased proliferation. One study demonstrated that exogenous overexpression of 
MEG3 significantly increased the expression and activity of p53. This resulted in reduced cell 
proliferation and increased apoptosis in vitro and slower tumor growth in vivo (93). Another tumor 
suppressive mechanism attributed to MEG3 involves its regulation of Skp2, a component of the 
ubiquitin ligase complex responsible for degrading p27, a master cell cycle regulator. Briefly, 
MEG3 coordinates with miR-3163 to inhibit the translation of Skp2 which allows expression of 
p27 and eventually inhibits cell growth (94). Additionally, through a miRNA mediated 
mechanism, MEG3 has been shown to enhance the sensitivity of NSCLC cells to cisplatin. Cells 
with low MEG3 expression demonstrated resistance to cisplatin, which was reversed via 
exogenous overexpression of MEG3, mediated by a miR-21-5p/SOX7 signaling axis (95). It is 
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also important to note that in addition to the mechanisms outlined above, MEG3 has also been 
suggested as a prognostic marker in NSCLC, as low expression of the lncRNA correlates with 
poor survival (96). 
 
GAS5 
Growth arrest specific transcript 5 (GAS5) is another tumor suppressor lncRNA found 
expressed in multiple tissues, but downregulated in a number of cancer types including NSCLC. 
Overall, it has been associated with a number of signaling pathways such as cell cycle, cancer cell 
metabolism, proliferation, and apoptosis (59). One study revealed GAS5 was downregulated in 
NSCLC tissues when compared to normal adjacent tissues suggesting its function as a tumor 
suppressor. Further investigation in the same study revealed that exogenous expression of GAS5 
in NSCLC cell lines slowed cell proliferation and decreased colony formation ability as well as 
induced apoptosis (97). Another tumor suppressive mechanism in NSCLC attributed to GAS5 is 
its ability to regulate glucose signaling. In summary, GAS5 functions in a delicate feedback loop 
with glucose signaling. It was shown that high glucose fed NSCLC cells downregulated the 
expression of GAS5 which increased proliferation and migration, while exogenous overexpression 
of GAS5 attenuated the affect through direct interaction with TRIB3, an important mediator of 
glucose signaling (98). GAS5 has also been shown to interact with miRNAs to affect NSCLC cell 
proliferation, metastasis and radiation sensitivity. For example, GAS5 can function as a ceRNA 
for miR-205. In short, miR-205 suppresses the translation of the tumor suppressor protein PTEN. 
GAS5 therefore promotes the expression of PTEN by sponging miR-205. Expression of PTEN 
results in slower proliferation and decreased migration and invasion in NSCLC cells (99). 
Additionally, GAS5 has been shown to sponge miR-135b, inhibiting tumorigenesis and promoting 
radiation sensitivity both in vitro and in vivo (100). Lastly, thanks to technological advances and 
the development of liquid biopsy methods, low levels of circulating GAS5 has been proposed as a 
potential biomarker for the prognosis and diagnosis of NSCLC (101,102). 
 
 Overall, it can be concluded that lncRNAs are an extremely important factor in the 
tumorigenesis and treatment of NSCLC. Unfortunately, a lot more work needs to be done in 
regards to the clinical applicability of lncRNAs.  
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IV. Radiation Therapy 
 
A. Overview 
 Radiation therapy (RT) is a major component of cancer therapy. Currently, there are 
multiple modalities (intensity modulated radiotherapy, image-guided radiotherapy, stereotactic 
body radiotherapy, etc.) utilized to administer radiation to tumors, typically combined with a 
chemotherapeutic agent which is dictated by the cancer type and location of the tumor. The 
clinically approved modalities use one of two kinds of radiation, photon radiation (x-rays and 
gamma rays) or particle radiation (electron, proton, or neutron beams). The major difference 
between photon radiation and particle radiation is the rate of energy emission. Overall, particle 
radiation has a higher linear energy transfer (LET), resulting in more DNA damage compared to 
photon radiation. However, photon radiation is more commonly used because the equipment 
needed to administer particle radiation is difficult to manufacture and much more expensive (103). 
Regardless of their differences, they 
both have proven effective in the 
treatment of most cancers, whether 
through curative or palliative care.  
 
The component shared amongst 
all types of radiation therapy is the 
mechanisms by which it kills cancer 
cells. The primary mechanism is by 
direct DNA damage, inducing double 
stranded (DSB) and single stranded 
breaks (SSB) (Fig. 8A). The secondary 
mechanism is by the creation of free 
radicals which signals cell stress and 
also causes DNA damage (104). DNA 
damage then triggers a number of 
molecular signaling cascades which 
attempt to fix the damage [non-
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homologous end joining (NHEJ), alternative end joining (alt-EJ), and homologous recombination 
(HR)] and slow/stop cell cycle 
progression, however the mass 
amount of stress and genomic 
instability typically overwhelms 
these repair mechanisms and 
results in senescence (permanent 
cell growth arrest), or cell death 
via apoptosis or necrosis (Fig. 8B 
and 8C) (104,105). Unfortunately, 
like most therapies, there are 
molecular mechanisms of 
resistance that can make treating 
cancers with radiation very difficult (Fig. 9). 
 
B. LncRNAs and Mechanisms of Cancer Cell Radiation Resistance 
While RT has proven to be an effective strategy for treating multiple types of cancers, 
cancer cells are notorious for adapting to circumvent cell death. These mechanisms of resistance 
span multiple molecular pathways (Fig. 9) and can be intrinsic or acquired, which makes 
overcoming them very difficult in terms of therapy and leads to poor prognosis. Some well-known 
examples include apoptosis resistance, hijacking of the DNA damage repair pathway, expression 
of stem cell like factors, and epithelial-to-mesenchymal transition (106). Additionally, as 
previously stated, lncRNAs play a role in nearly every molecular pathway so it is no surprise that 
lncRNAs have been shown to respond to and regulate RT sensitivity in multiple cancer types (Fig. 
10) (107). For instance, in glioblastoma, colorectal, and gastric cancers lincRNA-p21 has strong 
interactions within the Wnt/β-catenin pro-survival pathway which mediates resistance to radiation 
with respective mechanisms within the pathway specific to each cancer type (108–110). LincRNA-
ROR has been associated with radioresistance in hepatocellular carcinoma by sequestering miR-
145 which allows upregulation of RAD18, a factor responsible for DNA damage repair (111). It’s 
also been shown to regulate the same miRNA in colorectal cancer, and promotes radioresistance 
via negative regulation of miR-145/p53 pathway resulting in apoptotic resistance (112). The 
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lncRNA NEAT1 has been shown to influence EMT in nasopharyngeal carcinoma via negative 
regulation of miR-204 leading to the upregulation of ZEB1, promoting EMT and enhancing 
radiation resistance in vitro and in vivo (113). Furthermore, the lncRNA TUG1 has also been 
shown to promote EMT via sponging of miR-145 and upregulating ZEB2 in bladder cancer (114). 
While these examples are only a small sample of the studies investigating the roles of lncRNAs in 
cancer radiotherapy, it is clear that lncRNAs are a potential area of therapeutic and prognostic 
value for multiple cancer types. 
  
C. LncRNAs in NSCLC Radiation Response 
 While there have been great strides in understanding the mechanisms of lncRNAs in 
radiation response, only a handful have been characterized in non-small cell lung cancer (NSCLC). 
The tumor suppressive lncRNA GAS5 (Growth Arrest Specific Transcript 5) has shown the ability 
to sensitize NSCLC cell lines to radiation. One of these studies proposed a mechanism where 
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GAS5 is able to work as a competing endogenous RNA (ceRNA) and sequester or “sponge” the 
miRNA miR-135b. Another study showed that GAS5 functions through a miR-21/PTEN/Akt 
signaling axis. Interestingly, both studies showed increased ability for cells to undergo apoptosis 
following exogenous expression of GAS5(100,115). The lncRNA PVT1 (Plasmacytoma Variant 
Translocation 1) has also shown potential in regulating radioresistance in NSCLC by acting as a 
ceRNA for the miRNAs miR-195 and miR-424-5p. While there is no further mechanism described 
in regards to miR-195 other than increased apoptosis following administration of RT when PVT1 
was knockdown, PVT1 sponges miR-424-5p and stabilizes the protein CARM1, promoting an 
anti-apoptotic phenotype. This results in upregulated Bcl-2 (anti-apoptosis protein) and matrix-
metalloproteinases MMP-2 and MMP-9 (important for cell adhesion, migration and invasion), 
which was all attenuated upon knockdown of PVT1 or overexpression of miR-424-5p, increasing 
radiosensitivity (116,117). 
 
In addition to GAS5 and PVT1, there other examples of lesser known lncRNAs which have 
been shown to regulate the radiosensitivity of NSCLC cells. For instance, the lncRNA CYTOR 
(Cytoskeleton Regulator RNA) can also sponge miR-195 similarly to PVT1. Briefly, high 
expression of CYTOR correlates with poor patient survival and functions as an oncogene by 
promoting increased proliferation, migration, invasion, and radioresistance in NSCLC cell lines 
by acting as a molecular sponge for miR-195. By sequestering miR-195, CYTOR allows for the 
upregulation of miR-195 targets such as, YAP and WNT3A which are regulators of stem-
cell/developmental molecular pathways implicated in radioresistance(118). Another example is 
the lncRNA FAM201A (LncRNA Family with Sequence Similarity 201-member A). Along with 
high expression being associated with radiation resistance and poor prognosis in NSCLC patients, 
FAM201A functions in mediating radioresistance by sequestering miR-370, which promotes 
expression of EGFR and HIF-1α, both of which have been associated with pathways involved in 
mediating resistance to RT (119).  
 
In conclusion, lncRNAs are clearly an important factor in regulating cancer cell 
radiosensitivity. However, more studies are needed to fully understand the plethora of mechanisms 
these complex RNAs can elicit in cancer cells. Furthermore, many have been proposed as 
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prognostic indicators in some cancers (120), but more clinical studies are necessary to fully classify 
them as relevant molecular biomarkers. 
 
V. The Y Chromosome in Cancer 
 
A. Overview 
 The human Y chromosome (ChY) has long been considered a genetic wasteland with no 
value beyond its roles in male development and fertility (121). This is due in large part to the 
miniscule number of genes found on ChY compared to other chromosomes in the human genome. 
The total number of annotated genes currently reported is 568, of which only 71 have been 
described as protein-coding, and of those 71, many of the proteins belong to the same family 
resulting in a minor 27 distinct protein coding genes. The rest are considered to be potential non-
protein-coding genes and pseudogenes (122).  
 
 Structurally, ChY is split into three major regions: MSY, PARs and the heterochromatic 
block (Fig. 11). The male specific region (MSY) is comprised of euchromatin and contains the 
majority of the annotated coding genes along with some pseudogenes. The pseudoautosomal 
regions (PAR1 and PAR2), which contain a small number of coding genes, are the only portions 
of ChY that share homology with the X chromosome, and are the only parts of ChY which undergo 
meiotic recombination. The remaining region is typically referred to as the heterochromatic block, 
comprises roughly half of the q arm of ChY, and has been described as transcriptionally inactive 
(123). 
 
Interestingly, ChY is commonly lost in aging somatic cells, otherwise referred to as mosaic 
loss of chromosome Y (LOY). This phenomenon has been observed for decades and was first 
considered a simple physiological consequence of aging in male tissues, and considering the 
limited number of non-essential genes, it has been largely ignored in terms of human biology (124). 
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However, recent evidence suggests a prognostic or pathological role for LOY. Just within the last 
two decades there has been an increase in research surrounding ChY. Many have found negative 
correlations with changes in ChY or LOY and pathologies such as cardiovascular disease, 
Parkinson’s, schizophrenia, age related macular degeneration, cancer and overall mortality in men 
(125–129). Unfortunately, more information is still needed in regards to the genetic information 
of the ChY in order to acquire a complete understanding of the full potential of ChY in human 
disease. 
 
B. ChY in Cancer 
 Overall, men are more likely to develop and die from cancer (72). Many theories have been 
offered to explain the disparities in cancer incidence and survival between the sexes, most of which 
are attributed to differences in hormone regulation, immune surveillance, and external factors (e.g. 
tobacco use). Numerous studies have also shown associations with genome instability, aneuploidy 
and cancer risk and mortality primarily for somatic chromosomes, enabling the identification of 
strengths and weaknesses in different cancers (130,131). However, while all of these have been 
fairly well elucidated, it is only recently that changes in ChY, especially LOY, has emerged as an 
additional factor in regards to male cancer susceptibility, tumorigenesis and survival.  
 
 Studies done in prostate cancer have eluded that LOY is beneficial for tumorigenesis and 
could potentially be used as a biomarker. Utilizing the prostate cancer cell line PC-3, one study 
revealed that restoration of ChY to the cells resulted in less tumorigenic phenotypes in vitro and 
in vivo (132). Another study showed that different ChY haplotypes could potentially be used to 
assess prostate cancer risk (133). More recently, a group identified the ChY specific histone 
demethylase KDM5D as a potential ChY linked tumor suppressor as its loss resulted in more 
aggressive prostate tumors (134). LOY has also been implicated in increased risk for developing 
testicular germ cell tumors (135). Additionally, in male breast cancer, it’s been shown that the 
ChY gene TMSB4Y is a possible tumor suppressor and that loss of the gene via loss of ChY 
promotes a more tumorigenic phenotype (136). An additional study determined that clonal ChY 
in male breast cancer can begin as early as ductal carcinoma in situ (DCIS), and is primarily 
associated with Estrogen Receptor (ER) and Progesterone (PR) negative breast cancer subtypes 
(137). In addition to prostate, testicular, and male breast cancer, LOY has been observed in other 
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cancers including head and neck squamous cell carcinoma, urothelial bladder cancer, clear cell 
renal cell carcinoma, pancreatic adenocarcinoma, and NSCLC, all of which describe LOY as 
beneficial for the respective tumor types (138–141). Additionally, here have been multiple studies 
investigating LOY in the blood as prognostic indicator for patient survival or a biomarker for 
cancer risk. The overall findings within these studies conclude that LOY negatively correlates with 
patient survival and carcinogenesis (142–144). Interestingly, it was also noted that smoking is an 
external factor that can accelerate LOY, which adds to the already known fact that smoking has a 
major role in the development of multiple types of cancers (145). 
 
C. ChY LncRNAs in Cancer 
 Due to incomplete sequencing data, the non-coding regions of ChY still remain an elusive 
source of potential in cancer cell biology. However, there are a few studies that have sought to 
begin identifying and characterizing ncRNAs, specifically lncRNAs from ChY. Currently, 
however, there are only 2 publications describing a role for the ChY lncRNA TTTY15. 
Interestingly, in prostate cancer TTTY15 behaves in an oncogenic capacity and is found 
upregulated in patient tumor samples, but the opposite is seen in NSCLC (146,147). Since these 
are the only two studies available, it is obvious that more information is needed to fully elucidate 
the effects of ChY lncRNAs in cancer.  
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Abstract 
Numerous studies have implicated changes in the Y chromosome in male cancers, however few 
have investigated the biological importance of Y chromosome non-coding RNAs. Here we 
demonstrate a group of Y chromosome-expressed long non-coding RNAs (lncRNAs) involved in 
male non-small cell lung cancer (NSCLC) radiation sensitivity. Radiosensitive male NSCLC cell 
lines demonstrated a dose-dependent induction of linc-SPRY3-2/3/4 following irradiation, not 
observed in radioresistant male NSCLC cell lines. Cytogenetics  revealed the loss of chromosome 
Y (LOY) in the radioresistant male NSCLC cell lines. Gain- and loss-of-function experiments 
indicated that linc-SPRY3-2/3/4 transcripts affect cell viability and apoptosis. Computational 
prediction of RNA binding proteins (RBPs) motifs and UV Crosslinked Immunoprecipitation 
(CLIP) assays identified IGF2BP3 (an RBP involved in mRNA stability) as a binding partner for 
the linc-SPRY3-2/3/4 RNAs. The presence of linc-SPRY3-2/3/4 reduced the half-life of known 
IGF2BP3 binding mRNAs, such as the anti-apoptotic HMGA2 mRNA, as well as the oncogenic 
c-MYC mRNA. To assess the clinical relevance of these findings, we examined the presence of 
the Y chromosome in NSCLC tissue microarrays and the expression of linc-SPRY3-2/3/4 in 
NSCLC RNAseq and microarray data. We observed a negative correlation between the loss of the 
Y chromosome or linc-SPRY3-2/3/4, and overall survival. Thus, l i nc -SPRY3-2/3/4 expression and 
LOY cou ld  rep resent  an important marker of radiation therapy in NSCLC. 
 
Graphical Abstract 
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Statement of Significance 
This study describes previously unknown Y chromosome-expressed lncRNA regulators of 
radiation response in male NSCLC.  Furthermore, our findings show a correlation between loss of 
chromosome Y and radioresistance. 
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I. Introduction 
 
Lung cancer is the most commonly diagnosed cancer worldwide and is the number one 
cause of cancer-related mortality (1). While there have been great strides in advancing treatment 
modalities for NSCLC, radiation therapy (RT) resistance remains a significant challenge. Previous 
studies have demonstrated mechanisms of radioresistance that include alterations in proteins 
involved in cellular response to DNA damage, the repair of DNA, apoptosis, hypoxia, and cell 
cycle regulators, among others (2,3). Regulatory non-coding RNAs have also been implicated in 
the development of radioresistance in NSCLC (4). 
 
Regulatory non-coding RNAs include mature microRNAs (miRNAs) of around 22 
nucleotides and long non-coding RNAs (lncRNAs) of >200 nucleotides (5). Studies have shown 
that most LncRNAs do not contain an open reading frame and could regulate a wide variety of 
processes through diverse mechanisms, including acting as signals (e.g. enhancers of 
transcriptional regulation), guides (e.g. recruitment of chromatin modifiers enzymes), or 
competing endogenous RNAs (e.g. sequestering miRNAs or RNA binding proteins) (6). The 
dysregulation of the expression and function of lncRNAs has been implicated in numerous cancer 
types, suggesting their potential use as biomarkers, prognostic indicators, or therapeutic targets 
(7). In NSCLC, lncRNAs have been associated with nearly every facet of cancer cell biology (8). 
Several lncRNAs have been associated with the development of resistance to radiotherapy (9). 
Examples of this include MALAT1 and HOTAIR, which are responsible for inhibiting apoptosis 
and promoting epithelial to mesenchymal transition thereby aiding in radioresistance (10).  
 
Non-coding RNA genes, including those coding for lncRNAs have been mapped to every 
human chromosome, including the X and Y chromosomes (11). LncRNAs that map to the X 
chromosome include XIST, which is critical for the initiation of X-inactivation. The dysregulation 
of XIST has been shown in multiple cancers (7,12). Other X chromosome lncRNAs include TSIX 
and XACT, which also function in regulating X chromosome inactivation (12). In contrast, few 
studies have considered the possibility that the Y chromosome contains genes encoding regulatory 
RNAs (13-15). Only 27 distinct protein-coding genes are present on the Y chromosome, most of 
which function in sex determination and male fertility (16,17). The remaining are considered 
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potential non-coding genes and pseudogenes (18). This suggests the Y chromosome is an untapped 
source of non-coding information, and could potentially provide new insights into numerous 
diseases - including NSCLC.  
 
Here we report, for the first time, the importance of the lncRNAs linc-SPRY3 (also known 
as lnc-BPY2C): linc-SPRY3-2, linc-SPRY3-3, linc-SPRY3-4 (linc-SPRY3-2/3/4) in male NSCLC 
radiation response. Gain and loss of function experiments demonstrated that linc-SPRY3-2/3/4 are 
involved in radiation vulnerability of male NSCLC cells and tumor samples containing 
chromosome Y or linc-SPRY3-2/3/4. Together our findings suggest a role of male-specific 
lncRNAs in NSCLC radiation sensitivity. 
 
II. Materials and Methods 
 
Cell Culture  
Non-small cell lung cancer cell lines H460, H820, H157, H1299, A549, and WVU-Ma-0005 were 
cultured with DMEM (Sigma-Aldrich, St. Louis, MO, USA, D7777). H1650 and Ma-ALK-0001 
cells were grown in RPMI (Corning, Corning, NY, USA, 50-020-PC). DMEM and RPMI media 
was supplemented with 10% fetal bovine serum (Gemini Bio-products, Sacramento, CA, USA, 
100-106), L-glutamine (Gibco-LifeTech, Grand Island, NY, USA, 25030-081), HEPES (GE 
Healthcare Life Sciences, Logan, UT, USA, SH30237.01), penicillin–streptomycin (Gibco, 
15140-122), and amphotericin B (Gibco, 15290-026). Human bronchial epithelial cells (HBEC) 
were cultured with keratinocyte-SFM supplemented with bovine pituitary extract, human 
recombinant epidermal growth factor, and L-glutamine (Gibco, 10724-011). All cells were grown 
in a humidified incubator at 37°C in the presence of 5% CO2. Cell lines HBEC, H460, H820, 
H157, A549, H1299, and H1650 were kindly provided by Dr. Erik A. Bey (Indiana University) 
and patient derived cell lines WVU-Ma-0005 and Ma-ALK-0001 were kindly provided by Dr. 
Patrick C. Ma (Pennsylvania State University).  
 
Microarray analysis 
For global lncRNA expression, we used the GeneChip® Human Transcriptome Array 2.0 
(ThermoFisher Scientific, Affymetrix, Santa Clara, CA, USA) that assesses 22,829 non-protein 
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coding human genes. Microarray processing was carried out in the West Virginia University 
Genomics Core Facility. Briefly, 1 μg of total RNA was labeled using the Flashtag RNA labeling 
kit (Genisphere, Hatfield, PA, USA) according to the manufacturer's instructions. Each sample 
was hybridized to the array at 48°C and 60 rpm for 16 hours then washed and stained on Fluidics 
Station 450 (Fluidics script FS450_0003) and finally scanned on a GeneChip® Scanner 3000 7G 
(Affymetrix, Santa Clara, CA, USA). Feature intensities were extracted by using GeneChip® 
Human Transcriptome Array 2.0 library files. Array data was deposited into the NCBI Gene 
Expression Omnibus (GEO) database (GEO accession #GSE147708). 
 
Quantitative RT-PCR 
Total RNA was extracted using Trizol Reagent (Ambion, Austin, TX, USA, 15596026) per 
manufacturer’s instructions, then treated with Turbo DNAfree DNase (Invitrogen, Carlsbad, CA, 
USA, AM1907) for 25 minutes at 37ºC. RNA concentrations were determined with a Nanodrop 
2000 Spectrophotometer. 0.5 – 1 μg of total RNA was converted to cDNA using the iScript cDNA 
synthesis kit (Bio-Rad, Hercules, CA, USA, 170-6891), followed by qRT-PCR using the 
SsoAdvanced Universal SYBR Green Supermix (Bio-Rad, 172-5271) and several pair of primers 
to specifically amplify the genes of interest in this study (Supplementary Table S4). Relative 
expression was calculated using the double delta CT method (relative expression = 2-ΔCT; where 
ΔCT =CT (Target RNA) – CT (endogenous control RNA)), where the endogenous control for 
lncRNA and mRNA was GAPDH and/or UBC. 
 
Virtual Northern Blot 
Total RNA (60µg) from 8Gy treated H460 cells was resolved on a 1.2% formaldehyde denaturing 
agarose gel overnight. The gel was imaged (to serve as ladder) and then fragmented into 25 
fractions of equal size and RNA was recovered from each fraction by gel extraction. The recovered 
RNA was then used for qRT-PCR analysis of each individual lncRNA. The values generated by 
qRT-PCR were plotted as a fraction of the total RNA. Plotted values were a mean of three technical 
replicates per band. 
 
Clonogenic Cell Survival Assay 
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Cells were seeded in triplicate 60mm gridded dishes containing 4 mL of media at 250 cells per 
dish. Cells were treated with sham or a single dose of radiation (2Gy, 4Gy, or 8Gy), and then 
colonies were allowed to form for 10-15 days. Colonies were fixed and stained with crystal violet 
in 33% methanol, and manually counted using a microscope. Surviving fraction values relative to 
the sham controls were plotted as a function of radiation dose. 
 
Viral Transduction of shRNAs 
HEK-293T cells were transfected with the lentiviral plasmid pLKO-shScramble (Addgene #1864) 
or pLKO.1-TRC cloning vector (Addgene #10878) containing shRNA sequences against linc-
SPRY3-2, linc-SPRY3-3, or linc-SPRY3-4 and lentiviral packaging plasmids (PsPax2 Addgene 
#12260, and VSV-G Addgene #8454) using calcium phosphate transfection.  Lentivirus was 
collected after 48 hours, filtered (0.45 µm) and supplemented with polybrene (1 μg/mL, 
MilliporeSigma, Burlington, MA, USA, TR-1003-G). WVU-Ma-0005 or H460 cells were exposed 
to lentivirus for 16-72 hours and allowed to recover for 48 hours post infection. Infected cells were 
stably selected via puromycin treatment (1.0-2.5 μg/mL) for 72 hours. Efficiency of shRNA 
knockdown was measured using qRT-PCR. 
 
Nucleofection of Y Chromosome BAC 
The bacterial artificial chromosome (BAC) RP11-88F4 clone, from the RPCI-11 Human Male 
BAC Library (containing a 95,171bp insert from ChrY:58,819,440-58,914,611 [GRCh37/hg19]), 
was purchased from the Children’s Hospital Oakland Research Institute and introduced to cells by 
nucleofection. A549 cells (4x106 cells/cuvette) were briefly resuspended in nucleofection buffer, 
and 16 μg of RP11-88F4 or pBACe3.6 (control) plasmid DNA was added. The cuvette was placed 
on the Amaxa Nucleofector II device and the appropriate program was selected (Nucleofector® 
Program X-001). Immediately after the Nucleofection process ended, cells were resuspended in 
rescue media and transferred into 6-well plates and incubated at 37ºC under 5% CO2. Expression 
of linc-SPRY3-2/3/4 was measured 48 hours post transfection by qRT-PCR. 
 
Flow Cytometry 
Cell viability and apoptosis were evaluated via Guava Eascyte HT Flow Cytometer (Millipore). 
Guava Viacount (Luminex, Austin, TX,  4000-0040) reagent was used for analysis of cell viability 
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and Guava Nexin (Luminex, 4500-0455) reagent for apoptosis per manufacturer’s instructions. 
Cells were plated at equal densities in a 6-well plate, then sham treated or treated with a single 
dose of radiation (8Gy). Cells were trypsinized and collected 24, 48 and 72 hours after treatment. 
Parameters for the flow cytometer were set using sham controls. 
 
Tumor Growth Delay Assay (TGD) 
shControl or shlinc-SPRY3-2 (sh1) cells were trypsinized and suspended at 5 x 106 cells/mL in 
Matrigel. 1 x 106 cells were injected subcutaneously into the right flanks of male nude mice 
(Nu/Nu-088, Charles River, Wilimgton, MA, USA). Once tumors reached ±150 mm3, RT was 
initiated. Treatment groups (3 animals each) included sham treated control (0Gy) and radiation 
(20Gy, 5 fractions). Tumor volume and depth was measured using ultrasound imaging (Vevo 
2100, FUJIFILM VisualSonics Inc.). Measurements were quantified using the Vevo LAB 2.2.0 
software. Tumors were assessed until they reached >800mm3, day 21 after initiation of treatment, 
or mice showed evidence of morbidity. Relative tumor volume was determined by normalizing 
measured volumes to the starting volume (Day 0) of each respective animal. 
 
UV Crosslinking and Immunoprecipitation (CLIP) 
CLIP was performed according to the original protocols with some modifications (19,20). The 
detailed method is described in the Supplementary data. 
 
RNA Stability Assay 
Cells were treated with 3µg/mL of Actinomycin D and then collected at 0 hours, 3 hours, 6 hours 
and 9 hours post treatment. RNA was then extracted and used for subsequent qRT-PCR analysis. 
C. elegans RNA was added as an exogenous spike for qRT-PCR (70 ng/µL) to amplify the worm 
specific gene Ama-1. Each time point was normalized to the 0 hour control. 
 
siRNA Transfection 
Cells were seeded at 3.5x105 cells per well in a 6-well dish. siRNAs were transfected utilizing the 
RNAiMax Lipofectamine reagent according to the manufacturer’s standard transfection protocol. 
300pmol of scramble control siRNA (Horizon ON-TARGETplus Non-targeting Control siRNA 
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#2, D-001810-02-05) was used. For the targeted lncRNA siRNAs, 100pmol of each linc-SPRY3 
specific siRNA was used to create a pool with a total concentration of 300pmol. 
 
Irradiation  
Radiation protocols were carried out on an Xstrahl XenX small animal radiation research platform 
(Suwanee, GA, USA). The XenX was commissioned following the AAMP Task Group 61 
protocol for clinical irradiators of 40-300 kV (11439485). Dosage of experimental design was 
confirmed using Gafchromic EBT3 film (31198412, 29923495). Mice were anesthetized via 
isoflurane inhalation for the duration of each treatment. Each tumor was treated to a total dose of 
20Gy over 5 fractions given every other day with a 1.2 cm circular fixed collimator at a dose rate 
of 3.62Gy/min corrected for tumor volume per mouse. For cells, a similar confirmation of dose 
rate for the experimental setup was determined by Gafchromic EBT3 film. Cells were treated in 
single fraction doses of 2Gy, 4Gy, or 8Gy with a variable collimator at a dose rate of 1.7Gy/min. 
 
DNA FISH AND Tissue Array Analysis 
DNA FISH in cell lines was performed and quantified by the WVU Cytogenetics Laboratory. 
DNA FISH for the tissue arrays was performed as previously described with the following 
modifications (21). Slides were first baked at 60°C before proceeding through the protocol. Slides 
were deparaffinized with Skipdewax (Insitus Biotechnologies, Albuquerque, NM, USA, #T213) 
for 20 minutes at 80°C followed by three washes with distilled water for 2 minutes each. This 
process was repeated three times. The SRY probe (Cytocell Ltd., Tarrytown, NY, USA, LPU 026-
A) was allowed to hybridize for 22 hours. All tissue arrays were purchased from US Biomax, Inc. 
(Derwood, MD, USA, Lung: OD-CT-RsLung01-009, Testis: T231a, Cervix: T103). Imaging for 
representative images for the tissue array FISH was performed via epifluorescent microscopy on 
a Nikon A1R/N SIM-E microscope. Imaging for quantification of Y chromosome in the lung tissue 
array was performed on an Olympus VS120 Slide Scanner microscope. Quantification of Y 
chromosome FISH in the lung TMA was done using IMARIS software. Kaplan-Meier method was 
used to estimate the survival curves and log-rank test was used to assess the difference of survival 
curves between groups. TMA data for each patient was evaluated by percentage of Y chromosome 
positive cells out of the total cells examined, where the cut-off point to define high and low was 
obtained from the classification and regression tree. 
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RNA Seq and microarray Analysis from NSCLC patient data 
RNA-Seq data for patients diagnosed with NSCLC were obtained from the Gene Expression 
Omnibus (GEO) database (accession #GSE81089) (22). The expression of linc-SPRY3-2 was 
measured by TPM (transcripts per millions reads) by salmon (23). A TPM value below 0.1 was 
deemed as not-expressed. The threshold was determined by comparing to the values obtained from 
female patients, where linc-SPRY3-2 should not express. The survival period was estimated as  
days between surgery and vital date (i.e., day of death or latest contact per the definition from 
GSE81089). For the microarray data, the expression of linc-SPRY3-2 from male Early Stage Lung 
Squamous Cell Carcinomas patients were obtained from GEO database (accession #GSE74777) 
based on Affymetrix Human Transcriptome Array 2.0. The survival analysis was done by 
comparing the top 10% high expressing patients of linc-SPRY3-2. The survival curves were made 
with the survival R package, and p-value was calculated by log-rank test. 
 
Cell Fractionation 
Cells were pelleted and immediately processed for cell fractionation to extract RNA (protocol 
adapted from previous publication (24). Pelleted cells were disrupted using an autoclaved glass 
Dounce homogenizer. Homogenate was centrifuged to pellet the nuclear fraction and the 
cytoplasmic fraction (supernatant) was collected.  Each fraction was then treated with DNase I 
(New England Biolabs) for 20 minutes at 37ºC and then RNA was extracted using Trizol Reagent 
(Life Technologies) per manufacturer’s instructions. Once the RNA was extracted it was treated 
with Turbo DNAfree DNase (Ambion) for 20 minutes at 37ºC.  RNA concentrations were obtained 
using a Nanodrop 2000 Spectrophotometer (Thermo Scientific). qRT-PCR for cell fractionations 
was normalized using an exogenous spike of C. elegans RNA (70 ng/µL) and the worm specific 
gene Ama-1. 
 
Statistical Analysis 
Data are presented as mean ±SD, ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001. The statistical significance 
between experimental groups was determined by ANOVA followed by  Tukey’s multiple 
comparisons test. Analyses were performed using GraphPad Prism V8 and Microsoft Excel 2013. 
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III. Results 
 
Identification of radiation-responsive lncRNAs expressed from the Y chromosome 
To identify lncRNAs potentially involved in radiation response of NSCLC cells, we 
profiled the expression of over 20,000 human lncRNAs in the male NSCLC H460 cell line 
irradiated with 7 Gy of ionizing radiation (IR), compared to unirradiated (0 Gy) H460 cells 24 
hours post-treatment. Using a change in gene expression of 1.5-fold or more, we identified 106 
lncRNAs as up-regulated following exposure to radiation, while 59 lncRNAs exhibited down-
regulation (Supplementary Fig. S1, Supplementary Table S1). Among the highest upregulated 
lncRNAs, we observed changes in transcripts annotated as linc-SPRY3-2, linc-SPRY3-3, and linc-
SPRY3-4, also known as lnc-BPY2C-4, lnc-BPY2C-25, and lnc-BPY2C-2, respectively. 
Surprisingly, the linc-SPRY3-2/3/4 transcripts map to a region of the Y chromosome 
heterochromatic block known as the DYZ1 region that contains a single H3K27Ac mark suggesting 
transcription in this region (Fig. 1A). The DYZ1 region has been described as genetically inert 
since it is composed of heterochromatin and, due to its highly repetitive nature, remains poorly 
sequenced (16). Previously attempted sequence analyses of the human Y chromosome have 
revealed numerous copies of the pentanucleotide repeat motif 5’-TTCCA-3’ in the DYZ1 region 
(25,26). Only one previous publication has shown expression of two non-coding RNAs 
(AK128024.1 and AY598346.2) from the DYZ1 region in a testis-specific manner (27). The linc-
SPRY3-2/3/4 sequence fragments obtained from the online database LNCipedia (28) contain 
several 5’-TTCCA-3’ repeat motifs (Fig. 1B) and partially overlap with AK128024.1 and 
AY598346.2 (Supplementary Fig. S2), further supporting that these lncRNAs are transcribed 
from the DYZ1 region of the Y chromosome. Using the linc-SPRY3-2/3/4 sequence fragments, we 
designed primers to specifically amplify each linc-SPRY3 transcript in order to perform virtual 
northern blot analysis. Using RNA from 8Gy treated H460 cells, we found two peaks of 
amplification migrating around 5Kb and 1Kb regardless of which linc-SPRY3  primers were used. 
This suggests linc-SPRY3-2/3/4 could be partial sequences of a longer lincRNA transcript(s). 
(Supplementary Fig. S3). 
 
We next developed qRT-PCR assays of the linc-SPRY3 transcripts to assess their 
expression in H460 cells following exposure to a single dose of IR (8Gy) at different time points 
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post-treatment versus non-irradiated controls. We observed a 5-fold induction in the expression of 
the linc-SPRY3-2/3/4 transcripts four hours post-exposure to radiation, that increased to almost 15-
fold after eight hours and remained elevated for at least twelve hours after treatment (Fig. 1C). 
Furthermore, H460 cells exhibited a dose-dependent increase from 5-fold (2Gy) to 50-fold (8Gy) 
in the expression of linc-SPRY3-2/3/4 after 72 hours post-exposure to IR (Fig. 2B). 
 
Linc-SPRY3-2/3/4 expression reveals a dose responsive signature to IR 
In order to expand our findings, we examined the expression of the linc-SPRY3 transcripts 
in several male NSCLC cell lines: the radiosensitive cell lines H820 and H157, and three 
radioresistant lines: H1299, A549 and H1650 (29-33). We also included two early passage male 
patient-derived NSCLC cell lines: WVU-Ma-0005 and Ma-ALK-0001. Clonogenic cell survival 
assays were performed to determine and verify the radiation response of these NSCLC cell lines. 
Our clonogenic assay data confirmed the radiosensitivity of H460 and H820 as well as the 
radioresistance of A549 and H1299, which were used as controls for the characterization of the 
response of the patient-derived cell lines. Our data showed that the WVU-Ma-0005 cell line is 
radiosensitive and the Ma-ALK-0001 cell line is radioresistant (Supplementary Fig. S4). Next, 
cells were treated with a single dose of IR (2Gy, 4Gy, or 8Gy) and collected 72 hours post-
treatment. Controls were established by treating the cells identically in parallel and omitting the 
irradiation step. We observed that human bronchial epithelial cells (HBEC), which served as a 
normal control, the radiosensitive cell lines H820, WVU-Ma-0005 and H157 demonstrated a dose-
dependent increase in expression of the linc-SPRY3 RNAs, (Fig. 2A-D, Supplementary Fig. S5H) 
similar to H460 cells. In contrast, the radioresistant cell lines A549, H1299, Ma-ALK-0001 and 
H1650 showed minimal to no expression of these lncRNAs when compared to no retro-
transcription (RT) controls (Fig. 3E-G and Supplementary Fig. S5I). To confirm that this 
expression profile is specific to male radiosensitive NSCLC cells, we investigated the expression 
of the linc-SPRY3 transcripts in two established female NSCLC cell lines H1975 (radiosensitive) 
and H1819 (radioresistant) (29). qRT-PCR revealed no amplification signal above background in 
the female cell lines, a finding consistent with the Y-specific mapping of the linc-SPRY3 genes 
(Supplementary Fig. S6). Finally, we assessed the coding potential and cellular location of the 
linc-SPRY3 RNAs in H460 and WVU-Ma-0005 cells. In both cell lines, we detected linc-SPRY3 
RNA species exclusively in the nucleus (Supplementary Fig. S7A and S7B) and we found no 
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coding probability in any of the lncRNA transcripts (Supplementary Fig. S7C) supporting our 
hypothesis of their potential non-coding function.  
 
Loss of the linc-SPRY3 transcripts in the radioresistant cell lines is due to loss of the Y 
chromosome 
The differences in the expression of the linc-SPRY3 transcripts in radiosensitive and 
radioresistant NSCLC cell lines prompted us to hypothesize that radioresistant lines harbored 
genetic changes involving chromosome Y. There are reports of changes in the Y chromosome in  
cancers dating back several decades that include evidence for the mosaic loss of chromosome Y 
(LOY) (21,34-41). LOY involves the loss of the entire Y chromosome and occurs in human male 
tissues as a consequence of aging, however, only recent studies have begun validating a correlation 
between LOY and cancer biology (18,21,36-38,40-45). Using  DNA-FISH, we investigated the 
sex chromosome status of our panel of cell lines. As expected, the immortalized HBECs showed 
a normal male genotype containing a single copy of the X and Y chromosomes (Fig. 2H). The 
radiosensitive cell lines (H460, H820, and H157) possessed multiple copies of both the X and Y 
chromosomes, while the patient-derived cell line WVU-Ma-0005 contained a single copy of the X 
and Y chromosomes (Fig. 2I-K and Supplementary Fig. S5L). Interestingly, the radioresistant 
cell lines A549, H1299, Ma-ALK-0001 and H1650 showed complete loss of the Y chromosome 
(Fig. 2L-N and Supplementary Fig. S5M). Cytogenetic analysis and quantification of LOY in 
all the NSCLC cell lines verified our DNA-FISH analysis, (Supplementary Table S2) suggesting 
that loss of the linc-SPRY3 transcripts in radioresistant cell lines is due to LOY, and that these 
noncoding RNAs and potentially other genes mapping to the Y chromosome could influence the 
response of cells to radiation. 
 
The DYZ1 region of the long arm of the Y chromosome restores radiosensitivity 
As described above, the repetitive nature of the sequences around the gene(s) coding for 
the linc-SPRY3 transcript(s) (Fig. 1B) means no complete sequence(s) for these RNAs exists 
hindering gene-specific gain-of-function studies. However, we were interested to determine if a 
bacterial artificial chromosome (BAC, RP11-88F4) encompassing the DYZ1 region of the long 
arm of the human Y chromosome where the linc-SPRY3 transcript(s) are located (a 95,171bp insert 
from ChrY:58,819,440-58,914,611 [GRCh37/hg19]) could alter the response of the Y 
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chromosome negative, radioresistant NSCLC cell line A549 to IR. After 72 hours, we extracted 
DNA from the nucleofected cells and performed PCR for the BAC plasmid (pBACe3.6) to 
determine efficiency of the nucleofection (Supplementary Fig. S8). Next, we detected the 
expression of the three linc-SPRY3 transcripts in the BAC-transfected A549 cells (A549_88F4) by 
RT-PCR, but not in the A549 BAC control cells (A549_Ctrl) (Fig. 3A). 
 
We measured cell viability and apoptosis in the A549_Ctrl and the A549_88F4 cells after 
a single dose of 8Gy IR. Notably, the A549_88F4 cells showed significantly worse cell viability 
when compared to control cells in response to treatment (Fig. 3B). Additionally, A549_88F4 cells 
showed increased apoptosis compared to control cells after IR with this difference reaching 
statistical significance at 48 and 72 hours (Fig. 3C). These experiments suggest that the DYZ1 
region of the long arm of the Y chromosome harbors genes that influence the response to IR, which 
includes the linc-SPRY3 family. To obtain further evidence to support this hypothesis, we 
conducted a series of loss-of-function studies using shRNAs to reduce the levels of the linc-SPRY3 
transcripts in NSCLC cells. 
 
 First, we designed and validated two shRNAs; one targeting a linc-SPRY3-2 sequence (sh1) 
and one a linc-SPRY3-3 sequence (sh2) (Supplementary Table S3). Interestingly, we observed a 
significant reduction in the levels of all three linc-SPRY3 RNAs in H460 and WVU-Ma-0005 cells 
(Fig. 3D and 3G), consistent with our hypothesis that linc-SPRY3 transcripts may be a longer 
lincRNA transcript. Both H460 and WVU-Ma-0005 cells expressing the linc-SPRY3 shRNAs 
exhibited increased survival and reduced apoptosis after 8Gy IR in comparison to control cells 
(Fig. 3E-F & 3H-I); consistent with a loss of linc-SPRY3 transcripts expression resulting in 
resistance to radiation. 
 
We next sought to determine if reducing the expression of the linc-SPRY3 transcripts would 
result in IR resistance in vivo. Briefly, 6-8 week old mice were injected with H460 or WVU-Ma-
0005 cells harboring either the shCtrl or sh1 constructs. Once tumors reached a volume of 150mm3, 
mice were treated with fractionated IR to a total dose of 20 Gy, mimicking the clinical procedures 
for patients with NSCLC (Supplementary Fig. S9A). Ultrasound imaging was used to ensure 
accurate measurement of both tumor depth and volume, the appropriate settings for IR 
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administration, as well as the tracking tumor growth (Supplementary Fig. S9B-C). Untreated 
mice showed rapid development of tumors regardless of the type of shRNA used (Supplementary 
Fig. S9D-E). As expected, IR treated mice exhibited slower tumor progression, while sh1 tumors 
showed larger tumor volumes both during and after IR compared to shCtrl tumors. This suggests 
that loss of linc-SPRY3 transcripts results in tumors with higher resistance to RT (Fig. 3J-K and 
Supplementary Fig. S9D-E).   
 
The linc-SPRY3 transcripts interact with the RNA binding protein IGF2BP3 and affect RNA 
stability in HMGA2 and c-MYC mRNAs 
In an attempt to identify a potential mechanism for the linc-SPRY3-2/3/4 RNAs we utilized 
A daTabase of RNA binding proteins and AssoCiated moTifs (ATtRACT) software (46) to predict 
RNA binding proteins (RBPs) potentially interacting with the linc-SPRY3 transcripts. The analysis 
revealed 13 potential RBPs interacting with the linc-SPRY3 transcripts but the largest number of 
predicted binding sites across all three family members was the RBP Insulin Like Growth Factor 
2 mRNA Binding Protein 3 (IGF2BP3, also known as IMP3) (Fig. 4A). To confirm the predicted 
association of IGF2BP3 with the linc-SPRY3 RNAs, we performed UV crosslinking and 
immunoprecipitation (CLIP) for IGF2BP3 in irradiated H460 cells. RT-PCR of the recovered RNA 
revealed that IGF2BP3 does indeed directly interact with all three linc-SPRY3 family members as 
well as the known binding partner HMGA2 mRNA (47) but not with the control GAPDH (Fig. 
4B). IGF2BP3 is a known RBP whose functions include stabilizing mRNAs. Two such targets 
include c-Myc and HMGA2 (48). These two targets were of specific interest to us, since previous 
studies have shown that downregulation of c-Myc and HMGA2 results in an increase in apoptosis 
in multiple cancers including lung cancer (49-54). 
 
In order to confirm that the association of IGF2BP3 with the linc-SPRY3 family members 
affects its ability to target and stabilize c-Myc and HMGA2, we performed RNA stability assays 
using Actinomycin D (ActD) to stop global transcription in A549 cells with or without the 
expression of the linc-SPRY3 transcripts (A549_Ctrl and A549_88F4 cells) as well as the 
knockdown of the linc-SPRY3 transcripts by a pool of siRNAs (siPool). qRT-PCR analysis 
revealed more rapid degradation of HMGA2 and c-Myc mRNAs in the A549_88F4 siCtrl cells 
when compared to A549_Ctrl siCtrl cells but GAPDH mRNA was not affected (red bar compared 
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to black bar) (Fig.4C).  Furthermore, we observed rescue of c-Myc and HMGA2 mRNAs 
stabilization in the A549_88F4 siPool cells after the knockdown of the linc-SPRY3 transcripts 
(Fig. 4C and Supplementary Fig. S10). Overall, these data suggest that when the linc-SPRY3 
RNAs are present they could potentially act as competing endogenous RNAs (ceRNAs) for 
IGF2BP3, thereby preventing it from stabilizing its mRNA targets c-Myc and HMGA2 affecting 
apoptosis response. 
 
Y chromosome loss and loss of the linc-SPRY3 RNAs are potential poor prognostic indicators 
for male NSCLC 
To assess the potential clinical relevance of the presence or absence of the Y chromosome 
and radiation sensitivity and resistance, we performed DNA-FISH for the Y chromosome on a 
lung cancer tissue microarray and quantified LOY for 30 male cores as well as a testicular cancer 
core (positive control) and a cervical cancer core (negative control). Representative images taken 
of male lung cancer cores and a testicular cancer core reveal numerous Y chromosome positive 
cells, while images taken of female lung cancer cores and a cervical cancer core reveal no 
detectable presence of the Y chromosome DYZ1 (Supplementary Fig. S11). Using images from 
male cores of the NSCLC tissue array, we applied a custom image analysis pipeline to determine 
the percentage Y chromosome positivity. The representative images demonstrate the DNA-FISH 
of a primary Y chromosome negative core (Fig. 5A, inset is absent of punctate dots) and a heavily 
Y chromosome positive core (Fig. 5C, arrows in inset indicate punctate dots). Figures 5B and 5D 
show the result of the image analysis in which Y chromosome negative cells are artificially colored 
purple and Y chromosome positive cells are artificially colored red. We next used the supplied 
clinical data to perform Kaplan-Meier analysis. Our analysis revealed a trend towards a negative 
relationship between Y chromosome loss and patient survival. Though not statistically significant, 
the trend revealed worse survival for those patients with < 25% Y chromosome positivity (Fig. 
5E).  
 
Finally, we accessed the publicly available microarray data (GSE74777) containing 107 
Early Stage Lung Squamous Cell Carcinomas (96 male) and the NSCLC short-read RNAseq 
dataset (GSE81089) containing 198 samples (95 male) to assess the expression of the linc-SPRY3-
2 transcript and clinical outcomes (the expression of the other two lncRNAs was only detected in 
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limited number of patients in the RNAseq dataset and therefore were not considered). Interestingly, 
male patients with high linc-SPRY3 transcripts expression (top 10%) from the microarray data 
showed a better surviving outcome than the rest of the patients (Fig. 5F).  Furthermore, in the 
RNA-seq study, male patients with tumors expressing low levels of linc-SPRY3-2 exhibited a 
worse overall survival than those in which their tumor did express linc-SPRY3-2 (Supplementary 
Fig. S11I ). Further studies are needed to validate these initial findings (statistically not 
significant), but the trends observed in two independent studies suggest that the presence of  the Y 
chromosome and the expression of linc-SPRY3 RNAs warrants further analysis for their functions 
in radiation response of male NSCLC tumors. 
 
IV. Discussion 
 
In this study the unbiased expression profiling of lncRNAs, following the irradiation of a 
NSCLC cell line, revealed the induced expression of three annotated lncRNAs that map to the 
highly repetitive, heterochromatic DYZ1 region of the Y chromosome: linc-SPRY3-2, linc-SPRY3-
3, and linc-SPRY3-4. Further investigation revealed expression of this group of lncRNAs is IR 
dose dependent and begins approximately 4 hours after administration of IR and maintained 
through 72 hours (Fig. 1). Interestingly, expression of these lncRNAs was only detected in 
radiosensitive cell lines, but not in radioresistant cell lines, regardless of their oncogenic driver 
mutations (Supplementary Table S2). Cytogenetic analysis of all cell lines showed loss of the Y 
chromosome in the radioresistant cell lines, while the radiosensitive cells lines retained their Y 
chromosome, explaining the differences seen in linc-SPRY3-2/3/4 expression (Fig. 2). Gain-of-
function and Loss-of-function experiments demonstrated that the linc-SPRY3 RNAs are important 
for cellular response to IR as statistically significant changes were seen in cell viability and 
apoptosis (Fig. 3). In vivo experiments further confirmed these observations as knockdown of the 
lncRNAs promoted radioresistance in the NSCLC cellular phenotype.  
 
Additionally, we have provided significant evidence that these lncRNAs could act as  
competing endogenous RNAs (ceRNAs) for the RNA binding protein IGF2BP3 (also known as 
IMP3) (Fig. 4). In normal tissues, IGF2BP3 is primarily expressed during embryonic development, 
but its overexpression has been associated with numerous cancer types and as such has been 
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classified as an oncogenic protein (48,55). More specifically, it has been previously shown that 
IGF2BP3 is upregulated across all NSCLC subtypes and that its loss leads to increased apoptosis 
(56). As a RBP, IGF2BP3 regulates several genes primarily by binding and stabilizing target 
mRNAs in order to increase translation efficiency (48). Two such targets, as mentioned previously, 
are c-Myc and HMGA2. Interestingly, previous studies have shown that downregulation of c-Myc 
results in increased radiosensitivity by promoting apoptosis (49,50). Additionally, while there is 
little to no previous evidence of a role for HMGA2 in radiation sensitivity, there are multiple 
studies characterizing its relationship to apoptosis (52-54). Moreover, HMGA2 expression is 
controlled by the transcription factor c-Myc (57) which suggests a potential feedback loop 
interaction. Based on our data, we propose the hypothesis that the presence of the linc-SPRY3-
2/3/4, following IR, sequester IGF2BP3 and inhibit the stabilization of c-Myc and HMGA2 which 
results in downregulation of their proteins making the cells more vulnerable to apoptosis following 
IR. On the other hand, we cannot discard the possibility that the linc-SPRY3 transcripts could 
regulate the expression of c-MYC and HMGA2 at the transcriptional level. Lastly, DNA-FISH 
analysis, microarray analysis, and  RNA-seq revealed a negative correlation between loss of the Y 
chromosome and loss of linc-SPRY3-2 expression and overall patient survival, respectively (Fig. 
5). This establishes, for the first time, a connection between the Y chromosome, the linc-SPRY3 
transcripts, and how male NSCLC cells respond to radiation. 
 
In conclusion, we show for the first time the importance of a Y chromosome derived group 
of lncRNAs in regulating male NSCLC radiation response. We provide significant evidence that 
the linc-SPRY3-2/3/4 transcripts are potentially tumor suppressive and their loss via LOY 
contributes to radioresistance in NSCLC cells. We also provide evidence that these lncRNAs 
directly bind IGF2BP3, preventing it from stabilizing its targets HMGA2 and c-Myc which we 
believe contributes to the radiosensitive phenotype. Moreover, we show a trending negative 
correlation between Y chromosome and linc-SPRY3 loss and patient survival. We do, however, 
acknowledge the limitations of this study. More data is needed to fully validate a clinically relevant 
relationship of both the Y chromosome and linc-SPRY3-2/3/4 family in NSCLC patient survival. 
It would also be interesting to investigate the behavior of these lncRNAs in an acquired resistance 
model, utilizing isogenic radioresistant cell lines generated from radiosensitive parental cells like 
the H460 and WVU-Ma-0005 cell lines. 
 57 
 
Considering the dose dependent response in expression observed in the radiosensitive cell 
lines, we speculate that these nuclear lncRNAs could be involved in apoptosis and/or the DNA 
damage response and repair pathway. We also hypothesize that linc-SPRY3 transcripts and the Y 
chromosome could eventually be used as biomarkers for cancer radiotherapy. Overall, we believe 
that more attention should be given to the Y chromosome, as many of its non-coding regions 
remain uncharted. This has left a vast untapped resource in the realm of cancer cell biology that 
has yet to be explored.   
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VII. Figure Legends 
Figure 1: Microarray analysis reveals a family of Y chromosome, radiation inducible long 
non-coding RNAs.  
(A) Y chromosome schematic obtained from the UCSC Genome Browser demonstrating the 
genomic location of the three linc-SPRY3 transcripts in the DYZ1 region (also known as lnc-
BPY2C). (B) Linc-SPRY3 transcripts sequences. Highlighted sections indicate pentanucleotide 
repeats. The black underline regions show the sequences target by the shRNAs and siRNAs used 
in this study (C) qRT-PCR analysis of the linc-SPRY3 family members validating the radiation 
induced expression in H460 cells. Time course expression following a single dose of 8Gy IR of 
linc-SPRY3-2/3/4. GAPDH mRNA was used to normalize qRT-PCR analysis. Error bars represent 
SD from the mean (n=3). 
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Figure 2: Radiation sensitive and radiation resistant NSCLC cell lines show significant 
difference in the expression of the linc-SPRY3 family due to Y chromosome loss. 
qRT-PCR analysis of (A) HBEC and radiosensitive cell lines (B) H460, (C) H820, and (D) WVU-
Ma-0005, demonstrates a dose dependent response in linc-SPRY3 expression. qRT-PCR analysis 
of radioresistant cell lines, (E) A549, (F) H1299, (G) Ma-ALK-0001, shows little to no change in 
linc-SPRY3 expression. Values are relative to untreated control (0Gy) of the same collection day. 
GAPDH mRNA was used to normalize qRT-PCR analysis. Error bars represent SD from the mean 
(n=3). (H-N) Cytogenetic analysis via DNA-FISH reveals complete loss of the Y chromosome in 
the radioresistant cell lines while HBECs and radiosensitive cell lines retain their Y chromosome. 
Images are a representative from 200 counted cells. 
 
Figure 3: Linc-SPRY3 RNAs are important for cell survival following 8Gy irradiation 
(A)  RT-PCR analysis shows expression of the linc-SPRY3 family in BAC RP11-88F4 
nucleofected A549 cells. (B-C) Overall cell viability and apoptosis were measured by flow 
cytometry. Y chromosome BAC nucleofection results in lower cell viability and increased 
apoptosis compared to control in radioresistant A549 cells after 8Gy IR. (D, G) qRT-PCR analysis 
reveals effective knockdown of the linc-SPRY3 RNAs in  radiosensitive cell lines H460 and 
WVU-Ma-0005. (E-F, H-I) Knockdown of the linc-SPRY3 family in both H460 and WVU-Ma-
0005 cells using two different shRNAs against linc-SPRY3 family (sh1 and sh2) resulted in better 
overall cell viability and increased resistance to apoptosis when compared with shControl (shCtrl) 
after 8Gy IR. Untreated controls are provided to demonstrate baseline cell viability and apoptosis. 
(J-K) Tumor growth delay assay (n = 3) shows higher resistance to radiation of the sh1 tumors 
relative to shCtrl tumors in both H460 and WVU-Ma-0005 animal experiments. Mean relative 
tumor volumes are plotted. Error bars represent SD from the mean (n=3) (A-I). Error bars represent 
SD from the mean of 3 mice in each group (J-K). Untreated tumor controls are represented in 
Supplementary Fig. S9. ANOVA was used to determine statistical significance. 
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Figure 4: The linc-SPRY3 family act as molecular sponges for IGF2BP3 preventing it from 
stabilizing HMGA2 and c-Myc.  
(A) Predicted binding motifs (using WebLogo3) of IGF2BP3 in each linc-SPRY3 transcript. (B) 
RT-PCR amplification of the recovered RNA from IGF2BP3 CLIP assays of untreated (No 
Radiation) or treated (8 Gy) H460 cells. The lanes are as follows (from left to right): Input RNA, 
IgG Supernatant, IGF2BP3 Supernatant, IgG Immunoprecipitation, IGF2BP3 
Immunoprecipitation. HMGA is provided as a positive control and GAPDH as a negative control 
for IGF2BP3 interaction. Gel images are a representative of duplicate experiments. (C) 
Actinomycin D (ActD) RNA stability assays show rapid degradation of HMGA2 and c-Myc 
mRNA when the linc-SPRY3 RNAs are present (A549_88F4 siCtrl). siRNA knockdown rescues 
mRNA stability of HMGA2 and c-Myc (A549_88F4 siPool). GAPDH is provided as a negative 
control. Error bars represent SD from the mean (n=3) 
 
Figure 5: The DYZ1 region of the Y chromosome and the linc-SPRY3 family show negative 
correlations with patient survival. 
(A-D) Representative images from the imaging analysis performed on 30 cores from a lung cancer 
tissue array to determine the percentage of Y chromosome DYZ1 positive cells. Y chromosome 
positive cells are red and Y chromosome negative cells are purple. (E) Kaplan-Meier analysis of 
the 30 cores analyzed for Y chromosome DYZ1 positivity. (F) Survival curves for NSCLC male 
patients (GSE74777). 
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IX. Supplemental Information 
 
Supplementary Table S1 
LncRNA  Gene Transcript Cluster ID Fold Change ANOVA p-value FDR p-value 
AF092843 TC12002437.hg.1 4.26 0.000022 0.000414 
linc-OCIAD2-1  TC04002544.hg.1 4.17 0.000007 0.000159 
linc-LOC100132288-2  TC21000805.hg.1 3.88 0.000028 0.000496 
linc-SPRY3-4  TC0Y000283.hg.1 3.17 0.162867 0.440186 
linc-SPRY3-3  TC0Y000284.hg.1 3.04 0.09976 0.322973 
BC036485  TC03003223.hg.1 2.74 0.00001 0.000226 
linc-POTED-9  TC21000560.hg.1 2.73 0.071853 0.258323 
linc-ZNF25-4  TC10002568.hg.1 2.55 0.005738 0.036702 
linc-CDH6-5  TC05002316.hg.1 2.49 0.000003 0.000094 
linc-FCGR1B-9 TC01005759.hg.1 2.43 0.000086 0.001207 
BC057782  TC09002209.hg.1 2.3 1.12E-07 0.000007 
AK025384  TC16001789.hg.1 2.15 9.63E-07 0.000037 
linc-SPRY3-2  TC0Y000285.hg.1 2.13 0.187334 0.479358 
AK054573  TC17002305.hg.1 2.11 0.000099 0.001344 
S81264 TC17002307.hg.1 2.11 1.37E-08 0.000002 
AF085983  TC02004620.hg.1 2.07 6.60E-09 9.36E-07 
NR_027299  TC03002817.hg.1 2.07 1.70E-07 0.00001 
AX750576  TC17002329.hg.1 2.03 7.14E-07 0.000029 
linc-NAA35-2 TC09002052.hg.1 2.01 0.000004 0.000112 
NR_026866  TC03002367.hg.1 1.93 7.03E-07 0.000029 
BC033874 TC01006039.hg.1 1.89 0.000209 0.002472 
BC061593  TC05002175.hg.1 1.89 3.79E-09 6.30E-07 
BX537506  TC08002539.hg.1 1.89 5.12E-09 7.85E-07 
AY665470  TC12002292.hg.1 1.89 8.29E-10 2.12E-07 
NR_044995  TC13001319.hg.1 1.85 2.64E-07 0.000013 
BX647541  TC16001788.hg.1 1.85 2.70E-10 1.07E-07 
AF172940 TC02003138.hg.1 1.83 1.90E-08 0.000002 
M73837  TC10002092.hg.1 1.83 0.000549 0.005416 
linc_luo_466 TC06002911.hg.1 1.81 0.313329 0.633221 
EF210211 TC07002321.hg.1 1.81 2.36E-08 0.000002 
AF086401  TC07002818.hg.1 1.81 0.000009 0.000209 
NR_028034   TC10002196.hg.1 1.79 5.54E-07 0.000024 
S47380  TC04002187.hg.1 1.78 0.003206 0.022936 
NR_033258  TC02004623.hg.1 1.77 1.23E-08 0.000001 
linc-C7orf66-2  TC07003112.hg.1 1.77 0.000043 0.000692 
AK021785  TC11003067.hg.1 1.77 7.20E-07 0.000029 
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CR542200  TC04002080.hg.1 1.76 0.000565 0.005548 
AF321824  TC08002559.hg.1 1.75 0.000075 0.001082 
BC040985 TC03002416.hg.1 1.74 1.03E-08 0.000001 
S83545  TC05002797.hg.1 1.74 2.33E-07 0.000012 
NR_027140  TC08002257.hg.1 1.74 0.000011 0.000245 
AY820830  TC06003084.hg.1 1.73 6.40E-08 0.000005 
ENST00000537998 TC12002680.hg.1 1.73 0.000002 0.000054 
linc-GRM1  TC06003110.hg.1 1.72 0.000749 0.006988 
NR_036684  TC16001604.hg.1 1.71 5.09E-08 0.000004 
linc-ZNF626-1  TC19002390.hg.1 1.71 0.017129 0.087898 
linc-FCGR1B-6  TC01005756.hg.1 1.7 0.001 0.008855 
AK057151 TC07002222.hg.1 1.7 0.000029 0.0005 
NR_036431  TC0X002160.hg.1 1.69 0.002693 0.019933 
linc-ELTD1-11 TC01005583.hg.1 1.67 0.000003 0.00008 
AJ420500  TC06002615.hg.1 1.67 0.000453 0.004635 
NR_027783  TC0X001624.hg.1 1.67 9.46E-08 0.000006 
AK056630  TC07002487.hg.1 1.66 0.013477 0.073006 
AF007193 TC07002493.hg.1 1.65 0.020372 0.100857 
X55077  TC12002396.hg.1 1.64 2.21E-08 0.000002 
AF086343 TC10002011.hg.1 1.63 0.000542 0.005365 
linc-NBPF9-3  TC01006417.hg.1 1.62 0.000033 0.000559 
AK026778  TC02004622.hg.1 1.61 0.000051 0.000787 
D87470  TC11003246.hg.1 1.61 0.000013 0.000278 
uc001gla.1  TC01004846.hg.1 1.6 0.000001 0.000044 
AK123435  TC01005963.hg.1 1.6 0.000898 0.008093 
linc_luo_506  TC07002386.hg.1 1.6 0.00063 0.006047 
BC014926  TC14001766.hg.1 1.6 3.72E-07 0.000018 
AF049885  TC04002887.hg.1 1.59 3.44E-11 3.00E-08 
L12143  TC06002402.hg.1 1.59 1.06E-07 0.000007 
BC006127 TC12002414.hg.1 1.59 0.003111 0.022429 
NR_003136  TC15002630.hg.1 1.59 0.028675 0.131215 
linc-C1QTNF1-5  TC17002394.hg.1 1.59 1.60E-07 0.000009 
M34339  TC17002615.hg.1 1.59 0.000753 0.007018 
L26969  TC05003038.hg.1 1.58 0.000017 0.00033 
linc-PPP2R3B-2 TC0X001951.hg.1 1.58 0.294838 0.61422 
linc-TMEM88B-1  TC01004129.hg.1 1.57 0.133895 0.390383 
AK094779  TC01004217.hg.1 1.57 0.000004 0.000117 
linc-C5orf43-1  TC05003020.hg.1 1.57 0.000192 0.002313 
NR_037623 TC15002291.hg.1 1.57 0.002041 0.015904 
linc-FOXF1-4  TC16001680.hg.1 1.57 0.133609 0.389902 
NR_036501  TC07002242.hg.1 1.56 0.000008 0.000193 
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AK125888  TC08002503.hg.1 1.56 0.000873 0.007912 
AK026716  TC0X001693.hg.1 1.56 0.003961 0.027195 
X69207  TC11002905.hg.1 1.56 0.004246 0.028736 
U80232  TC06002661.hg.1 1.55 0.00013 0.00168 
AF085942  TC07002488.hg.1 1.55 0.048528 0.194753 
linc-MAOA-2  TC0X001666.hg.1 1.55 0.005446 0.035176 
linc-ZNF25-1  TC10002567.hg.1 1.54 0.017415 0.088988 
AF029311 TC17002638.hg.1 1.54 0.000007 0.00016 
linc-NBPF9-7  TC01004681.hg.1 1.53 0.02606 0.121819 
AK056155  TC01004870.hg.1 1.53 0.000009 0.0002 
AF086224 TC01006049.hg.1 1.53 0.01442 0.076986 
AF113008  TC08001925.hg.1 1.53 0.185875 0.477108 
DQ088985  TC15002378.hg.1 1.53 0.013512 0.073148 
linc_luo_524  TC07003197.hg.1 1.52 0.000422 0.004397 
CR626472  TC11003277.hg.1 1.52 0.000022 0.000402 
OTTHUMT00000328528 TC02003287.hg.1 1.51 0.122727 0.369369 
uc002vef.2  TC02003799.hg.1 1.51 1.17E-09 2.61E-07 
AK311114  TC06003872.hg.1 1.51 2.95E-10 1.13E-07 
NR_002211  TC17002074.hg.1 1.51 0.000358 0.00385 
uc002jdy.1 TC17002746.hg.1 1.51 0.000001 0.000043 
NR_027882  TC19002194.hg.1 1.51 0.000001 0.000046 
linc_luo_333  TC01004684.hg.1 1.5 0.004694 0.031159 
linc_luo_1805  TC01005654.hg.1 1.5 0.190779 0.484473 
NR_028308  TC02004133.hg.1 1.5 0.002093 0.016232 
uc011hki.1  TC06002389.hg.1 1.5 0.336701 0.656202 
AJ459855  TC06003566.hg.1 1.5 0.188301 0.480849 
BC040303  TC06003704.hg.1 1.49 0.000003 0.000093 
linc-ANKRD20A1-12  TC09001955.hg.1 1.49 0.000091 0.001259 
AL049370  TC10002117.hg.1 1.49 0.013632 0.073681 
BC033316  TC01004199.hg.1 -1.49 0.001105 0.009591 
linc-CCDC80-2  TC03003030.hg.1 -1.49 0.029249 0.133067 
DQ459608  TC04002625.hg.1 -1.49 3.08E-07 0.000015 
linc-ZFP57-2  TC06003570.hg.1 -1.49 2.17E-07 0.000012 
AL833059  TC09002185.hg.1 -1.49 0.003138 0.022584 
NR_027280  TC19002180.hg.1 -1.49 0.000034 0.000579 
AY211918  TC01004531.hg.1 -1.5 0.005576 0.035907 
NR_027157 TC12003031.hg.1 -1.5 0.000005 0.000129 
NR_036462  TC01004175.hg.1 -1.51 0.002087 0.016199 
linc-PPIAL4F-5 TC01005804.hg.1 -1.51 0.002016 0.015731 
linc-AADAT-2 TC04002818.hg.1 -1.51 0.235108 0.545485 
D86978  TC07002605.hg.1 -1.51 0.000018 0.000342 
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CR601575 TC11003430.hg.1 -1.51 0.002021 0.015764 
linc_luo_778  TC13001572.hg.1 -1.51 0.000666 0.006327 
NR_028323  TC02004129.hg.1 -1.53 0.000013 0.000272 
uc002eea.2  TC16001872.hg.1 -1.53 0.013494 0.073083 
CR598627  TC07002576.hg.1 -1.54 0.001751 0.013987 
linc-NBPF9-14  TC01004671.hg.1 -1.55 0.000047 0.000741 
L13804  TC13001407.hg.1 -1.55 0.013766 0.074222 
NR_033302  TC01004881.hg.1 -1.56 0.005702 0.036507 
NR_037669  TC07002868.hg.1 -1.56 0.009795 0.056413 
linc-GRAMD1B-1 TC11002922.hg.1 -1.56 6.54E-07 0.000027 
uc010hrq.1  TC03003054.hg.1 -1.57 0.007241 0.044382 
Z70768  TC09002468.hg.1 -1.57 0.000078 0.00112 
CR614667  TC06003537.hg.1 -1.58 0.001279 0.010817 
CR595160  TC14001578.hg.1 -1.58 0.000315 0.003473 
NR_026778  TC01006247.hg.1 -1.59 0.011804 0.065552 
U87167  TC0X001927.hg.1 -1.59 0.001597 0.012952 
BC005221  TC10002200.hg.1 -1.6 0.020556 0.101559 
NR_003105  TC15002245.hg.1 -1.6 0.013286 0.07218 
AB451448  TC01005350.hg.1 -1.61 0.000522 0.005197 
DQ470079  TC04002368.hg.1 -1.61 0.000775 0.007175 
linc-DHRS7B-5  TC17002115.hg.1 -1.61 0.010224 0.058437 
NR_036608  TC17002792.hg.1 -1.61 0.00002 0.000372 
linc-ZNF791-1  TC19001991.hg.1 -1.62 0.098672 0.320528 
linc-ZNF131-4  TC05002352.hg.1 -1.63 0.000329 0.003603 
ENST00000499627 TC01005364.hg.1 -1.65 0.000279 0.003145 
CR595668  TC0X001880.hg.1 -1.65 1.67E-08 0.000002 
BC105606 TC10002226.hg.1 -1.65 0.000159 0.00198 
AF333388  TC01006221.hg.1 -1.66 7.35E-07 0.00003 
NR_034041  TC17002724.hg.1 -1.67 0.00003 0.000515 
AL833658  TC06003604.hg.1 -1.68 0.004967 0.032589 
S70154  TC06003166.hg.1 -1.69 0.000541 0.005356 
linc-PDZD7  TC10002799.hg.1 -1.7 0.0004 0.004211 
NR_026978  TC18000697.hg.1 -1.7 0.003329 0.023636 
D83986  TC22001090.hg.1 -1.73 4.21E-08 0.000003 
NR_024526  TC02003640.hg.1 -1.74 0.005067 0.033116 
D82345  TC0X002162.hg.1 -1.74 0.000219 0.00258 
AF086045  TC18000953.hg.1 -1.74 0.012803 0.070056 
NR_033142  TC01005497.hg.1 -1.77 0.000836 0.007633 
CR616786  TC06003578.hg.1 -1.81 0.00002 0.000374 
DQ648894 TC02003219.hg.1 -1.85 0.011223 0.063019 
uc010fnw.1  TC02003637.hg.1 -1.9 0.023072 0.110835 
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uc002ufj.3  TC02003679.hg.1 -1.99 0.010288 0.058714 
DQ656056  TC09002285.hg.1 -2.04 0.000016 0.000318 
AK307939  TC10002686.hg.1 -2.07 0.000458 0.004673 
uc002zdj.1  TC21000762.hg.1 -2.2 2.53E-07 0.000013 
CR622106  TC12002644.hg.1 -2.34 0.000154 0.001929 
AK021443  TC10002227.hg.1 -2.51 0.011029 0.062107 
 
Supplementary Table S1: Differentially expressed lncRNAs after IR in H460 cells 
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Supplementary Figure S1 
 
Supplementary Figure S1: Microarray analysis of differentially expressed lncRNAs after IR 
in NSCLC cell line H460. Heat map of lncRNAs microarray data comparing H460 no radiated 
(Control) against H460 irradiated (7Gy) after 24 hrs. Only lncRNAs differentially expressed are 
shown 
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Supplementary Figure S2 
>AK128024.1 Homo sapiens cDNA FLJ46143 fis, clone TESTI2053561 (1986bp) 
(with AY598347.3 fragment is called AK47) 
CCATTCCTTTCGAGCCCTTTCAATTTGAGTCCATTCCTTTCCAGTCCATTTCACTCCAGTCCATTACTAT
CCATTCCATACCATTCCATCCCATTCCATTCCATTCCATTCCATTCCATTCCATTCCATTACATTCCATT
CCATTCCATTGCATTCAATTCCATTCCATTCCATTGCACTGCACTCCATTCCATTACATTCTACTCTATC
TGAGTCGGTTTTATTGCATTAGATTCTATTCCATTGGATTACTTTCCATTCGATTACCTTCCATTCATGT
ACATTCCATTCCAGTCAATTACATTCGAGTTCATTACATTACATTCCAGTATATTCCATTGTATTCGATC
CCATTCCTTTCAATTCCATTTCATTCGACTCCATTATATTCGATTCCATTCCACTCGAATCCATTCCATT
AGAGGACATTCCATTCCAATGCATTCCTTTCCATTCCATAGCATTCCATTGCATTCGATTCCATTCCATT
TGATGCCATTCCATTTGATGCCATTCCATGACATTCCATTCCATTCGAGTCCATTCCGTTCCAATTCATT
CCATTCCGTTTCATGAAATTCGAGTCCTTTCCAGTACATTTCATTCCAATCCCATCCAATCCAATCTACT
CCATTCAATTCCTTTCCATTCCATTTGATTAGATTCCATTGACTTGATTCCATTCAGTTTGATTCCATTC
CGTGAAATTTCGTTCCATTCTATTCCATTGCATTACTTTCCATTCAATTCCATTCCATTTCATTTCAGTC
CATTCGCTTCCTTTCCTTTCGATTCAATTCCATTTGATTCCACTCCATTCTATGCGATTTCATTCCAATC
GATTCAATTCCATTCGATGACATTCCTTTCGTTTCCATTCCATTCGAGTCCATTCAATTTGAGCATTCGT
GTCCATTCTATTCGAGTCCATTCCATTACCGTCTATTCTATTCCCTTCCATTCCTGTTGATTCAATTTCA
TTCCCTTCCATTCGATTCCTTTCCATTCGATTCCATTCCTTTCCATTCCATTCCATTCGTTCCCACTCCA
TGTGATTTCATTCCATTCCAGTCCATTATATTCGAGTCCACTCCACTCCATTCTATTACATTCAATTCCT
TTTGAGTCCGTTCCATAACACTCCATTCATTTCGATTCCATTTCTTGCCAGTTTTCTTCCATTTTATTCC
ATTCCGTTCGATTCCATTCCATTCGATTGCATTCCATTCGAATCCTTTCCATTCCATTTCATTCCATTCC
TTTCTATTCCATTCCATTTCATTCGATTTGATTCCATTCTGCTCTATTCCATTCAATTCTTTTTCATTCC
ATTCGAATCCTTTCTATTGCAGTCCATTCTATTCGAGTCCATTCCAATCCCTTCCATTCCATTCAATTAC
AGTCCATTCCAATAGATTCCATTCCTTTGCCTTCCATTCGAATCCATTCCATTCTAGTCCATTCCATTTG
AGTCCATTCCATTCCATTCCATTCTATTCCTTTCCAATCCATTCGATTCCATTCGATTCAATTCCATTTG
ATTCTCTTTCATTCTATTTTATTCCATGCCATTTGATTGCATTGCATTCCATTCCGTTTGATTGCAGTCC
ATTCAAGAAAGTTCCATTCCAGTCCATTGCTTTCCAGTCCATTCCATTCCACTCTAGTCTATTCCACTCC
ATTCCTTTCCATTCCATTCCATACTATTCCATTCCATTCCTTTGCATTCCGTTTCCAATCTATTCGAGTC
CATTGCATTCCAGTCCAATCCATTCGATTACATTCCTTTTGATTCCCTGCCAGTCGATTGCATTGCATAC
TAGACCATTCCAAAGGAGTCCATTCCATTCTATCTCAACACTTTCCATTCCACTCTGTTCGAGTCCATTC
CATTCCAGTCCATTTAATTCAAGGGCATTCCATTCCATTCCATTCTATTCCATTCCATTCCATTTCATAT
TATTCCATTCCATTCAATTCCATCTCTCCAGATGATTCCATTCCATTCTATACCATTGCTCTCTGTTCCA
TTCCATTCCATCTGTCTCCATTCCTTTCGTTTCGATTCCTTTCCATTCCATTCCATTACATTTGATCCTA
TTTTATTAAATTGCATTCTATTCGAGTGATTTCCATTCGAGTCCTTTCCATTCGATTCCATTCCCCACTG
ACGCCGGCGCTACTTACAGTTGGCGGGGCAAAAAAAAAAAAA 
Lnc-SPRY3-2 
Lnc-SPRY3-4 
AY598347.3 sequence (591-816) 
Splicing region 
 
>AY598346.2 Homo sapiens heterochromatic block map Yq12 transcribed 
DYZ1 sequence mRNA, partial sequence (1441) 
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GGTTCCGTACGATTCCATTCCTTTGGAATCCATTCCATTGGAGTCCATTCACTTCCAGAACATTCCATTC
CAGTCGAATCCATTCGAGTACATTCCATTCCGTGGCTGTCCATTCCATTCCGTTTGATGCCATTCCATAC
GATTCCATTCAATTCGAGACCATTCTATTCCTGTCCATTCCTTGTGGTTCGATTCCATTTCACTCTAGTC
CATTCCATTCCATTCAATTTCATTCGACTCTATTCCGTTCCATTCAATTCCATTCCATTCGATTCCATTT
TTTTCGAGAACCTTCCATTACACTCCCTTCCATTCCAGTGCATTCCATTCCAGTCTCTTCAGTTCGATTC
CATTCCATTCGTTTCGATTCCTTTCCATTCCAGCCCATTCCATTCCATTCCATTCCTTTCCTTTCCGTTT
CATTAGATTCCATTGCATTCCATTTCATTCAATTCAATTCCGTGCTATTCAATTTGATTCATTTCCATTT
AATTCCATTCCATTAGATTCCATTCCGTACGATTCCATTCCTTTGGAATCCATTCCATTGGAGTCCATTC
ACTTCCAGAACATTCCATTCCAGTCGAATCCATTCGAGTACATTCCATTAAAGTTCATAACATTCTAATA
CATTCCATTCCATTGCATTCCATTCCATTCCATTCGATGCCATTCGATTCCATTCCATGCCAAATCATTG
CATTCCTTTCCATTCCGTTCCTATCAATTCCATTCCATTCGATTTAGTTCGATTCTATTCACTTCCATTC
CATTCGATTCCATTCCATTGGAGTCAATTCCTTTCGACACCCAGCCTTTCCAGTCAATGATTTTGGATTC
CATTTTTTTGCATTCCATTACATTCTATGACATTCGATTCCGTTTCATTGCATTCCATTCCATACATTTT
TATTCCATTCGAGACCGTAGCATTCCACTTTATTCCAGGCCTGTCCATTACACTACATTCCCTTCCATTC
CAATGAATTCCATTCCATTCCAATCCATTCCTTTCCTTTCGCTTGCATTCCATTCTATTCTCTTCTACTG
CATACAATTTCACTCCATTCGTTCCCATTCCATTCAATTCGATTCCACTCAATTCCATTCCATTTGTTTC
CATTCTCTTCGATTCCATTTCTTTATATTCCATGCCATTCGATTCCATTCTATTGGATTGCATTACATTC
GTGTTCATTCCATTCCAGACCATTCCATTTGACTCCATTCCTTTCGAGCCCTTTCAATTTGAGTCCATTC
CTTTCCAGTCCATTTCACTCCAGTCCATTACTATCCATTCCACACCATTCCATTCCATTCCATTCCATTC
CATTCCATTCCATTCCATTCCATTCCATTCCATTCCATTCCATTCCATTCCACTGCACTGCACTGCAGTC
GGACTACGCGAGTGAACTTCCCTAAAAAAAAAAAAAAAAAA 
 
Lnc-SPRY3-3 
Splicing region 
 
Supplementary Figure S2: Overlapping sequences between linc-SPRY3-2/3/4 and clones 
AY598347.3 and AY598346.2 
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Supplementary Figure S3 
 
 
 
 
 
 
 
Supplementary Figure S3: Virtual 
northern blot analysis of linc-SPRY3-2/3/4 
in H460 cells demonstrates potential 
transcript size. (A) Schematic outlining the 
virtual northern blot method. (B) Virtual 
northern blot reveals two large peaks, one at 
~5kb and one at ~1kb. (C) These two peaks 
align when the individual graphs are merged. 
Similar peaks are seen when a second set of 
primers for linc-SPRY3-2 and linc-SPRY3-3 are used. GAPDH was used as a control.  
  
A 
B 
C 
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Supplementary Figure S4 
Supplementary Figure S4: Clonogenic cell survival assay shows the radiation response of a 
panel of male NSCLC cell lines. Clonogenic cell survival assay shows the relative radiation 
response of a panel of male NSCLC cell lines. Surviving fractions are plotted as a function of dose. 
Error bars represent SD from the mean of triplicate measurements from a single experiment. 
Shown here is a representative of two independent experiments with similar result. 
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Supplementary Table S2 
Cell Line Driver 
Mutation 
Observed 
Radiation 
Response 
% Y Chromosome 
(+) Cells 
H460 KRAS Sensitive 98% 
H820 EGFR Sensitive 100% 
H1299 NRAS Resistant 0% 
A549 KRAS Resistant 0% 
WVU-Ma-
0005 Unknown Sensitive 100% 
Ma-ALK-
0001 ALK Fusion Resistant 0% 
 
Supplementary Table S2: Cell lines used in this study.  
Outline of the observed radiation response of each cell line used in this study color coded to 
correspond with Supplementary Fig. 2. Cytogenetic analysis and quantification were performed 
by the WVU Cytogenetics Laboratory in the Department of Pathology, Anatomy and Laboratory 
Medicine. The percentages shown are a result of the quantification of a population of 200 cells. 
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Supplementary Figure S5 
 
 
 
 
Supplementary Figure S5: Radiation response of cell line panel normalized to the 
housekeeping gene UBC and two additional NSCLC cell lines. (A-G) qRT-PCR analysis of the 
linc-SPRY3 family normalized to UBC. (H-I) qRT-PCR analysis of the linc-SPRY3 family in the 
additional radiosensitive cell line H157 and radioresistant cell line H1650 normalized to GAPDH. 
(J-K) qRT-PCR analysis of the linc-SPRY3 family in the additional radiosensitive cell line H157 
and radioresistant cell line H1650 normalized to UBC. (L-M) Y chromosome DNA FISH of H157 
and H1650 cells. 
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Supplementary Figure S6 
 
Supplementary Figure S6: Female NSCLC cell lines show no expression of the linc-SPRY3 
family. qRT-PCR analysis of the linc-SPRY3 family in female NSCLC cell lines (A) H1975 and 
(B) H1819. Cells were plated at equal density and treated with one dose of radiation (2Gy, 4Gy, 
or 8Gy) and collected 72 hours after treatment. Values are relative to untreated control of the same 
collection day (0Gy). GAPDH mRNA was used to normalize qRT-PCR analysis. Error bars 
represent SD from the mean of triplicate experiments. 
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Supplementary Figure S7 
 
 
 
Supplementary Figure S7: Cell fractionation of radiosensitive cell lines reveals nuclear 
localization of the linc-SPRY3 family.  qRT-PCR analysis of the linc-SPRY3 family in 
fractionated (A) H460 and (B) WVU-Ma-0005 cell lines. The dotted line represents the total 
relative RNA of each experiment. Mature β-Actin mRNA was used as a cytoplasmic control and 
U6 small nucleolar RNA was used as a nuclear control. Error bars represent SD from the mean of 
triplicate measurements from a single experiment. Shown here is a representative of three 
independent experiments with similar result. Normalization was done using C. elegans total RNA 
as an exogenous spike for the amplification of worm specific ama-1 gene. (C) Coding probability 
(CP) scores of the linc-SPRY3-2/3/4 showing no coding probabilities for these lncRNAs (a CP of 
0.364 and above is considered a coding RNA). Coding-Potential Assessment Tool (CPAT) was 
used for these calculations. 
 
  
Sequence Name RNA size ORF size Ficket Score Hexamer Score Coding Probability
LINK-SPRY3-2 776 300 0.6237 -0.237668123 0.010878132
LINC-SPRY3-3 211 201 0.6739 -0.173233267 0.006943647
LINC-SPRY3-4 204 0 0 0 0.000300644
coding probability (CP) cutoff: 0.364
C 
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Supplementary Figure S8 
 
 
Supplementary Figure S8: PCR of the pBACe3.6 plasmid backbone in A549 cells 
Lane 1: A549 Parental cells, Lane2: A549 cells nucleofected with the empty vector pBACe3.6, 
Lane 3: A549 cells nucleofected with the BAC clone RP11-88F4. GAPDH is provided as a loading 
control. DNA was extracted using the Thermo Scientific GeneJET Genomic DNA Purification Kit 
(#K0722) following the manufacturers protocol for adherent cells. PCR was run using the 
SsoAdvanced Universal SYBR Green Supermix (Bio-Rad, 172-5271). PCR products were 
resolved on a 1% agarose gel with ethidium bromide. 
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Supplementary Figure S9 
 
Supplementary Figure S9: In vivo study scheme and untreated controls for the tumor growth 
delay assays. (A) Schematic detailing the tumor growth delay assay. (B and C) Representative 
images of ultrasound measurements utilized in determining tumor volume and depth respectively. 
(D) Tumor growth delay assay with untreated controls for H460 shCtrl and sh1 cells. (E) Tumor 
growth delay assay with untreated controls for WVU-Ma-005 shCtrl and sh1 cells. 
 
  
A B C 
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Supplementary Figure S10 
 
Supplementary Figure S10: siRNA knockdown of linc-SPRY3 RNAs in A549 cells 
nucleofected with the BAC clone RP11-88F4. Representative replicate from triplicate 
experiments. Error bars represent SD from the mean of 3 technical replicates. 
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Supplementary Figure S11 
 
Supplementary Figure S11: Representative images of DYZ1 fluorescent in situ hybridization 
in tissue microarrays. (A-C) Images taken of male cores from the lung cancer tissue microarray. 
(D-F) Images taken of female cores from the lung cancer tissue microarray. (G) Image taken of a 
core from the testis tissue microarray as a positive control. (H) Image taken of a core from a 
cervical cancer tissue microarray as a negative control. (I) Survival curves for NSCLC male 
patients (GEO GSE81089) which express and do not express linc-SPRY3-2. P-value by log rank 
test. 
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Supplementary Table S3 
  
   
 
shRNA/siRNA Sequences 
  
ID Target Sequence Hairpin oligo sequences 
sh1 
GAAUCCAUUCCA
UUAGAGGAC 
FWD 
CCGGGAATCCATTCCATTAGAGGACCTCG
AGGTCCTCTAATGGAATGGATTCTTTTTG 
linc-SPRY3-2 REV 
AATTCAAAAAGAATCCATTCCATTAGAGGA
CCTCGAGGTCCTCTAATGGAATGGATTC 
sh2 
GCAUUCCAUUA
CAUUCUAUGA 
FWD 
CCGGGCATTCCATTACATTCTATGACTCG
AGTCATAGAATGTAATGGAATGCTTTTTG 
linc-SPRY3-3 REV 
AATTCAAAAAGCATTCCATTACATTCTATG
ACTCGAGTCATAGAATGTAATGGAATGC 
For cloning: 
AgeI/EcoRI 
 
 
ID Target Sequence siRNA sequences 
si-linc-SPRY3-2 
GAAUCCAUUCCA
UUAGAGGAC 
5’-GTCCTCTAATGGAATGGATTC-3’ 
si-linc-SPRY3-3 
GCAUUCCAUUA
CAUUCUAUGA 
5’-TCATAGAATGTAATGGAATGC-3’ 
si-linc-SPRY3-4 
GAGUCCGUUCC
AUAACACUCC 
5’-GGAGTGTTATGGAACGGACTC-3’ 
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Supplementary Table S4 
 
 
  
qRT-PCR/PCR Primer Sequences  
Primers Sequence (5'-3') 
linc-SPRY3-2 FWD CATCCAATCCCATCTACTCCAT 
linc-SPRY3-2 REV TAGAATGGAACGAAATTTCACG 
linc-SPRY3-3 FWD TCCAGTCAATGATTTTGGATTC 
linc-SPRY3-3 REV GGAATAAAGTGGAATGCTACGG 
linc-SPRY3-4 FWD GTCCACTCCAC CCATTCTA 
linc-SPRY3-4 REV CGAACGGAATGGAATAAAAT 
linc-SPRY3-2 FWD (2nd set) TCCAGTCCATTTCACTCCAG 
linc-SPRY3-2 REV (2nd set) TGCAATAAAATCGACTCAGATAGA 
linc-SPRY3-3 FWD (2nd set) CCGTTTCATTGCATTCCA 
linc-SPRY3-3 REV (2nd set) GCAAGCGAAAGGAAAGGA 
GAPDH FWD CCACTCCTCCACCTTTGAC 
GAPDH REV ACCCTGTTGCTGTAGCCA 
UBC FWD 
UBC REV 
GATTTGGGTCGCAGTTCTTG 
CCTTATCTTGGATCTTTGCCTTG 
Beta-Actin FWD AGCACAGAGCCTCGCCTTT 
Beta-Actin REV CCACGATGGAGGGGAAGAC 
U6 FWD GTGCTCGCTTCGGCAGCACATAT 
U6 REV AAAAATATGGAACGCTTCACGAA 
C. elegans ama-1 FWD GGAGCTCGAGTGGATCTTCG 
C. elegans ama-1 REV GCGCAGAGAGTATCCTGGAC 
pBACe3.6 FWD 
pBACe3.6 REV 
TTGAGTCTGCAAAAGGACTTGA 
GATTGATGTGTCATCAGCGTCT 
HMGA2 FWD 
HMGA2 REV 
GCCCCAGGAAGCAGCAA 
TCGAACGTTGGCGCCCCCTA 
C-MYC FWD 
C-MYC REV 
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Ultra-Violet Radiation Crosslinking and Immunoprecipitation (CLIP) 
 
Reagents 
 
NET-2 Buffer (Nuclease-free) stored at 4C  
(150 mM NaCl; 0.05% NP-40; 50 mM Tris-HCl, pH7.4)      500 
mL 
2 M Sodium Chloride (NaCl)        37.5 mL 
Surfact-Amps NP-40 (10% Nonidet P-40)        2.5 mL  
1 M Tris, pH 7.4 (tris(hydroxymethyl)aminomethane)                    25 
mL 
Bring volume up to 500 mL with Nuclease-free water, autoclave 
Add Protease inhibitor and RNasin just before using 
 
Proteinase K Buffer (Nuclease-free) 
(50 mM Tris-Cl, pH 7.5, 5 mM EDTA, 1.5% SDS, 300 mM NaCl)    100mL 
1 M Tris-Cl (Tris(hydroxymethyl)aminomethane hydrochloride), pH 7.5      5 mL 
0.5 M EDTA (Ethylenediaminetetraacetic acid)         1 mL 
10% SDS (sodium dodecyl sulfate)        15 mL 
2 M NaCl (Sodium Chloride)         15 mL 
Mix and bring volume up to 100 mL with Nuclease-free water; autoclave. 
 
BSA Solution (Nuclease-free) stored at 4 
(2 mg/mL)          100 mL 
BSA (Bovine serum albumin)       200 mg 
Mix and bring volume up to 100 mL with Nuclease-free water; autoclave. 
 
1X PXL (wash buffer made fresh) 
1x PBS (tissue culture grade; no Mg++, no Ca++)      9.89 mL 
0.1% SDS (0.01 ml of 10% SDS in 0.99 ml water)     0.01 mL 
0.5% sodium deoxycholate (5 mg in 1 ml water)      0.05 
mL 
0.5% NP-40 (4.7 ul in 1 ml water)       0.05 mL 
 
Protocol 
 
1. 72 hours before Day 1 (if using treated cells) 
 Treat cell lines with 8Gy radiation (6cm dishes) 
 Let incubate for 72 hours before beginning. 
 
2. Day 1 – UV X-linking, BCA assay and Bead Prep (complete this for all samples) 
 Aspirate media from cells. Rinse with tissue culture grade PBS, remove, and replace 
PBS. 
 UV irradiate using Stratalinker (On  energy  value  start) with the dish lid off. 
Can irradiate 2 6cm dishes at a time. MUST be on ice. Irradiate one time for 400 
mJ/cm2, rotate the plate 90° and irradiate an additional 200 mJ/cm2. 
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 Collect suspension (scrape) for all dishes, pellet cells at 2500 rpm for 5 min at 4°. 
 Resuspend pellet in (~3x dry volume) of tissue culture grade PBS; quick spin at 4°, 
remove supernatant and freeze pellets at -80° until use. 
 Resuspend each tube of cross-linked lysate using 700 µl of 1X PXL + 300 µl of 
HALT protease. 
 Add 15 µL RNAsin and let sit on ice for 10 min. 
 Add 30 µl of RQ1 DNAse or DNAse 1 (Promega, M6101 or NEB) to each tube; 
incubate at 37° for 5 min, 1000 rpm. 
• Supernatant was collected after 10 min centrifugation at 16,000Xg at 4 C 
• Quantitate protein with BCA assay…100 ug of each lysate was used for IP  
 
*Clip end of pipette tip before pipette beads 
 
 600 µL Protein G-Sepharose beads in 1.5mL tube; wash beads (spin at 4° C for 3 min 
at 1000 rpm, then remove supernatant) 2 times with about 500 µL PXL buffer each 
wash (protein G beads are stored at 4°C).  
 Block Protein G Sepharose beads with 900 uL of 2 mg/mL BSA for 1hr or overnight 
at 4°C (BSA stored at 4°C). 
 
3. Day 2 - Immunoprecipitation 
 Wash beads 2 times with 500uL PXL Buffer each time (Did not add RNasin/PI 
during the washes to save reagents). After last wash, add 600 µL of PXL, 6.0 µl 
HALT, and 15 µl RNasin. 
 Measure out the volume of lysate (100 ug) determined from BCA assay. Divide 
supernatants into 2 1.5mL tubes (2 antibodies – IGF2BP3, Abcam #177942 and IgG, 
Abcam #172730). 
 Preclear lysates by adding 90uL of blocked/washed beads to each lysate; incubate for 
1hr at 4°C on rotator. 
 Spin down precleared beads/lysate at 4°C 1,000 rpm for 3 min (low speed when 
working with beads). 
 Transfer supernatant into new tubes and discard beads used for preclearing; bring up 
to equal volume (500 µl).  
 Add desired antibody to remaining lysates (8 ug antibody/lysate). Incubate for 3 hrs at 
4°C on rotator. 
 Add 50uL of blocked/washed beads to each lysate/antibody tube; Incubate for 1hr at 
4°C on rotator. 
 Spin down lysate/antibody/beads at 4°C 1,000 rpm for 3 min (low speed when 
working with beads). 
 Divide supernatant into 2 tubes (IP supernatant for RNA and protein).  
 Wash pelleted beads 5 times with about 200 uL each wash with NET2-Buffer (Spin 
down beads at 4°C 1,000 rpm for 3 min. add the following volumes of RNasin to 
each wash: 
o Wash 1: 14 uL RNAsin 
o Wash 2: 14 uL RNasin 
o Wash 3: 6 uL RNasin 
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o Wash 4: 3 uL RNasin 
o Wash 5: 3 uL RNasin 
 Take 25% (125uL) of beads for Western Blot analysis -> Spin down beads at 4°C 
1,000 rpm for 3 min.  
o Spin  remove supernatant  resuspend in 50 µl PXL buffer 
o Add 10 µL 5X LSB and boil at 100°C for 5 min to remove protein from beads 
 Spin down remaining 75% (375uL) of beads at 4°C 1,000 rpm for 3 min. Incubate 
beads with Proteinase K Buffer (150ul) (w/ 300 mM NaCl) and 1.5mg/mL proteinase 
K (11.25uL of 20mg/mL) for 30 min at 50°C. 
 Then incubate beads for 60 min at 70°C  (Add 0.5 uL RNasin/sample). 
 RNAs (from beads and supernatant) were recovered with phenol/chloroform 
extraction 
o Add same volume of Phenol-chloroform-isoamyl alcohol/tube. 
o Vortex 20 seconds (10 up and 10 angled). 
o Centrifuge 10 minutes at 11,400 rpm at RT. 
o Transfer aqueous phase to another centrifuge tube w/ 50 µL of 3M Sodium 
Acetate (NaOAc), at pH 5.2. 
o Add 1 mL of 100% Ethanol (precooled to -20˚ C), fill to top of tube, add 1 μL 
of GlycoBlue (15 μg/μL) Store at -20˚ C overnight or for a few days to 
increase yield. 
 
4. Day 3 – Finish RNA extraction 
 Spin down RNA for 15 minutes at 11,400 rpm in micro-centrifuge at 4˚C. 
 Aspirate Ethanol (leave a little). 
 Wash with 500 uL of 75% Ethanol (precooled to -20˚C); don’t shake just add. 
 Spin down for 1 minute at 11,400 rpm. 
 Aspirate Ethanol, remove any remaining with pipette.  
 Re-suspend RNA pellet in 20 μL of Nuclease-Free water (Ambion). 
 DNase treat samples. 
 Collect supernatant. 
 Quantify samples. 
 Store RNA in -80 until use. 
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CHAPTER 3 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
For decades, biomedical research has focused on the central dogma of molecular biology; 
DNA is the blueprint, RNA is the messenger, and proteins are the functional mediators. However, 
thanks to the Encyclopedia of DNA Elements (ENCODE), which determined that <3% of the 
human genome gives rise to functional proteins, this dogma has started to be challenged (1,2). The 
emergence of functional non-coding RNAs (ncRNAs) has revealed that the realm of human 
biology is much more complex than previously thought, and researchers have only begun to scratch 
the surface of their impact in molecular biology and disease. We now know that a single ncRNA 
can function in numerous ways, in numerous pathways, which makes their study imperative to 
understanding human disease (3,4). 
  
 Long non-coding RNAs (lncRNAs) are ncRNAs >200 nucleotides long, lack a functional 
open reading frame, and have emerged as vital regulators of many important genes and signaling 
pathways in human cells. Furthermore, their dysregulation has been implicated in multiple cancer 
types, and current studies are focused around identifying mechanisms of carcinogenesis and their 
potential as biomarkers for cancer diagnosis and/or prognosis (5). Lung cancer is the number one 
cause of cancer related mortality and in late stages is notoriously resistant to therapy (6,7). Our 
group’s overall goal is to elucidate the roles of ncRNAs in regulating radiation therapy responsive 
genes and signaling pathways in an attempt to identify potential therapeutic targets or biomarker 
candidates. Therefore, we set out to investigate potential ncRNAs, specifically lncRNAs, involved 
in lung cancer radiation therapy response. 
 
 Not only have previous studies showed radioresponsive lncRNAs, but many lncRNAs have 
been implicated in the radioresistance of cancers (8,9). A few of the mechanisms identified include 
regulation of anti-apoptotic pathways, DNA damage repair pathways, and promotion of epithelial-
to-mesenchymal transition (EMT). Therefore, in the initial stages of the project presented in 
Chapter 2, we began with a microarray analysis utilizing RNA from a well- known non-small cell 
lung cancer (NSCLC) cell line (NCI-H460) treated with ionizing radiation to identify candidates 
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for study. Not surprisingly, we found hundreds of differentially expressed lncRNAs and among 
the highest upregulated genes we discovered a three-member family; linc-SPRY3-2, linc-SPRY3-
3, and linc-SPRY3-4 (also known as lnc-BPY2C-4, lnc-BPY2C-25, and lnc-BPY2C-2, 
respectively) (Chapter 2, Fig. S1 and Table S1). Unexpectedly, further investigation into the linc-
SPRY3 transcripts on LNCipedia revealed that they were transcribed from the Y chromosome 
(ChY), and to our knowledge, were the first examples of Y chromosome linked lncRNAs (Chapter 
2, Fig. 1A).  
 
 It was determined that the linc-SPRY3 family maps specifically to the DYZ1 region of the 
heterochromatic block of the q arm of ChY. Interestingly, this region has been traditionally 
described as genetically inert, and is characterized by a 3.4 kilobase pentanucleotide tandem repeat 
sequence which can vary in the number of copies from 2000-4000 within the heterochromatic 
block (10). Beyond structural characterizations, investigations into its use in forensics, gender 
verification in sports, or as a tool for monitoring genomic instability in males, there is little known 
about the DYZ1 region (11–14). This is not surprising considering its suggested lack of 
transcriptional potential. Our study challenges this notion and proposes that more attention should 
be paid not only to this region but to ChY in general.  
 
We demonstrate that the linc-SPRY3 transcripts are upregulated after exposure to radiation 
in cells that have retained ChY (Chapter 2, Fig. 1C, Fig. 2A-D, and Fig. S5A-D, H and I). It is 
well-known that radiation induces a signaling cascade to trigger cell death. Amongst these signals 
is changes in chromatin structure to turn specific genes on and off in order to promote the necessary 
gene expression for cellular responses (15). It the context of the linc-SPRY3 RNAs, it would be 
interesting to tease out changes in the chromatin marks of the DYZ1 region in response to 
radiation. As there is currently little to no sequencing data available for the q arm of ChY, using 
tools such as the UCSC Genome Browser has proven difficult and unsuccessful. Therefore, 
identifying chromatin changes in the DYZ1 region would allow for the identification of potential 
promoter sites within the region. Furthermore, specifically identifying the promoter(s) of the linc-
SPRY3-2/3/4 transcripts would allow for investigation into upstream regulators of their 
expression.  
 
 95 
 
 One of the major limitations to the study presented in Chapter 2 is the lack of full sequences 
for linc-SPRY3 transcripts. The sequence fragments we were able to mine from LNCipedia.org 
gave us enough information to design primers for quantitative reverse transcriptase PCR (qRT-
PCR), but without the full sequences we were unable to perform methods such as, northern 
blotting, RNA fluorescent in situ hybridization (FISH), and cloning to exogenously express the 
lncRNAs. This also prevents us from determining if the linc-SPRY3 RNAs are a family of 
lncRNAs or one large transcript. An attractive option for attempting to sequence the linc-SPRY3 
family is the Oxford Nanopore minION platform. This technology is one of few that can perform 
direct RNA long read sequencing. Based on the data we acquired from virtual northern blot 
analysis, we predict that the SPRY3 lncRNAs are roughly 5 kilobases long, and the near perfect 
alignment of peaks between all three family members further supports the hypothesis that these 
three family members could be one large transcript, originally classified as 3 transcripts due to 
realignment errors because of the highly repetitive nature of their sequences (Chapter 2, Fig. S3).  
 
Long read sequencing has shown much higher accuracy at reading highly repetitive 
sequences, and the ability to perform direct RNA sequencing is much more ideal as it removes the 
need to generate a cDNA library, a step which usually involves fragmenting the DNA which is 
then read and aligned to a reference genome (16–18). If successful, minION sequencing would 
provide the full sequence(s) of the linc-SPRY3 RNAs. This would then allow us to perform more 
rigorous studies on their structure and function and ultimately better understand their roles and 
potential clinical relevance in NSCLC which are further explained in the below paragraphs. 
 
An extremely useful tool to studying RNA is RNA fluorescent in situ hybridization (FISH), 
and it has become the gold standard for identifying transcript localization (19). Unfortunately, 
successful RNA FISH relies on sequence specificity in order for the fluorescent probes to hybridize 
to a transcript of interest. This has made it a challenge to visualize the compartmentalization of 
linc-SPRY3-2/3/4 using fluorescent microscopy. We did attempt to utilize the sequence fragments 
that we currently have to design Stellaris RNA FISH probes, but were not successful. Therefore, 
it is important that we define the complete sequence(s) in order to be able to move forward with 
this method. However, we have been able to identify that these lncRNAs are nuclear via cellular 
fractionation (Chapter 2, Fig. S7). An even more important use for this method is its applications 
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in determining clinical relevance. Successful RNA FISH would enable us to use patient tissue 
samples such as a tumor microarrays to better elucidate if the linc-SPRY3-2/3/4 correlate with 
patient therapeutic response and/or survival. Considering the tumor suppressive characteristics we 
have observed regarding the linc-SPRY3-2/3/4 in vitro and in vivo, and the survival trends seen 
using microarray and RNA-seq data (Chapter 2), we predict that a more in depth analysis with a 
large patient cohort would demonstrate a negative correlation between loss of the linc-SPRY3 
RNAs and patient outcomes.  
 
Another important method used for characterizing novel RNAs is northern blotting. 
Briefly, northern blotting is a method used to visualize RNA expression and determine transcript 
size, somewhat similar to the way western blots are used to look at protein expression. Northern 
blots traditionally use radiolabeled (e.g. 32P) oligonucleotide probes (cDNA or RNA) which are 
complementary to a transcript of interest. In order to design a probe, the sequence of a target RNA 
is necessary, therefore identifying the full sequence of the linc-SPRY3 RNAs is needed in order 
to perform this method. Like RNA FISH, we attempted to synthesize northern blot probes based 
on the sequence fragments mined from LNCipedia, but were unsuccessful at detecting the linc-
SPRY3 transcripts. qRT-PCR has been essential in assaying the expression of these lncRNAs, 
however, how large these transcripts are or if they are a family or a single large transcript is still 
uncertain. The ability to perform traditional northern blots would complement the data from the 
previously mentioned virtual northern blots and allow us to better ascertain the potential size(s) of 
the linc-SPRY3 transcript(s). 
 
 Identifying the full sequence(s) of linc-SPRY3-2/3/4 would also be imperative for 
designing expression vectors (retroviral or lentiviral vectors) to better characterize the effect and 
molecular functions of these RNAs. A standard in most molecular biology based projects is the 
ability to knockdown and overexpress genes of interest. While we were very successful at 
suppressing the expression of the SPRY3 lncRNAs via short-hairpin RNA (shRNA) lentiviral 
constructs, the opposite proved to be more difficult. However, we were able to circumvent the 
traditional methods of exogenous expression such as cloning the lncRNAs into a viral vector by 
utilizing an old tool in a new way: transient expression of the linc-SPRY3 RNAs by transfecting a 
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bacterial artificial chromosome containing the human Y-chromosome fragment where these 
lncRNAs are expressed. 
 
Bacterial artificial chromosomes (BACs), bacterial plasmids which contain large fragments 
of DNA, are tools that were vital for the completion of the Human Genome Project and the 
completion of sequencing numerous other genomes (20,21), but we were able to take advantage 
of this technology in a different way. Since we could not clone linc-SPRY3-2/3/4 into an 
expression vector, we acquired two ChY BAC clones from bacpacresources.org, RP11-80F8 and 
RP11-88F4. These BACs were chosen because they both contain large fragments of the q arm 
from the human ChY which includes the DYZ1 region. Fortunately, we were able to introduce 
these BACs to the radioresistant NSCLC cell line A549 via nucleofection and subsequently detect 
robust expression of the SPRY3 lncRNAs by qRT-PCR. Additionally, we determined that 
restoration of linc-SPRY3-2/3/4 expression via BAC nucleofection resulted in a more 
radiosensitive phenotype in vitro (Chapter 2, Fig. 3A-C). While these data were very exciting, 
there are some drawbacks to the method. This system is highly transient, meaning lengthy studies 
such as in vivo tumor growth delay assays are not possible. Also, there is the potential of 
introducing unknown ChY factors that might be present in the ChY fragment within the BACs 
which could influence cellular response to radiation. Therefore, fully sequencing linc-SPRY3-
2/3/4 would enable us to generate a more stable and pure expression system and allow us to 
investigate their functions more specifically and more in depth. 
 
 Another future route in regards to studying the linc-SPRY3 family, is fully vetting the 
molecular mechanism(s) by which they regulate NSCLC cell response to radiation. Our group has 
previously shown that cell lines that express the SPRY3 lncRNAs are more sensitive to ionizing 
radiation, thus we sought to determine a potential mechanism by which they mediate this effect 
(Chapter 2, Fig. 2, Fig. S4, Fig. S5, Table S2). Through in silico analysis followed by UV-
crosslinked immunoprecipitation (CLIP) we identified the RNA binding protein (RBP) insulin 
growth factor 2 binding protein 3 (IGF2BP3; also known as IMP3) as a direct binding partner of 
linc-SPRY3-2/3/4 (Chapter 2, Fig. 4A and 4B). IGF2BP3 presented as an interesting target 
because previous studies have demonstrated that it is consistently upregulated in numerous tumor 
types when compared to normal adjacent tissue controls, including lung adenocarcinoma (ADC, 
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LUAD) and lung squamous cell carcinoma (SCC, LUSC) (Fig.1 and Fig. 2 black box), as well as 
mediates multiple oncogenic mechanisms in cancer including radioresistance (22–24).  
 
While CLIP is a good 
start at demonstrating the 
interaction between linc-
SPRY3-2/3/4 and IGF2BP3, 
additional experiments to 
confirm the interaction are still needed. In addition to confirming the CLIP experiments in other 
NSCLC cell lines, it would be complementary to perform multiplexed RNA FISH for linc-SPRY3-
2/3/4 and IF for IGF2BP3 to visualize co-localization of the RNA with this RBP. Furthermore, as 
linc-SPRY3-2/3/4 expression is induced upon treatment with radiation, RNA FISH/IF could reveal 
clues towards confirming our ceRNA hypothesis as we predict there would be higher enrichment 
 99 
 
of IGF2BP3 in the nucleus versus cytoplasm in treated cells as linc-SPRY3-2/3/4 would sequester 
the RBP to the nucleus. 
 
According to previous studies, IGF2BP3 has multiple targets, and among them is HMGA2 
and the oncogene c-Myc, both of which have ties to regulating cell viability and apoptosis (25,26). 
IGF2BP3 regulates these targets by stabilizing their mRNA which allows for their translation (27–
29). We hypothesized that when the linc-SPRY3 RNAs are expressed, they act as ceRNAs to 
sponge IGF2BP3. This in turn prevents stabilization of its targets, c-Myc and HMGA2, resulting 
in a shorter half-life of their mRNA and subsequent downregulation in expression. To confirm 
this, we performed actinomycin-D RNA degradation assays which revealed that expression of the 
SPRY3 lncRNAs resulted in faster degradation of the mRNAs of HMGA2 and c-Myc (Chapter 2, 
Fig. 4C). The RNA degradation assay data was obtained from manipulated A549 cells without 
radiation, and while these data provided valuable results, they only revealed the tip of the iceberg 
of a potential mechanism for the SPRY3 lncRNAs. Future experiments should include the same 
RNA degradation assay in other cell lines and confirm downregulation in expression of HMGA2 
and c-Myc at the protein level (Western blots). Furthermore, since we provide evidence that 
increased mRNA degradation of HMGA2 and c-Myc is as a result of IGF2BP3 being sequestered 
by the SPRY3 lncRNAs, which are only upregulated in radiosensitive cell lines following 
radiation, it is imperative that we perform knockdown experiments of IGF2BP3 and look at mRNA 
degradation of HMGA2 and c-Myc as well as cellular response (e.g. viability and apoptosis) to 
radiation.  If our hypothesis is correct, and the linc-SPRY3 transcripts do sequester IGF2BP3 as 
its primary function, then exogenous overexpression of IGF2BP3 should promote a more 
radioresistant phenotype in radiosensitive cell lines similar to what was seen upon knockdown of 
linc-SPRY3-2/3/4, and knockdown of IGF2BP3 in radioresistant cell lines should lead to increased 
sensitivity to radiation.  
 
It is also important to consider the other functions of IGF2BP3 which could be regulated 
by the linc-SPRY3 RNAs. We provide significant evidence of a downstream effect on the ability 
of IGF2BP3 to stabilize mRNA targets such as c-Myc and HMGA2, two targets that were chosen 
because of their proven roles in regulating cell viability and apoptosis in cancer cells. However, 
IGF2BP3 is a prolific RBP with thousands of predicted targets and multiple functions aside from 
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mRNA stability which include miRNA biogenesis, RNA degradation, and RNA localization (Fig. 
3) (30). These pathways would provide alternative avenues of study regarding the potential 
molecular functions mediated downstream of the linc-SPRY3/IGF2BP3 interactions.  
 
 Numerous studies investigating lncRNAs have revealed that many of them have multiple 
functions, and moreover interact with more than one binding partner which can be DNA, RNA, or 
proteins (31). We have provided evidence of a direct interaction between linc-SPRY3-2/3/4 and 
the RBP IGF2BP3, but we cannot discount other potential interactions of linc-SPRY3 RNAs. In 
order to investigate other potential interactions, we could employ the method of chromatin 
isolation by RNA purification (ChIRP). Briefly, biotinylated probes are designed complementary 
to a transcript of interest ( in our case the linc-SPRY3 RNAs) and incubated with lysates from 
crosslinked cells. Next, magnetic streptavidin beads are used to recover hybridized RNA and 
anything potentially bound to that RNA due to crosslinking. The recovered material can then be 
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subjected to sequencing for DNA elements or RNA binding partners, or mass spectrometry for 
protein binding partners. As mentioned previously regarding other suggested methods, the linc-
SPRY3-2/3/4 sequence(s) will need to be determined first so effective probes can be designed to 
pull down the lncRNAs. In our hands it would be interesting to perform this using lysates from 
cells either treated or untreated with radiation and then compare the recovered DNA/RNA/protein 
to identify primary interactions in response to radiation. 
 
An additional aspect of the project presented in Chapter 2 that should be investigated in 
more depth is the use of ChY as a predictive marker for patient response to radiation therapy as 
well as overall survival. Previous studies have implicated loss of ChY (LOY) as a marker for poor 
prognosis/survival in multiple cancer types (32–37). Furthermore, data we collected utilizing ChY 
DNA FISH from a NSCLC tumor microarray (TMA) revealed a trending negative correlation 
between LOY and overall survival in males, though the sample size was too small to provide 
statistical significance (Chapter 2, Fig. 5). We intend on increasing the sample size by adding more 
TMAs in an attempt to reach statistical significance. Additionally, in an attempt to build on this, 
we initiated a retrospective study in collaboration with Dr. Malcolm Mattes of Rutgers Cancer 
Institute of New Jersey (formerly WVU Cancer Institute) to examine LOY using ChY DNA FISH 
in treatment naïve NSCLC tumor samples. The goal of this study is to determine if LOY could be 
used as a predictive biomarker for patient response to radiation therapy. Our current hypothesis is 
that patients whose tumors exhibit high LOY will respond worse to radiation than those whose 
tumors have managed to retain ChY. If correct, this could eventually lead to a clinical trial to 
validate LOY as a predictive biomarker for radiation therapy use in male NSCLC patients.  
 
 While our group has primarily focused on ChY and linc-SPRY3-2/3/4 in NSCLC, we also 
have an interest in pursuing similar studies outlined above and in Chapter 2 in other cancer types. 
It is well documented that disparities between the sexes, independent of race, exist in both 
incidence and survival for the vast majority of cancer types (Fig. 4). Many mechanisms have been 
proposed to explain these disparities, though most are primarily attributed to differences in sex 
hormone function and regulation (38,39). It is only recently that the sex chromosomes and their 
resident genes have gained significant attention in regards to their roles in regulating 
carcinogenesis, though the X chromosome has received far more attention than ChY. A recent 
 102 
 
PubMed search using the keywords X chromosome and cancer resulted in nearly 4,000 
publications, versus Y chromosome and cancer which yielded less than half that at ~1,700 
publications.  
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Overall, we believe that ChY as a whole and its genes, discovered and undiscovered, 
deserve a lot more attention. Additional studies into their relationship to cancer could provide a 
better understanding of the rampant sex disparities seen in incidence and mortality across multiple 
cancers leading to the development of precision medicine not just informed by diagnostic standards 
such as cancer type and driver mutations but by inherent sexual differences. 
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  Project Summary 
• Treat cells with radiation and extract 
RNA 
 
• Send for microarray analysis 
 
• Identify significantly up and 
downregulated genes 
1. Identification of Candidate LncRNAs 
2. Characterization of Linc-SPRY3-2/3/4 
  
• UCSC Genome Browser reveals the linc-
SPRY3 RNAs originate from the Y 
chromosome  
 
 
 
 
• qRT-PCR Analysis reveals a dose dependent 
increase in expression of linc-SPRY3-2/3/4 in 
radiosensitive male NSCLC cell lines but not 
in radioresistant cell lines 
•  
• DNA FISH Reveals Y chromosome loss in 
radioresistant male NSCLC cell lines 
3. Manipulation of linc-SPRY3-2/3/4 expression changes NSCLC cell line radiosensitivity 
• Exogenous expression of linc-SPRY3-2/3/4 via Y chromosome BAC results in increased 
radiosensitivity in A549 cells 
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  3. Manipulation of linc-SPRY3-2/3/4 expression changes NSCLC cell line radiosensitivity (cont.) 
• Knockdown of linc-SPRY3-2/3/4 
via shRNAs results increased 
radioresistance in vitro and in vivo 
in H460 and WVU-Ma-0005 cells 
4. Evidence suggests the linc-SPRY3 RNAs function through sequestration of the RBP IGF2BP3 
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5. The Y chromosome and linc-SPRY3 RNAs have potential clinical relevance by showing 
trending negative correlations with male NSCLC patient survival. 
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I. Abstract  
  
 High-risk human papillomavirus (HPV) infection is one of the first events in the process 
of carcinogenesis in cervical and head and neck cancers. The expression of the viral oncoproteins 
E6 and E7 are essential in this process by inactivating the tumor suppressor proteins p53 and Rb, 
respectively, in addition to their interactions with other host proteins. Non-coding RNAs, such as 
long non-coding RNAs (lncRNAs) have been found to be dysregulated in several cancers, 
suggesting an important role in tumorigenesis. In order to identify host lncRNAs affected by HPV 
infection, we expressed the high-risk HPV-16 E6 oncoprotein in primary human keratinocytes and 
measured the global lncRNA expression profile by high-throughput sequencing (RNA-seq). We 
found several host lncRNAs differentially expressed by E6 including GAS5, H19, and FAM83H-
AS1.  Interestingly, FAM83H-AS1 was found overexpressed in HPV-16 positive cervical cancer 
cell lines in an HPV-16 E6-dependent manner but independently of p53 regulation. Furthermore, 
FAM83H-AS1 was found to be regulated through E6-p300 pathway. Knockdown of FAM83H-
AS1 by siRNAs decreased cellular proliferation, migration and increased apoptosis. FAM83H-
AS1 was also found to be altered in human cervical cancer tissues and high expression of this 
lncRNA was associated with worse overall survival, suggesting an important role in cervical 
carcinogenesis.  
 
II. Introduction 
 
 High-risk HPV infection (e.g. HPV-16) is one of the most common causes of cervical 
cancer (1-3), as well as a subset of head and neck squamous cell carcinoma (HNSCC) (1). The 
HPV oncoproteins E6 and E7 have been shown to contribute to carcinogenesis by modulating the 
degradation of human proteins, such as the tumor suppressors p53 (4) and Rb (5) as well as a 
plethora of other cellular proteins (2,3,6-8). The HPV-16 E6 protein can abrogate p53 function by 
proteasomal degradation as it forms a complex with E6-associated protein (E6AP) (9), or by 
targeting the p53 coactivator CBP-p300 (8,10). Upon transmission, HPV infects the 
undifferentiated keratinocytes at the basal layer of the stratified epithelia and its genome remains 
episomal maintaining low copy numbers. During the course of cancer development, the viral 
genome frequently becomes integrated into the host cell DNA (11). 
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 The recent discovery of different classes of non-coding RNAs (ncRNAs) expressed in 
human cells has opened a new chapter in the understanding of cellular processes, such as chromatin 
remodeling, transcriptional control, and post-transcriptional regulation. One of these classes of 
ncRNAs called long non-coding RNAs (lncRNAs) are defined as RNAs larger than 200 
nucleotides that are not translated into proteins. Recent findings indicate that lncRNAs are 
involved in gene regulation at the transcriptional level by functioning as signal, guide, decoy, or 
scaffold RNAs (12-14). Dysregulation of lncRNAs occurs in a variety of cancers, suggesting a 
potential use of these ncRNAs as biomarkers for diagnosis, prognosis, stage of cancer, and 
response to therapy (15-18). LncRNAs have been shown to be altered in cervical cancer (19-21), 
however, only a few publications have studied lncRNAs that are specifically regulated by the HPV 
E6 oncoprotein, such as MALAT1 and CCEPR (22,23). These lncRNAs were found altered in 
cervical cancer but it is unknown if these alterations are part of the early events in cervical 
carcinogenesis. A few studies have looked at aberrant expression of lncRNAs in progression from 
pre-malignant cervical intraepithelial neoplasia (CIN) to cervical cancer (24,25). For these reasons, 
it is important to understand if certain lncRNAs are important in the first stages of immortalization 
and transformation caused by HPV infections.  
 
 In this study, we demonstrated that the lncRNA FAM83H-AS1 (also known as onco-
lncRNA-3) is up-regulated in primary keratinocytes expressing HPV-16 oncogene E6 as well as 
HPV-16 positive human cervical cancer cell lines and cervical tumor samples. We show that 
FAM83H-AS1 is regulated by HPV-16 E6 through the presence of p300 instead of the tumor 
suppressor p53. Finally, we show that FAM83H-AS1 is involved with cellular proliferation, 
migration, and apoptosis and is associated with worse overall survival in cervical cancer patients.  
 
III. Results 
 
A. High-risk HPV-16 E6 oncoprotein alters host long non-coding RNAs in primary keratinocytes. 
 
 As an initial screen to identify host lncRNAs that are regulated specifically by HPV-16 E6, 
we developed a system to look specifically at the effect of E6 expression alone in primary human 
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foreskin keratinocytes (HEKa). HEKa were infected with a retroviral vector expressing HPV-16 
E6 oncogene or GFP as a control. After puromycin selection and stable expression of HPV-16 E6 
was confirmed by RT-PCR (Fig. S1), RNA was extracted, and samples were analyzed by RNA 
high-throughput sequencing (RNA-seq) to determine gene expression alterations in long non-
coding RNAs (lncRNAs). Following bioinformatics analysis, we found 151 up- and 100 down-
regulated host lncRNAs altered greater than 1.5-fold change when HPV-16 E6 was expressed in 
HEKa cells compared to GFP control (Fig. 1A, Table S1). From these host lncRNAs, we randomly 
chose 8 up- and 8 down-regulated host lncRNAs to validate our RNA-seq data by qRT-PCR. The 
expression of all the lncRNAs selected for validation followed the same trend of up- or down-
regulation found by RNA-seq (Fig. 1B). In order to determine the importance of these 251 
lncRNAs in cervical carcinogenesis, a variety of filtering methods were utilized to reduce our 
scope (see Methods section). After filtering, we performed preliminary experiments with many 
lncRNAs, however, some of our top altered lncRNAs from our RNAseq analysis of foreskin 
keratinocytes (HEKa) were not altered in cervical cells (HCK) with HPV-16 E6 expression (e.g. 
SNHG15). This is not surprising, as lncRNAs are known to typically be tissue specific (26). We 
also found differences in the expression of some lncRNAs between pre-malignant and cancerous 
cervical cells CaSki and W12/201402 to HCK (e.g. miR205HG). One of the up-regulated lncRNAs 
in our RNA-seq dataset, FAM83H-AS1 was intriguing. Its expression recently was found to 
correlate with poor overall survival in a variety of human cancers (27-32) but had not previously 
been shown in the context of cervical cancer. In addition, it was recently shown to be involved in 
regulating cellular processes associated with the hallmarks of cancer (e.g. proliferation and 
migration) (28,31,32).  To ensure that expression of FAM83H-AS1 is comparable to lncRNAs 
with well-known functions, we utilized our RNAseq dataset to compare their RPKM values (Table 
S2).  
 
B. FAM83H-AS1 expression is higher in HPV-16+ pre-malignant and cancerous samples.   
 
 Because many lncRNAs are known to be tissue specific (26) and our RNA-seq screening 
was performed with foreskin keratinocytes expressing HPV-16 E6 oncogene, it was critical to 
confirm the expression changes of FAM83H-AS1 in epithelial keratinocytes of the cervix where 
HPV naturally infects (11). Additionally, we considered that the E6 and E7 oncogenes can be 
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synergistic with each other (33), so we needed to develop a model that closely mimics HPV 
infection by using the entire HPV-16 genome. Therefore, primary human cervical keratinocytes 
(HCK) were transfected with the entire HPV-16 genome (by releasing the viral genome from a 
plasmid construct and circularizing it by ligation before transfection), then passaged several times 
(around 10-15 divisions) for growth selection of HPV positive immortalized cells. HPV-16 E6 and 
E7 expression was confirmed by RT-PCR (Fig. S2A), as well as p53 degradation through the HPV-
16 E6 pathway by Western Blot (Fig. S2B). After confirmation of HPV-16 oncogene expression 
in these cells, we named them JAMM-16. It was confirmed by qRT-PCR that FAM83H-AS1 is 
also up-regulated in JAMM-16 cervical keratinocytes expressing the entire HPV-16 genome in 
comparison to the parental cervical keratinocytes (Fig. 2A). We then used HPV-16 positive low-
grade cervical (W12/20863 [episomal HPV-16], W12/201402 [integrated HPV-16]) and 
carcinoma (CaSki [integrated HPV-16]) cell lines to investigate the expression of FAM83H-AS1. 
As shown in Figure 2B, we found higher expression of FAM83H-AS1 in all the HPV-16 positive 
cell lines in comparison to HCK cells. Interestingly, FAM83H-AS1 was expressed at lower levels 
in HPV-negative cervical cancer C33A cells compared to HCK as well as HPV-16 positive 
cervical cells (Fig. 2B). Furthermore, HPV-16 positive and HPV-negative head and neck 
squamous cell carcinoma (HNSCC) cell lines were compared, and higher expression of FAM83H-
AS1 was observed in the HPV-16 positive versus the HPV-negative HNSCC (Fig. 2C). Overall, 
we conclude that presence of HPV-16 correlates with elevated levels of FAM83H-AS1 expression 
in early stages of cervical carcinogenesis (newly immortalized JAMM-16 cells and cervical low-
grade pre-malignant cell lines) as well as cervical cancer and HNSCC cell lines.  
 
C. FAM83H-AS1 expression is regulated by HPV-16 E6 in a p53-independent, p300-dependent 
manner.  
  
 As shown in Figure 1, foreskin keratinocytes (HEKa) expressing HPV-16 E6 up-regulated 
FAM83H-AS1 expression. To further confirm HPV-16 E6 regulation of FAM83H-AS1 in cervical 
cells, cervical keratinocytes (HCK) stably expressing HPV-16 E6 were developed (Fig. S3). To 
measure if FAM83H-AS1 regulation could be affected by HPV-16 E7 oncogene in synergistic or 
antagonistic manner, we generated HCK stable cell lines expressing HPV-16 E7 or co-expressing 
HPV-16 E6 and E7 (Fig. S3). FAM83H-AS1 was up-regulated when cells expressed HPV-16 E6 
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or HPV-16 E6 and E7, but not when they expressed HPV-16E7 alone (Fig. 3A) suggesting a 
specific regulation by E6. To further confirm these findings, HPV-16 E6 was knocked down in 
CaSki (Fig. 3B, Fig. S4A) and W12/201402 (Fig. 3C, Fig. S4B) cell lines by two different siRNAs 
against HPV-16 E6-E7. FAM83H-AS1 expression was down-regulated after the reduction of 
HPV-16 E6 expression confirming the regulation of this lncRNA by HPV-16 E6. It is well known 
that one of the major HPV E6 targets is the tumor suppressor p53 (34), which is involved in the 
regulation of cell proliferation, DNA repair, and apoptosis (35). Interestingly, when we knocked 
down p53 in HCK by using two different siRNAs, we observed that FAM83H-AS1 expression did 
not change (Fig. 3D, Fig. S4C), suggesting a regulation by HPV-16 E6 in a p53-independent 
manner. It is also known that HPV-16 E6 is able to regulate the expression of other important 
genes in carcinogenesis such as hTERT through the regulation of transcriptional coactivators such 
as p300 (36). By using the UCSC Genome Browser (https://genome.ucsc.edu/) to investigate 
potential p300 binding site in the promoter region of FAM83H-AS1, we found three predicted 
p300 binding sites (Fig. 3E). In order to measure the potential regulation of FAM83H-AS1 by 
p300, we used two siRNAs against p300 and quantified FAM83H-AS1 expression. When p300 
was knocked down in primary cervical keratinocytes, FAM83H-AS1 expression was also reduced 
(Fig. 3F, Fig. S4D) suggesting direct and/or indirect p300 regulation of FAM83H-AS1. Previous 
publications have shown a greater affinity of HPV-16 E6 to interact with p300 in comparison with 
other high-risk HPV E6 such as HPV-18 E6(37). Interestingly, FAM83H-AS1 expression was 
found to be up-regulated in HPV-16 positive cell lines (Fig. 2), but down-regulated in HPV-18 
positive HeLa cells and HPV-31b positive CIN-612 cells (Fig. S4E).  Altogether, we found that 
FAM83H-AS1 is regulated by HPV-16 E6 independently of p53 but influenced by the presence 
of p300.  
 
D. FAM83H-AS1 is localized to the nucleus and does not regulate transcription of nearby 
FAM83H. 
  
 The cellular localization of lncRNAs can provide information on their potential function. 
Nuclear lncRNAs can regulate at the transcriptional level by interacting with critical epigenetic 
regulators and enhancing chromatin looping, as well as interact with splicing factors to regulate 
splicing (38). Meanwhile cytoplasmic lncRNAs have been found to function at the post-
 159 
 
transcriptional level as competing endogenous RNAs by acting as microRNA sponges and binding 
to mRNAs leading to the recruitment of RNA binding proteins that promote decay, suppress 
translation, or factors that initiate translation (39). For this reason, we investigated the cellular 
localization of FAM83H-AS1 in two HPV-16 positive cervical cell lines by cellular fractionation. 
We used U6 as a nuclear RNA control and β-actin mature mRNA as a cytoplasmic RNA control. 
We found significantly higher amplification of FAM83H-AS1 in the nuclear fractions in 
comparison to the cytoplasmic fractions by qRT-PCR in CaSki (Fig. 4A) and W12/201402 (Fig. 
4B) cells, suggesting that FAM83H-AS1 is a nuclear lncRNA. Because many nuclear lncRNAs 
can act in cis (38), we hypothesized that FAM83H-AS1 could regulate its nearby protein coding 
gene FAM83H. The lncRNA FAM83H-AS1 and protein coding gene FAM83H share a promoter 
region but are transcribed in opposite directions (27) (Fig. 3E, Fig. S5). FAM83H is required for 
the organization of the keratin cytoskeleton in epithelial cells (40) and has been shown over-
expressed in different tumor samples compared to their matching normal tissues (41). 
Interestingly, we found increased expression of FAM83H in HCK expressing HPV-16 E6 in 
comparison to parental HCK cells (Fig. S5B), but when we transfected an siRNA against 
FAM83H-AS1 in HPV-16 positive CaSki cells, we were unable to detect changes in FAM83H 
expression (Fig. S5C), suggesting that FAM83H-AS1 is not involved in regulation of FAM83H 
expression.  
 
E. FAM83H-AS1 knockdown in cervical cancer cells causes reduced cellular proliferation and 
migration, as well as induction of apoptosis.  
 
 To understand the significance of FAM83H-AS1 in cervical cancer cells, we analyzed the 
effects on cellular proliferation when FAM83H-AS1 was knocked down by siRNA in CaSki and 
W12/201402 cervical cells. First, knockdown efficiency of a pool of 4 individual siRNAs 
(SMARTpool), as well as each of the individual siRNAs, was evaluated by qRT-PCR. Knockdown 
of FAM83H-AS1 in CaSki with the siRNA SMARTpool was maintained over a time-course from 
24 to 120 hours, which was sufficient for all functional assays conducted (Fig. S6). All of the 
individual siRNAs, as well as the SMARTpool showed greater than 51% knockdown of FAM83H-
AS1 in CaSki (Fig. 5A) and greater than 49% in W12/201402 cells (Fig. S7A). Therefore, we 
decided to randomly choose two of the individual siRNAs and SMARTpool to knockdown 
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FAM83H-AS1 and monitor cellular functional changes. Two siRNAs against FAM83H-AS1 were 
transfected independently into CaSki and W12/201402 cells, cultured for 48 hours, and replated 
to measure cell proliferation by cell counting. In both CaSki and W12/201402 cells, we observed 
a decrease (≥48%) in cell number with knockdown of FAM83H-AS1 compared to control (Fig. 
5B, Fig. S7B). Cellular proliferation assay (CCK-8) showed that there was a decrease in cellular 
proliferation when FAM83H-AS1 is knocked down in CaSki cells and W12/201402 as monitored 
from 48 hours to 96 hours after replating. We found significantly less proliferation in CaSki (64% 
decrease) and W12/201402 (73% decrease) , in the siRNA FAM83H-AS1 knockdown compared 
to siRNA control cells at the 96-hour time point (Fig. 5C, Fig. S7C). We observed similar 
functional changes between the two individual siRNAs and the SMARTpool so for future 
functional assays we only used the siRNA SMARTpool. In order to identify changes in cell cycle 
that could explain the differences found in cellular proliferation after FAM83H-AS1 knockdown, 
we performed cell cycle flow cytometry analysis. CaSki and W12/201402 cells had a significant 
reduction (43% and 56%, respectively) of cells in S-phase when FAM83H-AS1 was knocked 
down in comparison to control suggesting that FAM83H-AS1 is important in the G2/S-phase 
transition (Fig. 5D, Fig. S7D). Other important hallmarks of cancer such as migration and 
resistance to apoptosis were measured after FAM83H-AS1 knockdown. We found that cellular 
migration was significantly decreased in CaSki and W12/201402 after siRNA knockdown of 
FAM83H-AS1 compared to siRNA control  (Fig. 5E, Fig. S7E). Also, we measured a significant 
increase in early and late apoptosis in CaSki and W12/201402 cells with knockdown of FAM83H-
AS1 compared to control cells by using Annexin V/PI staining and flow cytometry (Fig. 5F, Fig. 
S7F and S7G-H). W12/201402 cells with knockdown of FAM83H-AS1 showed a significant 
increase in necrosis (Fig. S7F), while only a slight increase in necrosis was observed in CaSki cells 
(Fig. 5F, Fig. S7H). Altogether, we observed significant alterations in cellular proliferation, cell 
cycle, migration, and apoptosis by the absence of FAM83H-AS1, suggesting an important role in 
cervical carcinogenesis.   
 
F. FAM83H-AS1 expression is increased in cervical cancer human tissues & is associated with 
worse overall survival.  
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 In order to extrapolate our findings into a more clinically relevant setting, we extracted 
RNA from pre-malignant and cervical cancer patient samples and analyzed the expression of 
FAM83H-AS1 by qRT-PCR. We found high expression of FAM83H-AS1 in the pre-malignant 
sample (CIN3) as well as the cervical cancer (CaCx) samples in comparison to normal cervix tissue 
(Fig. 6A). These findings corroborate our in vitro data suggesting an importance of FAM83H-AS1 
in clinical tumor samples at different stages of carcinogenesis. We also took advantage of the 
cervical cancer samples deposit in the TCGA database to compare the expression of FAM83H-
AS1 between normal cervix and cervical cancer samples obtained from different cancer stages 
(120 Stage I, 35 Stage II, 30 Stage III, 7 Stage IV, 4 Stage unavailable). The TCGA data showed 
elevated expression of FAM83H-AS1 (RPKM values) in cervical cancer patients compared to 
normal cervix control (Fig. 6B). This coincides with our previous observations of FAM83H-AS1 
expression being higher in cervical cancer cells lines (Fig. 2B). Finally, we used the TCGA data 
set from the TANRIC database to divide cervical cancer patients into high versus low expression 
groups and measured overall survival based on FAM83H-AS1 expression. Interestingly, we found 
that patients with higher FAM83H-AS1 expression yielded a worse overall survival than patients 
with lower FAM83H-AS1 expression suggesting a biological importance of this lncRNA in 
cervical cancer reflected in patients' clinical outcomes (Fig. 6C). Overall, we conclude that 
FAM83H-AS1 expression is elevated in cervical cancer patients and high expression correlates 
with overall poor survival. 
 
IV. Discussion 
 
 4.5% of all cancers worldwide are attributable to HPV infection. Almost all cervical 
cancers and a substantial amount of other anogenital and oropharyngeal cancers have been found 
to be infected by high-risk HPVs. HPV-16 and -18 contribute to 73% of HPV-associated cancers 
(42), implying a higher ability to induce tumorigenesis in comparison to other types of HPVs. 
Although the prevalence of HPV-associated cancers has decreased due to development of the 
preventative vaccine and early detection screening methods (2), there is still a great need for 
prognostic and therapeutic options specially to people already infected with HPV as well as those 
affected in less developed countries where the access to the vaccine is limited.  
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 Long noncoding RNAS (lncRNAs) have been shown to regulate a variety of critical 
cellular processes, including transcription and chromosome remodeling (12-14). Dysregulation of 
lncRNAs has been shown to be associated with the development and progression of many cancers 
(15-17), and interestingly they are commonly tissue specific (26) and only altered in one cancer 
type (32). Therefore, lncRNAs are currently being studied in the context of biomarkers for 
diagnosis and prognosis of cancer, as well as therapeutic targets (15-18).  
 
 Previous studies have shown that the high-risk HPV E6 protein expressed is clearly 
involved in the progression of carcinogenesis. HPV E6-regulation of non-coding RNAs such as 
microRNAs has been well studied (43), however long non-coding RNA regulation by high-risk 
HPV E6 needs to be studied further; there are only a couple lncRNAs shown to be specifically 
HPV-16 E6 regulated, including MALAT1 and CCEPR (22,23). To add to this field of study, we 
sought out to identify an HPV-16 E6 regulated gene that was altered from the early stages of HPV 
infection until carcinogenesis and therefore we considered to be important in both the development 
and progression of carcinogenesis. Thus, we developed a new HPV-16 positive cell line referred 
to as JAMM-16 to represent early infection, but also analyzed expression in established HPV-16 
positive cervical cell lines such as CaSki and W12 cells as well as pre-malignant and malignant 
cervical tumor samples. We found FAM83H-AS1 overexpression in W12/20863 and W12/201402 
(which came from a CIN2 tumor) similar to CaSki cells (cervical carcinoma). Additionally, in 
Figure 6A, the CIN3 (considered Stage 0 cervical carcinoma) patient sample shows similar 
expression to later stage cervical carcinoma (CaCx) samples. For this reason, we believe that 
FAM83H-AS1 up-regulation in pre-malignant cervical samples could be linked to the expression 
of viral oncogenes in early HPV infection.  
 
 From the host lncRNAs altered by HPV-16 E6 in our RNA-seq analysis (Fig. 1), we found 
several of these lncRNAs previously described to be altered in cervical cancers, confirming that 
our data aligned with former studies. For example, it was previously found that decreased 
expression of GAS5 is associated with poor prognosis of cervical cancer patients (44,45) as well 
as is tumor suppressive in other types of cancer such as breast cancer (46,47) and prostate cancer 
(47). Furthermore, GAS5 expression was also found altered in vitro in HPV-16 positive CaSki 
cells (44) and HPV-18 positive HeLa cells (45). Another lncRNAs affected in our study was H19. 
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It was shown previously that DNA methylation alterations at the IGF2/H19 imprinted domain may 
mediate the association between HPV and invasive cervical cancer (48) and high H19 expression 
has also been shown to be predictive of poor prognosis in cervical cancer (49) as well as in a 
variety of other human cancers, including HNSCC (50) and breast cancer (51).  
 
 A class of lncRNAs known as onco-lncRNAs were also interesting to us because, as the 
majority of lncRNAs are tissue specific (26), this group of lncRNAs exhibit differential expression 
across multiple cancers and are hypothesized to have conserved oncogenic or tumor suppressive 
functions. One such onco-lncRNA which was found in our RNA sequencing analysis of an E6-
regulated lncRNA is onco-lncRNA-3, referred to as FAM83H-AS1. This lncRNA is transcribed 
from chromosome 8 and its function in normal cells is unknown. It was first characterized in 2015 
(32), and as of now multiple publications have shown increased expression of FAM83H-AS1 in 
breast (29,32), lung (31,32), colorectal (28,30,32), kidney (32), bladder (32), and pancreatic 
cancers (27) and increased expression correlates with worse overall survival in most of these 
cancers (27,29-31).  Our findings show for the first time that FAM83H-AS1 is overexpressed in 
human cervical cancer (CESC) tissues and high expression in patients correlates with poor overall 
survival (Fig. 6).  
 
 According to previous studies, FAM83H-AS1 is an epithelial lncRNA (27) supporting our 
data obtained from foreskin and cervical keratinocytes. Determining the localization of a lncRNA 
can predict functionality of the lncRNA; our findings that FAM83H-AS1 is localized in the 
nucleus of cervical cancer cells (Fig. 4) is consistent with previous findings of its nuclear 
localization in lung cancer cells (14). Functionally, it has been found to be co-expressed with 
protein coding genes that were enriched for cell cycle-related genes (32), and knockdown of 
FAM83H-AS1 altered cell cycle (31,32), proliferation (28,31), migration (28,31), invasion (31), 
and apoptosis (28) in certain cancers. Our group shows here that in the context of cervical cancer, 
FAM83H-AS1 is involved in cell cycle, proliferation, migration, and apoptosis (Fig. 5). It is 
unknown if FAM83H-AS1 elicits its functions in cis or trans, but our findings suggest that 
FAM83H-AS1 does not elicit cis regulation on the nearby protein coding gene FAM83H (Fig. S5), 
which is up-regulated in a variety of human cancers. For this reason, it will be interesting in future 
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studies to identify the protein, RNA, and/or DNA interactions of FAM83H-AS1 in cervical 
cancers.  
 
 Previously, it was shown that FAM83H-AS1 regulates MET/EGFR signaling in lung 
cancer cells (31) and that when FAM83H-AS1 was downregulated it exhibited an anti-proliferative 
role by suppressing the Notch signaling pathway in colorectal cancer (28). To elucidate additional 
downstream targets of FAM83H-AS1, a group recently conducted RNA-seq on a pancreatic cancer 
cell line with siRNA knockdown of FAM83H-AS1 compared to control and identified gene 
alterations (78 activated and 68 inhibited targets) (27). Our group plans to determine if these 
downstream regulators are also involved in FAM83H-AS1 mediated functional changes observed 
in cervical cancer cells.  
 
 HPV-16 E6 and -18 E6 are well known to contribute to the degradation of p53, however, 
it is important to note that HPV-16 and HPV-18 vary in their interactions with other proteins to 
regulate carcinogenesis. For example, previous studies have shown that HPV-16 E6 directly 
interacts with CBP/p300 (8,10,37), but HPV-18 E6 appears to be unable to interact with p300 (37). 
This could be a possible explanation for variation in FAM83H-AS1 expression between HPV-16 
and -18 positive cancers observed in our study (Fig. 2, Fig. S4E). Supporting our data, another 
publication previously showed low expression of FAM83H-AS1 in HeLa (HPV-18 positive) cells 
(27). This information led us to elucidate the mechanism of FAM83H-AS1 up-regulation by E6 in 
a p53-independent and p300-dependent manner (Fig. 3, Fig. S4). This regulation is interesting 
because the majority of E6 regulation of several coding and non-coding genes is primarily through 
the p53 pathway. Interestingly, a previous study showed that overexpression of cyclooxygenase 
(COX-2) gene was the result of the recruitment of p300 to its promoter region via the 
overexpression of HPV-16 E6 protein in CaSki cells as well as the exogenous expression of HPV-
16 E6 in HPV-negative C-33A cells (52). Recently, p300 inhibitors such as C646 have been shown 
to be good candidates as anti-cervical cancer drugs, demonstrating the importance of p300 not only 
in the regulation of host genes but also of HPV viral genes (53). 
 
 In summary, the identification of FAM83H-AS1 up-regulation in the early stages of 
cervical carcinogenesis, correlation with overall survival in cervical cancer, and involvement in 
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different hallmarks of cancer contributes further evidence of the importance of this lncRNA in 
cancer. Further studies on this lncRNA could enhance the use of FAM83H-AS1 as a potential 
biomarker or therapeutic target in multiple cancers.  
 
V. Methods 
 
 Detailed experimental protocols are described in the Supplementary Methods section. All 
experiments were performed in compliance with the Institutional Biosafety Committee at West 
Virginia University, number 15-03-03.  
 
A. Cells 
 
 The following cell lines were used: human primary foreskin keratinocytes (HEKa) 
(Invitrogen, C-005-5C); human primary cervical keratinocytes (HCK) and J2-3T3 murine 
fibroblast feeder cells (obtained from Dr. Alison McBride's laboratory, NIH, Bethesda, MD); 
3T3M murine fibroblast feeder cells, as well as CaSki (HPV-16 positive), HeLa (HPV-18 
positive), and C-33A (HPV negative) cervical carcinoma cells (obtained from Dr. Daniel DiMaio's 
laboratory, Yale University, New Haven, CT); W12/201402 (HPV-16 positive) and W12/20863 
(HPV-16 positive) pre-malignant cervical cells (obtained from Paul F. Lambert, University of 
Wisconsin-Madison, Madison, WI); CIN-612 (HPV-31b positive) (obtained from Dr. Laimonis 
A. Laimins' laboratory, Northwestern University, Chicago, IL); UMSCC-1 (HPV negative), 
UMSCC-47 (HPV-16 positive), and UMSCC-104 (HPV-16 positive) head and neck squamous 
cell carcinoma (HNSCC) cell lines (obtained from Dr. Scott A. Weed's laboratory, West Virginia 
University, Morgantown, WV). Further details are in the Supplementary Methods section.  
 
B. High-throughput RNA sequencing 
  
 Three replicates each of human foreskin keratinocytes (HEKa) stably expressing HPV-16 
E6 or GFP were sent for RNA high-throughput sequencing (Illumina). FASTQ files were 
subsequently imported into Strand NGS suites for analysis. Reads were aligned to the human hg19 
reference genomes using the Bowtie algorithm. These were then quantified against Ensemble 
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transcript and including small and lncRNA annotations. Any lncRNA that were detected in human 
subjects were used for further analysis. Raw lncRNA counts were then normalized to the total 
number of lncRNA reads per sample and expression values calculated against the control samples. 
Further Mapping rate visualization done using Strand NGS software. In order to determine the 
importance of the lncRNAs obtained from the RNA-seq analysis, we used the following filtering 
strategy: First, only lncRNAs with reasonable expression (RPKM greater than 1) were analyzed 
further. Then, we used The Atlas of Noncoding RNAs in Cancer (TANRIC, MD Anderson Cancer 
Center) (54), which contains 297 sequenced human cervical squamous cell carcinoma and 
endocervical adenocarcinoma (CESC) patient data from The Cancer Genome Atlas (TCGA), to 
analyze the expression and clinical outcomes of these lncRNAs in patient samples. Finally, we 
searched previous publications to identify lncRNAs altered in other types of cancer and/or 
involved in hallmarks of cancer. To increase our novelty, we eliminated lncRNAs that were 
previously shown to be involved specifically in cervical cancer (e.g. H19).  
 
C. Functional Analysis  
 
 For cell counting experiments, CaSki cells were transiently transfected with Lincode 
Human FAM83H-AS1 siRNA SMARTpool (Dharmacon, R-188909-00-000), Individual: Lincode 
FAM83H-AS1 siRNA (N-188909-02-0002 and N-188909-04-0002), or Lincode Non-targeting 
siRNA #1 (Dharmacon, D-001320-01-05) using Lipofectamine® RNAiMAX according to 
manufacturer's instructions (Invitrogen). 
 
 CaSki cells were cultured with siRNA-containing media for 48 hours, re-plated in equal 
cell numbers (200,000 cells/well of 6-well), cultured for another 48 hours, and attached cells were 
re-counted with a hemocytometer.  
 
 For all other functional assays (CCK-8 cell proliferation, FACS cell cycle, transwell 
migration, annexin V-FITC/PI apoptosis), CaSki cells were transiently transfected with Lincode 
Human FAM83H-AS1 siRNA SMARTpool or Lincode Non-targeting siRNA #1 (Dharmacon, D-
001320-01-05) using Lipofectamine® RNAiMAX according to manufacturer's instructions 
(Invitrogen). Cells were incubated with siRNA-containing media for 24 hours then re-plated in 
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equal cell numbers for to initiate experiments described below. To monitor cell proliferation, 
transfected cells were plated in 96-well plates and after 24, 48, 72, and 96 hours analyzed with 
CCK-8 kit (Sigma-Aldrich) according to manufacturer's protocol. Alterations in cell cycle were 
determined by flow cytometry propidium iodide DNA staining. Transfected cells were plated 
in media containing 10% fetal bovine serum (FBS). Cells were allowed to attach and then were 
serum-starved for 24 hours. Samples were then fixed with ethanol, stained with propidium 
iodide, and analyzed by flow cytometry (Fortessa S10). For transwell migration assay, 
transfected cells were seeded onto upper chambers of transwell inserts (8µm pore size) with 
20% FBS chemoattractant in the lower chamber of 24-well plate. After 48 hours, migrated cells 
located on the underside of the transwell insert were stained with 0.5% crystal violet in 
methanol. Migrated cells were quantified using ImageJ software. To monitor apoptosis, 
transfected cells were plated and incubated 24, 48, and 72 hours. At desired time point, attached 
and floating cells were pelleted and co-stained with annexin V-FITC and propidium iodine and 
immediately analyzed by flow cytometry (Fortessa S10).  
 
VI. Data Availability 
 
 The RNA-seq raw data generated during and/or analyzed during the current study are 
available in the Gene Expression Omnibus (GEO-NCBI) repository, accession number: 
GSE115334. 
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XI. Figure Legends:  
 
Figure 1: Differential expression of host lncRNAs after expression of HPV-16 E6 in primary 
foreskin keratinocytes. (A) Waterfall plot of host lncRNAs altered 1.5-fold or greater in primary 
foreskin keratinocytes (HEKa) expressing HPV-16 E6 compared to uninfected HEKa by high-
throughput RNA sequencing (RNA-seq) analysis. Triplicates for each sample were sent for RNA-
seq. (B) qRT-PCR validation of representative differentially expressed host lncRNAs found by 
RNA-seq analysis. Red bars represent the lncRNAs up-regulated with HPV-16 E6 expression, and 
green bars represent the lncRNAs down-regulated with HPV-16 E6 expression. GAPDH mRNA 
was used to normalize the qRT-PCR analyses, which are shown relative to uninfected HEKa (grey 
bars).  
 
Figure 2: Increased FAM83H-AS1 expression in primary cervical keratinocytes containing the 
HPV-16 genome as well as in HPV-16 positive cervical cancer and head and neck squamous cell 
carcinoma cell lines. (A) qRT-PCR analysis showing the increase of FAM83H-AS1 expression in 
newly immortalized cervical keratinocytes expressing entire HPV-16 genome (JAMM-16) 
compared to uninfected primary cervical keratinocytes (HCK). (B) qRT-PCR analysis showing 
the increase of FAM83H-AS1 expression in HPV-16 positive cervical cell lines (CaSki, 
W12/20863, W12/201402) and decrease of FAM83H-AS1 in HPV negative cervical cancer cell 
line (C-33A) compared to uninfected cervical keratinocytes (HCK). (C) qRT-PCR analysis 
showing the increase of FAM83H-AS1 expression in HPV-16 positive head and neck squamous 
cell carcinoma (HNSCC) cell lines (UMSCC-47 and UMSCC-104) compared to HPV negative 
HNSCC cell line (UMSCC-1). All graphs in the figure show the average of two individual 
experiments. Similar results were obtained in at least three independent experiments. GAPDH 
mRNA was used to normalize the qRT-PCR analyses. Two-tailed t test results are indicted as ** 
p ≤ 0.01. 
 
Figure 3: Regulation of FAM83H-AS1 expression by HPV-16 E6 in a p53-independent, p300-
dependent manner. (A) FAM83H-AS1 expression by qRT-PCR analysis in cervical keratinocytes 
(HCK) stably individually expressing HPV-16 E6 or E7, or co-expressing E6/E7 compared to GFP 
control. (B-C) qRT-PCR analysis of HPV-16 E6 and FAM83H-AS1 expression in HPV-16 
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positive CaSki (B) and W12/201402 (C) cervical cell lines transfected with an siRNA against 
HPV-16E6 compared to siRNA control. (D) qRT-PCR analysis of p53 and FAM83H-AS1 
expression in HCK transfected with an siRNA against p53 compared to siRNA control. (E) 
Genome representative image showing location of FAM83H, FAM83H-AS1, and three predictive 
p300 binding sites in FAM83H-AS1 promoter region. (F) p300 and FAM83H-AS1 expression in 
HCK transfected with an siRNA against p300 compared to siRNA control. All graphs in the figure 
show the average of two individual experiments. Similar results were obtained in at least three 
independent experiments. GAPDH mRNA was used to normalize the qRT-PCR analyses. Two-
tailed t test results are indicted as * p ≤ 0.05 and ** p ≤ 0.01. CTRL, control.  
 
Figure 4: FAM83H-AS1 is localized in the nucleus in cervical pre-malignant and cancerous cell 
lines. (A) qRT-PCR of FAM83H-AS1 expression in fractionated HPV-16 positive cervical cancer 
CaSki (A) and pre-malignant W12/201402 (B) cell lines. U6 small nuclear RNA (snRNA) was 
used as a nuclear control RNA and mature Beta Actin was used as a cytoplasmic control RNA. 
Representative images; similar results were obtained in at least three independent experiments. 
Normalization was done using C. Elegans total RNA as an exogenous spike for the amplification 
of worm-specific ama-1 gene. Two-tailed t test results are indicted as ** p ≤ 0.01. 
 
Figure 5: FAM83H-AS1 knockdown altered cell proliferation, migration, and apoptosis in CaSki 
cells. (A) Knockdown efficiency of individual and SMARTpool siRNA against FAM83H-AS1 in 
HPV-16 positive CaSki cell line, measured by qRT-PCR analysis. Because of variations in the 
expression of GAPDH after the knockdown of FAM83H-AS1, we used UBC mRNA to normalize 
the qRT-PCR analyses. The graph shows average of two individual experiments. (B) CaSki cells 
were transfected with individual siRNAs against FAM83H-AS1, siRNA SMARTpool against 
FAM83H-AS1, or siRNA control for 48 hours. Cells were then re-plated in equal numbers 
(200,000 cells/well, represented by dashed line in graph) and cultured another 48 hours prior to re-
counting attached cells. Data were obtained in triplicate, and the graph shows the average of two 
individual experiments. (C) CaSki cells were transfected with individual siRNAs against 
FAM83H-AS1, siRNA SMARTpool against FAM83H-AS1, or siRNA control for 24 hours then 
plated in equal numbers. Transfected cells were analyzed for cellular proliferation assessment by 
CCK-8 assay at 48, 72, and 96 hours post-plating.  The graph shows the average of two individual 
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experiments; similar results were obtained in three independent experiments. (D-F) CaSki cells 
were transfected with siRNA SMARTpool against FAM83H-AS1 or siRNA control for 24 hours 
then plated in equal numbers for experiments. (D) Transfected cells were analyzed for cell cycle 
alterations by FACS analysis. CaSki cells with knockdown of FAM83H-AS1 exhibit less cells in 
S-phase of cell cycle compared to control cells. The graph shows the average of two individual 
experiments; similar results were obtained in three independent experiments. (E) Transwell 
migration of transfected cells was analyzed 48 hours post-plating in upper chamber with 
chemoattractant in lower chamber. The graph shows the average of three individual experiments. 
(F) Transfected CaSki cells were collected at 1, 2, and 3 days post-plating, stained with Annexin 
V/PI, and analyzed by flow cytometry to show alterations in apoptosis compared to siRNA control. 
The graph shows the average of three individual experiments. Two-tailed t test results are indicted 
as * p ≤ 0.05 and ** p ≤ 0.01. 
 
Figure 6: FAM83H-AS1 expression is increased in human cervical cancer tissues and correlates 
with poor overall survival. (A) Increased FAM83H-AS1 expression in human cervical cancer and 
cervical intraepithelial neoplasia (CIN) stage 3 patient samples compared to non-cancerous 
cervical tissue as measured by qRT-PCR analysis. (B) The Cancer Genome Atlas (TCGA) analysis 
of FAM83H-AS1 RPKM values in cervical cancer tissues (n=196) compared to non-cancerous 
tissues (n=3). (C) Survival plot of cervical squamous cell carcinoma and endocervical 
adenocarcinoma (CESC) patient data mined from TCGA with low (n=22) vs. high (n=174) 
expression of FAM83H-AS1. High expression of FAM83H-AS1 expression correlates with worse 
overall survival in CESC patients.  
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XII. Supplementary Tables  
 
Table S1: Host lncRNAs altered after expression of HPV-16 E6 in primary foreskin keratinocytes.  
 
Table shows details for each host lncRNA that was altered 1.5-fold or greater in primary foreskin keratinocytes (HEKa) 
expressing HPV-16 E6 compared to uninfected HEKa. Triplicates for each sample were sent for high-throughput RNA 
sequencing analysis. 
 
Gene ID Fold 
Change 
([HPV 
16E6 ] vs 
[Control]) 
Gene Symbol Chro
moso
me 
Start End Strand RPKM 
GFP 
Control
-1 
RPKM 
GFP 
Control
-2 
RPKM 
GFP 
Control
-3 
RPKM 
HPV-
16 E6-
1 
RPKM 
HPV-
16 E6-
2 
RPKM 
HPV-
16 E6-
3 
ENSG00000130600 4.99 H19 chr11 2016406 2022700 - 2.12904
93 
2.1426
256 
5.6363
993 
19.22
9809 
10.78
3182 
15.41
4708 
ENSG00000254236 3.54 KB-1639H6.2 chr8 104032415 104033656 - 0 0 0.2873
624 
3.250
996 
3.968
86 
3.449
8966 
ENSG00000244528 3.31 AC134873.1 chr2 243064438 243064620 + 1.27679
34 
2.8750
565 
2.7582
934 
6.186
408 
6.602
485 
9.019
768 
ENSG00000273413 3.07 RP11-
96C23.15 
chr10 88729994 88730583 - 8.39354
6 
0 0 4.790
1816 
7.013
6943 
7.246
6874 
ENSG00000228626 3.06 RP11-
495P10.9 
chr1 147760107 147761057 - 2.02880
84 
0.8839
2633 
2.2444
494 
6.981
7734 
5.038
5094 
3.696
5914 
ENSG00000230937 2.94 MIR205HG chr1 209602165 209606183 + 61.5482
64 
49.323
284 
62.656
292 
218.4
987 
181.1
5729 
121.9
17755 
ENSG00000254860 2.73 TMEM9B-AS1 chr11 8986222 8999074 + 0.80623
74 
1.7021
289 
0.6363
604 
4.052
271 
3.137
7754 
2.730
444 
ENSG00000249641 2.69 HOXC-AS5 chr12 54329112 54333427 - 0.95938
82 
1.8041
867 
0.9305
784 
3.716
362 
3.758
8704 
2.516
7224 
ENSG00000270168 2.56 LA16c-
380H5.4 
chr16 3051301 3052017 + 6.47689
87 
0.8551
222 
4.0893
016 
9.194
51 
7.053
4296 
6.857
7585 
ENSG00000235314 2.53 LINC00957 chr7 44078770 44081905 + 0.35596
678 
0.7332
8674 
0.7004
4947 
1.938
0348 
2.741
936 
3.045
2104 
ENSG00000230409 2.50 TCEA1P2 chr3 37317087 37318089 + 7.46950
8 
9.5921
29 
10.218
497 
22.00
8438 
24.91
3902 
20.84
6043 
ENSG00000233223 2.45 AC113189.5 chr17 7485282 7487390 - 1.45960
63 
2.9885
232 
2.0333
843 
3.720
071 
5.512
9123 
6.323
3705 
ENSG00000254192 2.36 CTC-558O2.2 chr5 168081518 168094766 + 1.23549
65 
0.9035
5885 
1.6458
715 
3.684
764 
2.919
8492 
2.477
2859 
ENSG00000251580 2.35 RP11-
539L10.3 
chr4 6672452 6675557 - 0.83309 1.3336
157 
1.0557
044 
2.159
164 
2.004
1137 
4.219
327 
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ENSG00000220804 2.29 AC093642.5 chr2 243030784 243102304 + 1.02285
7 
1.6583
912 
2.8178
344 
4.230
8583 
2.589
8807 
5.207
1075 
ENSG00000201428 2.28 RN7SKP71 chr12 112704881 112705198 + 0.05682
099 
0.2640
6604 
0.3352
5583 
0.033
64112
6 
0.464
84584 
11.79
032 
ENSG00000238107 2.27 RP11-
495P10.5 
chr1 147767287 147769663 + 1.19644
03 
0.5992
599 
0.7781
85 
3.452
5478 
1.896
4818 
2.127
1327 
ENSG00000228463 2.25 AP006222.2 chr1 227615 267253 - 0.92179
984 
1.8147
042 
2.4698
875 
3.840
908 
3.520
3686 
3.766
3238 
ENSG00000263934 2.22 SNORD3A chr17 19091329 19092027 + 56.5595
66 
96.541
93 
87.400
215 
115.8
12065 
101.6
3637 
442.5
1657 
ENSG00000267984 2.21 CTD-
2616J11.9 
chr19 51848423 51856547 + 0.03900
8502 
0 0 0.093
65486 
0 10.77
701 
ENSG00000200488 2.18 RN7SKP203 chr2 76672205 76672536 - 0.39458
07 
2.4766
135 
0.8919
96 
1.181
4926 
0.604
2596 
21.76
185 
ENSG00000255717 2.13 SNHG1 chr11 62619460 62623386 - 7.09001
87 
3.8827
178 
5.6702
17 
13.07
7036 
11.90
0302 
9.669
952 
ENSG00000259001 2.12 RPPH1 chr14 20811207 20811844 - 15.0019
23 
52.592
74 
31.222
376 
27.47
0306 
36.77
239 
231.4
2776 
ENSG00000234741 2.10 GAS5 chr1 173833038 173838020 - 75.5498
6 
34.682
1 
63.601
818 
141.4
7461 
116.2
6347 
93.72
997 
ENSG00000215039 2.08 CD27-AS1 chr12 6548167 6560733 - 0.66829
19 
0.8538
55 
0.8496
1987 
3.074
375 
1.768
162 
1.665
7759 
ENSG00000259970 2.06 AC099668.5 chr3 49721913 49722416 - 0.57804
507 
1.3075
932 
0.8779
387 
2.843
681 
2.354
5742 
1.696
4713 
ENSG00000254578 2.04 CTD-
2517M22.16 
chr8 145689200 145690484 + 2.56431
48 
1.6997
473 
2.1004
875 
4.821
358 
4.543
132 
3.554
0457 
ENSG00000202198 2.04 RN7SK chr6 52860418 52860748 + 77.7898
2 
202.92
421 
175.02
835 
174.8
5051 
183.0
6963 
733.0
992 
ENSG00000255831 2.04 AL139385.1 chr13 111291555 111292340 + 0 2.5623
991 
0 0 5.166
7576 
4.200
331 
ENSG00000271992 2.02 RP11-42O15.3 chr1 70910754 70911219 + 0.34897
357 
0.0900
998 
0.8007
2904 
2.295
6822 
1.722
0101 
2.083
4737 
ENSG00000227195 2.01 MIR663A chr20 26167556 26232162 - 0.89503
71 
1.0255
735 
1.4251
992 
1.545
9784 
1.247
556 
6.125
4115 
ENSG00000239002 1.98 SCARNA10 chr12 6619388 6619717 + 0.54754
776 
1.9084
775 
1.3999
47 
1.167
0413 
2.879
6296 
6.134
6283 
ENSG00000263917 1.97 RP11-53I6.2 chr18 29598792 29691742 + 1.69259
02 
0.7714
8676 
1.5012
345 
1.865
241 
3.775
4347 
2.767
804 
ENSG00000266929 1.96 RP11-
400F19.8 
chr17 40688528 40714080 + 2.64025
28 
2.2248
166 
2.0022
075 
4.118
1316 
4.623
1112 
4.685
91 
ENSG00000223891 1.96 OSER1-AS1 chr20 42839600 42854667 + 0.42706
716 
1.3540
938 
1.7394
654 
2.074
9772 
3.062
2957 
2.806
612 
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ENSG00000244879 1.96 GABPB1-AS1 chr15 50647525 50659636 + 1.49664
08 
1.0193
752 
1.1708
221 
2.835
0017 
2.036
269 
2.337
8665 
ENSG00000225976 1.96 RP11-
192N10.2 
chr10 29986832 29987157 + 4.10156
9 
1.4167
225 
3.0522
678 
4.856
7057 
5.441
2627 
5.069
306 
ENSG00000259827 1.95 RP11-
343H19.2 
chr16 56716382 56721719 + 3.48532
18 
2.4112
535 
2.5835
383 
3.920
711 
3.862
1109 
10.60
9867 
ENSG00000235499 1.95 AC073046.25 chr2 74212259 74213470 + 4.49410
3 
3.1759
024 
2.5058
224 
6.528
4495 
5.577
129 
7.256
5813 
ENSG00000258377 1.94 RP11-649E7.5 chr14 50087533 50090198 - 0 3.7360
387 
4.1599
88 
5.070
155 
4.762
3515 
4.735
923 
ENSG00000233825 1.94 RP11-
135A24.4 
chr10 32635427 32636107 + 2.00523
7 
0.9287
9003 
1.8029
468 
2.122
1492 
3.477
26 
3.551
1832 
ENSG00000269926 1.93 RP11-
442H21.2 
chr10 74034673 74035738 - 37.1678
16 
17.135
89 
27.302
435 
56.37
6045 
53.58
8455 
41.68
311 
ENSG00000261824 1.91 LINC00662 chr19 28175488 28284848 - 1.77218
08 
0.9460
5726 
1.4761
61 
3.744
9877 
2.442
1446 
1.996
9538 
ENSG00000267317 1.90 CTB-25B13.12 chr19 1457664 1462764 - 0.77052
76 
2.7577
708 
2.0533
23 
3.240
5212 
3.709
7907 
3.223
024 
ENSG00000179859 1.89 AC025335.1 chr17 7816642 7819271 - 2.48756
43 
3.6358
418 
4.2272
625 
7.583
128 
6.336
298 
5.399
1914 
ENSG00000257653 1.87 RP11-579D7.2 chr12 49159977 49161106 + 0.70771
77 
1.0421
093 
1.3791
414 
2.705
9877 
1.943
5432 
1.797
2413 
ENSG00000238271 1.87 IFNWP19 chr9 21455483 21456048 + 6.09118
27 
4.1468
25 
6.1276
43 
10.78
6538 
8.897
233 
10.57
8037 
ENSG00000224032 1.87 EPB41L4A-AS1 chr5 111496223 111499973 + 7.39583
83 
3.9629
142 
7.1221
61 
9.977
508 
12.22
6742 
11.20
5975 
ENSG00000257270 1.87 RP11-
521B24.5 
chr14 105934130 105936954 - 6.40190
6 
3.2108
22 
3.5815
47 
8.843
35 
7.365
5524 
7.390
7046 
ENSG00000257084 1.86 U47924.27 chr12 7072409 7073610 + 31.198 36.405
44 
20.322
99 
53.07
6824 
61.99
1566 
44.91
036 
ENSG00000225377 1.85 RP5-1103G7.4 chr20 300957 328868 - 2.56064
6 
3.4069
042 
5.1782
656 
6.993
363 
5.695
6306 
7.200
583 
ENSG00000239470 1.84 RP11-16F15.2 chr11 9681946 9682503 + 6.97289
23 
3.0191
91 
4.1343
21 
10.61
4801 
8.628
567 
5.930
6784 
ENSG00000198496 1.84 NBR2 chr17 41277627 41305688 + 0.83190
143 
1.0633
509 
1.4072
425 
2.247
7791 
2.288
2934 
1.808
5096 
ENSG00000203499 1.84 FAM83H-AS1 chr8 144816310 144828507 + 9.59697
8 
3.3299
105 
4.7020
435 
12.95
5384 
9.471
8895 
7.570
58 
ENSG00000177410 1.83 ZFAS1 chr20 47894715 47905797 + 211.102
16 
139.73
38 
252.70
905 
418.7
3697 
367.0
7626 
297.5
4745 
ENSG00000224891 1.83 AC007899.3 chr2 37375673 37376447 + 4.01025
72 
2.9299
183 
3.7727
127 
6.872
386 
6.110
306 
6.431
074 
ENSG00000214293 1.82 RSBN1L-AS1 chr7 77286977 77325582 - 1.88850 1.6980 1.8871 3.833 3.262 2.897
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9 832 909 9822 9604 0351 
ENSG00000250902 1.81 RP11-
301H24.4 
chr4 146435767 146438270 - 6.98976
66 
3.0939
543 
5.3921
43 
10.33
7118 
8.141
412 
8.172
936 
ENSG00000259375 1.81 RP11-
815J21.2 
chr15 86122277 86123409 - 1.83370
24 
1.1494
807 
1.1902
504 
1.597
2154 
2.884
9528 
3.210
236 
ENSG00000012171 1.80 SEMA3B chr3 50304990 50314977 + 0.94935
43 
0.3429
1044 
1.0639
977 
2.247
6633 
1.790
5937 
1.540
2615 
ENSG00000273344 1.79 PAXIP1-AS1 chr7 154795158 154797413 + 1.07325
18 
2.6334
62 
2.4573
538 
3.006
4073 
3.060
8828 
4.358
569 
ENSG00000260552 1.79 RP11-49I11.1 chr18 33759959 33767411 - 1.30548
33 
2.1372
445 
4.7266
11 
3.969
9843 
6.068
1834 
3.154
5815 
ENSG00000243004 1.79 AC005062.2 chr7 19958604 20180076 - 4.87558
13 
7.2985
44 
3.9218
314 
6.931
1867 
14.13
0893 
8.209
532 
ENSG00000196756 1.78 SNHG17 chr20 37049235 37063996 - 2.54244
57 
1.8823
376 
4.6329
513 
4.370
9865 
5.745
9593 
5.005
6214 
ENSG00000272906 1.78 RP11-
533E19.7 
chr1 179850742 179851730 - 0.29894
31 
1.2788
76 
1.0368
878 
1.577
8978 
1.703
776 
2.794
0536 
ENSG00000261771 1.78 DYX1C1-
CCPG1 
chr15 55647446 55790558 - 2.09689
38 
2.6955
016 
2.8982
72 
5.290
535 
4.608
052 
3.804
3263 
ENSG00000204054 1.78 LINC00963 chr9 132245730 132275947 + 1.01223
13 
0.8181
0194 
0.7509
8056 
2.690
7895 
1.890
5445 
1.125
3008 
ENSG00000269893 1.78 SNHG8 chr4 119199864 119200978 + 95.6830
75 
85.640
51 
110.78
4874 
193.3
1099 
208.9
9217 
126.6
07704 
ENSG00000269900 1.78 RMRP chr9 35657748 35658015 - 61.7190
86 
117.54
486 
105.27
629 
99.84
465 
121.5
6224 
352.0
1825 
ENSG00000265735 1.76 RN7SL5P chr9 9442060 9442347 + 89.3426
7 
171.01
642 
175.36
769 
146.4
969 
160.5
5365 
623.5
067 
ENSG00000229413 1.75 AC018638.1 chr7 128293740 128293989 - 2.08112
76 
0.8533
8426 
0.6139
542 
2.203
358 
1.459
3241 
3.445
703 
ENSG00000250299 1.74 MRPS31P4 chr13 53191693 53211581 + 0.99767
58 
0.6966
341 
0.8349
367 
2.199
7466 
1.885
6709 
1.279
5835 
ENSG00000226419 1.74 RP11-31F15.1 chr1 113499037 113542118 + 3.05203
82 
2.3166
275 
2.4479
396 
5.745
393 
4.417
4857 
3.588
944 
ENSG00000245060 1.74 LINC00847 chr5 180257957 180262726 + 2.51798
3 
1.9512
683 
1.9726
743 
3.667
7196 
3.663
7437 
3.780
457 
ENSG00000110811 1.73 LEPREL2 chr12 6937572 6949018 + 1.43181
74 
1.6433
642 
1.4975
213 
3.065
626 
2.159
1876 
2.762
544 
ENSG00000262160 1.73 RP11-96D1.11 chr16 68259872 68263048 - 1.01642
31 
1.7172
104 
1.3368
715 
2.896
4238 
2.114
6343 
1.976
8672 
ENSG00000250251 1.73 PKD1P6 chr16 15219099 15248421 - 4.10675
76 
2.8266
087 
4.4332
04 
4.759
571 
5.149
509 
10.82
3436 
ENSG00000203512 1.72 AL353662.2 chr9 34195642 34195883 + 1.73161
97 
0.8091
1475 
1.1475
528 
3.164
7897 
1.525
1368 
2.108
7782 
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ENSG00000227615 1.72 RP11-864N7.2 chr11 74456761 74457159 - 6.18152
57 
1.2890
593 
4.9579
773 
6.729
743 
6.448
0925 
4.633
6823 
ENSG00000257086 1.72 RP11-
783K16.13 
chr11 64014411 64016966 - 1.58257
52 
1.1539
651 
1.8851
668 
3.347
7898 
2.183
432 
2.384
6471 
ENSG00000230795 1.72 HLA-K chr6 29894236 29897009 + 0.61804
247 
1.1913
046 
1.5108
755 
1.330
7873 
2.285
3572 
2.992
5754 
ENSG00000180672 1.71 AC007362.1 chr2 206642540 206644433 + 1.37003
06 
0.6789
9704 
1.1776
617 
3.312
5985 
1.914
6636 
1.281
505 
ENSG00000254682 1.71 RP11-
660L16.2 
chr11 71159720 71163203 + 1.14260
32 
0.7100
659 
0.4964
7444 
1.667
6105 
1.925
3993 
1.792
3354 
ENSG00000267023 1.71 LRRC37A16P chr17 66121918 66148609 - 1.45405
14 
1.6921
17 
1.4601
423 
2.523
746 
2.944
7954 
2.423
118 
ENSG00000227081 1.71 RP11-
543P15.1 
chr12 3320775 3321096 - 7.24820
5 
1.5755
806 
5.4170
194 
7.375
556 
8.514
681 
4.918
4346 
ENSG00000223745 1.71 RP4-717I23.3 chr1 93727743 93811582 - 0.95840
377 
1.4749
708 
1.4199
601 
2.833
7555 
1.944
4739 
1.893
2604 
ENSG00000226752 1.70 PSMD5-AS1 chr9 123587106 123616651 + 0.90399
02 
0.6311
066 
1.0164
516 
2.319
7796 
1.464
0397 
1.481
2256 
ENSG00000227632 1.70 AC018804.6 chr2 130959885 130970201 + 1.50575
63 
2.2844
598 
2.4223
318 
2.553
2963 
4.621
544 
3.451
2596 
ENSG00000228327 1.69 RP11-
206L10.2 
chr1 700237 714006 - 3.12584
38 
1.0653
372 
3.5199
823 
3.532
1116 
3.393
6765 
4.746
0814 
ENSG00000228638 1.69 FCF1P2 chr3 48332283 48332865 - 0.71284
515 
0.7201
8015 
0.2133
4462 
2.789
1552 
1.738
6442 
0.814
9583 
ENSG00000258186 1.69 SLC7A5P2 chr16 21531151 21531686 - 8.26003 6.4758
79 
14.699
861 
13.65
3822 
13.00
4153 
21.40
1606 
ENSG00000225648 1.68 SBDSP1 chr7 72300004 72307909 + 10.7959
62 
11.587
327 
13.133
697 
19.68
8213 
19.81
655 
19.96
0356 
ENSG00000272711 1.68 RP11-
259N19.1 
chr2 75059782 75061114 - 1.45040
58 
1.1969
146 
1.6662
19 
3.884
3012 
2.328
7628 
1.503
2032 
ENSG00000256462 1.67 RP11-116G8.5 chr10 5566939 5567705 - 3.94108
49 
0 0 3.097
3866 
5.978
923 
0 
ENSG00000236439 1.67 RP11-175B9.3 chr1 202440937 202441258 - 6.70856
76 
3.0561
595 
4.4550
18 
7.306
8976 
8.068
728 
7.226
4347 
ENSG00000233016 1.67 SNHG7 chr9 139615818 139622636 - 3.80191
66 
2.5988
54 
3.9963
634 
4.894
757 
6.888
8636 
5.446
209 
ENSG00000234975 1.67 FTH1P2 chr1 228823162 228823574 + 2.36462
16 
8.7332
3 
5.5768
6 
7.877
958 
8.395
835 
8.092
968 
ENSG00000228998 1.66 RP11-697E2.7 chr15 90818266 90820841 + 1.66241
1 
1.0105
448 
1.4692
17 
2.458
5187 
2.098
612 
2.181
2184 
ENSG00000251022 1.66 THAP9-AS1 chr4 83814162 83822113 - 2.55584
17 
2.0884
433 
4.3881
38 
5.688
368 
4.508
133 
4.144
217 
ENSG00000256633 1.64 RP11-169D4.2 chr11 72295616 72299023 + 0.36736 0.2219 0.2809 0.585 1.582 2.773
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822 0487 7868 01613 57 093 
ENSG00000266754 1.64 RN7SL524P chr10 105734277 105734572 - 0.67657
28 
0.7092
3144 
1.0905
253 
2.662
4227 
0.618
2988 
1.791
2405 
ENSG00000260269 1.63 CTD-
2323K18.1 
chr15 75819491 75893546 - 1.65046
27 
0.9741
242 
0.6995
654 
3.534
106 
1.676
849 
1.202
5416 
ENSG00000260088 1.62 RP11-92G12.3 chr1 200638635 200663378 + 1.84138
01 
1.6593
088 
3.4227
7 
4.249
6977 
2.985
226 
3.536
2139 
ENSG00000267519 1.62 MIR24-2 chr19 13945330 13947173 - 4.72304
44 
4.5993
896 
8.6144
75 
9.827
661 
7.844
5435 
10.23
9091 
ENSG00000254681 1.61 PKD1P5 chr16 18458147 18495797 - 1.31439
34 
1.0079
812 
1.4375
087 
1.722
2397 
2.123
2183 
2.183
325 
ENSG00000197989 1.61 SNHG12 chr1 28905050 28909495 - 3.87161
02 
2.7489
998 
4.3954
32 
5.069
179 
5.840
756 
6.601
1386 
ENSG00000247315 1.61 AL034548.1 chr20 278214 280961 + 3.02354
24 
2.0685
76 
2.8194
673 
4.320
936 
4.353
7407 
3.915
0994 
ENSG00000251260 1.61 WDFY3-AS1 chr4 85724411 85731544 + 1.00389
2 
1.4533
712 
2.2153
144 
3.214
5927 
1.323
8585 
3.147
409 
ENSG00000250182 1.60 EEF1A1P13 chr5 14652047 14653438 - 9.46529 6.2075
24 
6.9742
58 
12.66
7569 
11.56
31275 
11.53
3177 
ENSG00000251143 1.60 RP11-849H4.4 chr11 71725337 71731956 + 3.97319
3 
6.8831
76 
5.2716
713 
9.131
103 
7.891
925 
8.129
692 
ENSG00000272888 1.59 AC013394.2 chr15 93425937 93441975 + 0.84985
04 
1.4388
658 
1.8384
619 
2.750
0532 
2.498
7977 
1.538
8129 
ENSG00000173295 1.58 FAM86B3P chr8 8086117 8102387 + 0.99347
425 
0.8375
4015 
1.0657
19 
1.652
3628 
1.481
0578 
1.727
7136 
ENSG00000271581 1.58 XXbac-
BPG248L24.12 
chr6 31324424 31325414 + 10.9642
39 
42.648
693 
30.244
503 
26.87
288 
45.12
537 
46.04
9137 
ENSG00000234694 1.58 RP1-92O14.3 chr1 43820355 43824329 - 1.44880
64 
2.5090
265 
1.8279
302 
3.333
9834 
4.057
3297 
1.937
6101 
ENSG00000231970 1.58 RP11-
452K12.7 
chr10 99160872 99179281 + 4.40716
4 
1.8063
688 
1.6439
916 
2.576
6385 
4.841
898 
4.122
6187 
ENSG00000258824 1.58 CTD-
2555O16.2 
chr14 64889653 64915275 - 0.54871
875 
0.3577
88 
0.8857
678 
2.461
6747 
1.143
732 
1.395
1521 
ENSG00000224886 1.58 BEND3P3 chr10 81444250 81444739 - 0.14750
265 
1.2424
577 
0.5076
731 
1.309
9444 
0.603
35094 
3.709
9042 
ENSG00000259623 1.57 RP11-156E6.1 chr17 40004770 40007699 - 1.19021
55 
0.7809
776 
1.3159
648 
2.417
0635 
1.441
4529 
1.755
5282 
ENSG00000214184 1.57 AC012487.2 chr2 109123971 109150652 - 1.13318
16 
1.5004
897 
1.6879
808 
2.188
2014 
1.909
4998 
2.645
182 
ENSG00000231864 1.57 RP11-
229P13.23 
chr9 139957987 139959033 + 2.14776
64 
0.5192
181 
1.6303
065 
3.468
3156 
2.224
2556 
1.746
7672 
ENSG00000259948 1.56 RP11-
326A19.5 
chr15 89744322 89744999 - 0 0 0 0 2.250
7296 
1.690
6314 
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ENSG00000203875 1.56 SNHG5 chr6 86370710 86388451 - 102.081
635 
49.028
21 
72.932
594 
136.5
7454 
115.0
8786 
87.77
891 
ENSG00000262944 1.56 RP11-473I1.9 chr16 9198705 9200618 + 4.37061
83 
3.5058
978 
5.2434
583 
9.294
138 
6.550
2 
4.981
1077 
ENSG00000223361 1.56 FTH1P10 chr5 17353804 17354733 - 1.12084
73 
1.9096
965 
3.1168
904 
3.494
8602 
3.568
4345 
2.014
9157 
ENSG00000234797 1.55 RPS3AP6 chr15 60060543 60061347 + 8.03755
8 
4.6485
057 
6.0571
284 
10.87
507 
9.480
915 
8.230
892 
ENSG00000186831 1.55 KRT17P2 chr17 18330175 18335162 + 2.67693
57 
5.9414
525 
8.2313
9 
8.073
757 
7.960
8884 
7.615
3316 
ENSG00000235298 1.55 RP11-575L7.8 chr9 86587148 86590692 + 0.99603
415 
0.1577
4745 
1.2684
056 
1.084
6498 
1.106
6335 
3.923
4712 
ENSG00000244398 1.55 RP11-
466H18.1 
chr11 16996240 16996560 - 210.415
99 
118.90
0734 
159.80
867 
323.5
744 
266.5
1407 
171.5
4987 
ENSG00000232956 1.54 SNHG15 chr7 45022622 45026560 - 4.96357
63 
4.2213
054 
6.0738
254 
7.899
4136 
7.568
8367 
7.776
898 
ENSG00000265688 1.54 MAFG-AS1 chr17 79885705 79888629 + 2.63169
65 
1.0524
323 
1.6549
61 
2.523
4575 
3.253
9558 
2.027
5886 
ENSG00000205746 1.54 RP11-
1212A22.1 
chr16 18428257 18488396 - 2.70093
97 
1.9503
261 
2.9362
893 
3.497
657 
3.365
603 
4.758
7376 
ENSG00000205763 1.53 RP9P chr7 32956427 32982788 - 1.58876
7 
2.6736 4.2468
457 
3.486
325 
3.794
6262 
4.901
2694 
ENSG00000260107 1.53 AC005606.15 chr16 2047655 2048375 + 9.51927
2 
5.6106
744 
7.2765
503 
8.348
566 
12.49
4355 
13.30
5827 
ENSG00000232445 1.53 RP11-132A1.4 chr7 100951627 100954266 + 6.63814
2 
1.0719
961 
3.6041
183 
4.977
168 
4.163
5494 
4.395
196 
ENSG00000204194 1.52 RPL12P1 chr6 33367836 33368333 - 8.81644
3 
4.4001
51 
10.382
515 
8.702
698 
12.67
3401 
12.93
3394 
ENSG00000254473 1.52 RP11-522I20.3 chr9 86322509 86328293 + 0.62335
21 
0.6170
2996 
0.9024
317 
2.064
1985 
1.439
8504 
1.178
33 
ENSG00000261971 1.52 RP11-
473M20.7 
chr16 3101992 3109371 - 0.38817
36 
0.9558
703 
1.3753
506 
1.559
6504 
1.193
0581 
2.581
4805 
ENSG00000235725 1.51 AC007389.3 chr2 65816700 65867311 - 0.91346
866 
0.7893
489 
1.0001
628 
1.792
3195 
1.434
173 
1.351
0778 
ENSG00000229212 1.51 RP11-561C5.4 chr15 85747141 85778026 - 1.54617
49 
2.1187
642 
2.2953
222 
2.896
4856 
2.832
387 
3.181
3629 
ENSG00000259328 1.51 RP11-
152F13.7 
chr15 82944773 82974312 + 1.00161
61 
1.3405
782 
1.1754
336 
1.238
5976 
1.825
4333 
2.403
051 
ENSG00000223396 1.51 RPS10P7 chr1 201487831 201499602 + 3.12924
72 
1.9355
738 
2.9419
267 
4.337
2602 
4.088
839 
3.454
8473 
ENSG00000269032 1.51 AC016629.7 chr19 59097525 59097723 + 0.32712
79 
0.8532
135 
0.6416
285 
0 2.120
2471 
1.611
3639 
ENSG00000203394 1.51 RP5-930J4.4 chr1 21069480 21070455 + 4.33596 2.2852 2.7163 5.946 4.018 3.844
 200 
 
37 726 084 6834 1866 3263 
ENSG00000225151 1.50 AC103965.1 chr15 84867600 84898888 - 7.19354
3 
9.0674
305 
8.6491
41 
13.35
8168 
12.31
3677 
11.67
2823 
ENSG00000244257 1.50 PKD1P1 chr16 16404198 16428047 + 2.76064
6 
1.8415
892 
2.8608
568 
3.244
7884 
3.438
1177 
4.434
0997 
ENSG00000267580 1.50 CTD-
2540B15.11 
chr19 33790840 33792074 + 1.09239
59 
2.0792
82 
1.7315
762 
2.528
3904 
2.831
5682 
1.866
6612 
ENSG00000267151 1.50 MIR2117 chr17 41522075 41528568 + 1.46409
5 
1.9914
546 
1.7382
286 
2.071
921 
3.630
837 
2.286
1967 
ENSG00000270055 1.50 CTD-
3092A11.2 
chr15 30780166 30782516 + 1.17078
79 
0.9375
974 
1.4183
607 
2.055
2423 
1.595
0989 
1.714
8618 
ENSG00000228989 1.50 AC133528.2 chr2 242629829 242633704 + 1.82867
69 
1.5681
707 
0.6850
529 
3.815
1476 
2.544
251 
0.348
43844 
ENSG00000262791 1.50 RP11-
961A15.1 
chr17 1629042 1641879 - 0.61560
89 
0.1723
9359 
0.3134
515 
1.525
6633 
0.680
255 
2.214
0858 
ENSG00000248092 1.50 NNT-AS1 chr5 43571696 43603332 - 2.29409
2 
2.9645
55 
2.8210
022 
4.673
5754 
3.726
381 
3.718
8199 
ENSG00000270232 -1.51 RP11-475J5.7 chr5 99381632 99382078 - 14.4310
055 
8.3597
29 
7.1948
752 
7.179
785 
5.739
9325 
6.123
285 
ENSG00000255125 -1.51 RP11-
685M7.5 
chr11 10804860 10823172 + 2.00767
5 
1.9517
535 
4.4939
42 
1.263
7898 
0.861
9299 
4.028
4314 
ENSG00000265415 -1.52 CTD-2510F5.4 chr17 57280038 57281190 - 2.19017
36 
1.3541
911 
1.1740
087 
0.709
3079 
0.546
59224 
0.912
0858 
ENSG00000232358 -1.52 RP5-
955M13.4 
chr20 49615907 49626556 + 10.9595
83 
13.578
551 
15.932
661 
5.993
6986 
10.71
9287 
10.58
0886 
ENSG00000231298 -1.52 LINC00704 chr10 4692377 4720346 - 3.50088
14 
0.8419
1686 
0.5089
952 
0.122
57986
5 
0 0.204
42243 
ENSG00000269834 -1.52 CTD-
3018O17.3 
chr19 52892095 52901019 - 0.42566
574 
3.0581
512 
1.1532
478 
0.938
63595 
0.609
15244 
0.861
5535 
ENSG00000228649 -1.53 AC005682.5 chr7 22893797 22901021 + 2.84680
3 
1.1739
081 
1.4650
004 
1.375
8489 
0.801
59485 
0.919
04426 
ENSG00000250234 -1.53 CTD-
2024P10.1 
chr5 34656517 34657355 - 2.84991
8 
3.6838
043 
2.7612
894 
1.368
9165 
1.759
3302 
3.366
3306 
ENSG00000260549 -1.53 MT1L chr16 56651388 56652730 + 32.0605
55 
7.0488
276 
13.661
485 
8.433
363 
8.580
506 
11.88
6822 
ENSG00000269983 -1.53 RP11-
497H16.9 
chr5 69745463 69746180 + 2.89407
18 
2.6753
237 
1.4972
115 
1.057
8682 
2.014
671 
1.510
466 
ENSG00000232656 -1.54 IDI2-AS1 chr10 1068606 1090138 + 8.97962 2.5590
303 
4.5844
545 
4.037
7965 
2.612
7467 
2.731
6613 
ENSG00000273132 -1.54 RP11-
350J20.12 
chr6 150173598 150174328 + 4.93389
4 
3.8961
434 
1.3101
063 
0.214
81651 
2.748
0006 
2.503
8617 
ENSG00000262413 -1.54 RP11-498C9.3 chr17 79825597 79826428 + 131.380 83.971 65.720 57.11 68.61 50.39
 201 
 
23 855 39 3407 178 401 
ENSG00000233144 -1.55 RP11-537A6.9 chr10 75141191 75143254 + 1.73480
49 
1.7642
145 
2.0247
85 
0.579
00864 
1.376
7893 
1.206
9995 
ENSG00000226963 -1.55 AC078883.4 chr2 173292502 173293331 - 3.65149 3.3694
608 
3.6925
917 
2.460
7828 
1.833
3695 
2.698
5145 
ENSG00000234327 -1.55 AC012146.7 chr17 5014763 5017674 + 1.95390
83 
2.4199
314 
1.5286
9 
0.984
7564 
1.408
148 
1.369
486 
ENSG00000259153 -1.56 RP6-65G23.3 chr14 71276922 71282120 + 1.99365
48 
2.7267
768 
1.2656
376 
1.045
882 
0.530
8814 
1.731
0688 
ENSG00000258791 -1.58 LINC00520 chr14 56247864 56263406 - 0.64874
68 
2.9121
616 
2.3695
24 
0.322
98782 
1.232
0567 
1.418
7404 
ENSG00000267776 -1.58 AC006116.24 chr19 56888073 56888653 - 2.15047
86 
3.7224
712 
2.8212
99 
1.832
4789 
1.608
6241 
1.933
2796 
ENSG00000257181 -1.58 RP11-611O2.5 chr12 69235068 69237017 - 5.82705
8 
7.4925
43 
6.0171
41 
4.169
096 
3.725
6134 
4.259
7303 
ENSG00000267774 -1.58 RP11-2N1.2 chr18 57363691 57364644 + 4.9585 2.7897
93 
5.2442
584 
1.467
508 
3.439
1992 
3.611
8386 
ENSG00000241749 -1.59 RPSAP52 chr12 66151800 66220754 - 3.20631
31 
1.0826
937 
1.4755
359 
0.093
51292 
0.572
23415 
1.282
0605 
ENSG00000268854 -1.59 CTD-
2545M3.2 
chr19 50983376 50986608 - 4.72710
04 
2.3693
736 
1.3470
087 
3.467
783 
1.066
7965 
1.013
8669 
ENSG00000224818 -1.59 RP11-134G8.8 chr1 201433511 201434274 - 3.14244
77 
7.4775
295 
3.8924
434 
2.826
5297 
2.930
994 
2.728
9903 
ENSG00000232815 -1.59 LINC00537 chr9 68413482 68414196 - 3.58854
34 
3.3276
02 
2.7501
92 
2.034
8413 
2.185
565 
1.820
1643 
ENSG00000241494 -1.61 RP11-796G6.1 chr14 102144280 102144717 + 3.58287
45 
1.8213
323 
2.3123
465 
1.848
1115 
1.181
2179 
1.666
4281 
ENSG00000258017 -1.62 RP11-
386G11.10 
chr12 49521565 49541652 + 27.8705
02 
18.402
964 
17.180
283 
12.05
1238 
12.65
8115 
13.56
6694 
ENSG00000034063 -1.62 UHRF1 chr19 4903092 4962165 + 6.74429
46 
1.2855
517 
2.7702
923 
2.075
5224 
1.767
3001 
1.536
0543 
ENSG00000254258 -1.62 RP11-398H6.1 chr8 140472305 140475259 - 4.54776
14 
7.7839
007 
6.3626
404 
3.925
3066 
3.584
0328 
3.740
049 
ENSG00000213412 -1.64 HNRNPA1P33 chr10 47133338 47133898 - 14.4520
4 
8.3262
005 
6.1332
52 
8.466
77 
4.197
107 
4.750
102 
ENSG00000126005 -1.64 MMP24-AS1 chr20 33804265 33865934 - 9.15239
3 
7.7007
318 
6.1065
493 
5.459
143 
5.335
1436 
3.377
0957 
ENSG00000172965 -1.65 MIR4435-1HG chr2 111953927 112252677 - 3.55057
67 
3.3823
805 
3.6901
011 
1.780
8807 
2.279
2993 
2.452
1575 
ENSG00000253161 -1.65 RP11-
150O12.1 
chr8 37278859 37411701 - 11.0290
21 
12.441
466 
9.9816
79 
6.311
8887 
8.075
069 
6.012
6433 
ENSG00000261068 -1.65 RP11-7K24.3 chr6 42059976 42061997 - 1.63533
17 
8.6070
25 
3.6644
359 
1.894
0854 
2.506
5024 
2.411
0541 
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ENSG00000187653 -1.66 TMSB4XP8 chr4 91759652 91760263 - 8.07511
6 
19.661
818 
14.503
13 
6.456
596 
7.568
5825 
10.31
9572 
ENSG00000226005 -1.66 RP11-
464C19.3 
chr10 3976711 3978005 + 1.07008
05 
1.8116
003 
2.9764
59 
0.289
62108 
0.678
89744 
1.258
3201 
ENSG00000250318 -1.67 CTA-963H5.5 chr22 31049864 31050801 - 1.83993
59 
2.2982
81 
1.8083
909 
0.734
8674 
0.672
6246 
1.651
6936 
ENSG00000240225 -1.67 ZNF542 chr19 56879468 56891197 + 2.40770
34 
2.6245
768 
2.5352
726 
1.434
9543 
1.558
2225 
1.541
5956 
ENSG00000240875 -1.68 LINC00886 chr3 156465135 156534851 - 8.04174
8 
2.8910
108 
2.4221
4 
2.591
8982 
2.259
8019 
2.029
531 
ENSG00000256663 -1.72 RP11-
424C20.2 
chr12 20704524 20705946 + 4.26013
66 
0.7228
8775 
1.1924
789 
0.947
2472 
0.934
9184 
0.820
1998 
ENSG00000241990 -1.72 RP6-109B7.3 chr22 46449585 46453090 + 7.39844
27 
3.9867
473 
4.8413
033 
3.091
525 
3.469
6312 
2.616
5955 
ENSG00000245112 -1.74 SMARCA5-AS1 chr4 144434625 144435788 - 0.00956
0357 
5.2469
225 
0 0 0.159
80777 
0 
ENSG00000259330 -1.74 LINC00984 chr15 40617417 40618916 + 4.89751 3.6402
433 
3.2306
47 
2.593
4253 
2.204
161 
1.912
7241 
ENSG00000235385 -1.75 GS1-600G8.5 chrX 13284167 13321571 - 4.73486
38 
22.813
477 
19.080
942 
3.339
2224 
14.33
58755 
8.066
61 
ENSG00000261065 -1.75 RP11-74C13.4 chr1 204100190 204101094 + 1.99908
89 
2.6730
783 
0.4170
3206 
0.414
32646 
0.868
4934 
0 
ENSG00000253618 -1.76 GRPEL2-AS1 chr5 148727679 148737205 - 1.68886
54 
3.2317
665 
0 0.215
5406 
0.803
7886 
0 
ENSG00000258232 -1.77 RP11-
161H23.5 
chr12 49658939 49667089 - 33.3097
57 
28.819
185 
28.912
59 
14.44
1423 
19.74
7879 
17.62
5807 
ENSG00000272734 -1.79 ADIRF-AS1 chr10 88725102 88731068 - 5.43516
25 
12.950
257 
11.457
844 
4.700
653 
5.038
381 
5.980
5155 
ENSG00000234546 -1.81 RP3-510D11.2 chr1 9242263 9252148 + 11.2780
56 
4.5766
697 
5.7239
7 
2.883
4605 
5.230
489 
3.284
4615 
ENSG00000258908 -1.82 RP11-
203M5.8 
chr14 20942948 20945248 - 7.68502
6 
3.8135
834 
4.4676
06 
2.660
3262 
2.985
3904 
2.748
8363 
ENSG00000272159 -1.83 RP11-
350N15.6 
chr8 38265566 38266260 - 7.30503
03 
2.4662
013 
2.9248
87 
1.585
6465 
2.061
9986 
2.634
9046 
ENSG00000226721 -1.84 EEF1DP2 chr9 95599108 95599950 - 0 6.2755
63 
0 0 0 0 
ENSG00000204556 -1.86 CTD-2514C3.1 chr20 25999468 26001320 + 3.08402
75 
2.3788
395 
1.0570
529 
1.181
9186 
0.448
66753 
1.024
0932 
ENSG00000197358 -1.86 BNIP3P1 chr14 28733596 28735180 + 4.02136
66 
6.1853
94 
4.5065
994 
2.335
3097 
2.544
7326 
2.919
4083 
ENSG00000235237 -1.88 RP1-151B14.6 chr22 37562797 37578890 + 5.69870
1 
5.5882
27 
3.9706
326 
2.796
2503 
2.296
2286 
2.966
6011 
ENSG00000237499 -1.89 RP11-356I2.4 chr6 138144810 138189370 - 2.07288 2.8674 2.2776 0.910 1.268 1.577
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89 767 296 7068 385 585 
ENSG00000235847 -1.89 LDHAP7 chr2 85004383 85005347 - 2.74156
7 
2.0703
194 
1.2152
584 
0.508
1032 
1.017
5685 
0.249
74425 
ENSG00000273038 -1.90 RP11-
479G22.8 
chr10 33176189 33178239 - 2.26414
06 
2.7482
634 
1.5507
42 
0.526
8092 
1.410
5644 
0.987
04404 
ENSG00000231991 -1.91 ANXA2P2 chr9 33624223 33625532 + 134.588
53 
110.10
068 
128.57
472 
52.56
764 
66.60
7285 
77.69
0636 
ENSG00000256929 -1.91 AC067852.1 chr17 40673736 40674065 + 3.25574 8.0733
17 
4.7597
175 
3.042
4023 
3.687
5687 
1.590
6979 
ENSG00000255959 -1.92 RP11-
804A23.2 
chr11 60603469 60610438 - 5.55156
56 
2.3799
477 
2.5062
263 
1.125
2497 
1.753
554 
2.367
571 
ENSG00000251292 -1.93 RP11-
380P13.2 
chr4 23724885 23735202 - 38.6029
8 
68.663
376 
43.137
657 
25.19
0517 
34.78
7884 
18.08
7368 
ENSG00000262410 -1.96 RP11-
388C12.8 
chr17 80702944 80703585 + 2.04051
07 
3.6950
738 
4.6220
4 
2.332
8707 
0.493
39446 
1.994
9535 
ENSG00000266088 -1.97 RP5-1028K7.2 chr17 38673278 38683254 + 4.31365
35 
1.3317
922 
1.3348
67 
0.232
17432 
0.229
15247 
0.586
2707 
ENSG00000255234 -1.98 RP11-
727A23.10 
chr11 82997171 83134559 + 74.2644
35 
131.67
998 
93.626
11 
40.38
3236 
64.51
9875 
45.11
061 
ENSG00000231826 -1.98 AC016735.2 chr2 43254992 43266686 - 16.923 4.0733
547 
5.2401
91 
4.893
341 
3.788
711 
2.493
266 
ENSG00000235823 -2.00 LINC00263 chr10 102133372 102143125 + 2.90408
5 
3.2670
798 
2.4657
273 
1.211
951 
1.841
8641 
1.311
8396 
ENSG00000265992 -2.00 ESRG chr3 54666149 54673884 - 233.581
45 
439.66
51 
314.18
79 
138.6
1157 
202.8
8977 
142.8
2372 
ENSG00000260834 -2.02 RP11-256I9.2 chr16 65224876 65268817 - 56.8772
7 
96.663
605 
70.333
88 
29.44
8397 
46.84
315 
33.75
8797 
ENSG00000256940 -2.06 RP11-
783K16.5 
chr11 64013436 64015689 + 13.2824
1 
9.2834
835 
8.4336
85 
6.031
071 
4.409
4415 
4.459
4874 
ENSG00000273387 -2.07 RP3-412A9.16 chr22 31478142 31479551 - 3.50702
29 
1.8962
02 
1.4603
726 
1.100
5665 
0.395
10265 
0.518
1117 
ENSG00000255021 -2.08 RP11-536I6.2 chr3 14313873 14345345 - 14.2297
64 
26.088
594 
15.773
34 
7.262
8064 
12.21
7939 
7.326
7016 
ENSG00000100181 -2.08 TPTEP1 chr22 17082777 17179632 + 20.2850
84 
40.960
05 
27.098
47 
11.95
8863 
17.23
5292 
12.10
646 
ENSG00000236673 -2.09 RP11-69I8.2 chr6 132223103 132241705 + 8.28539
9 
16.666
319 
10.295
293 
4.810
559 
6.592
9637 
4.929
272 
ENSG00000226792 -2.09 LINC00371 chr13 51656984 51746524 - 9.05261
9 
16.953
245 
10.620
668 
5.284
7075 
6.886
0707 
4.875
6647 
ENSG00000236824 -2.12 BCYRN1 chr2 47558199 47571656 + 12.5237
26 
24.176
477 
18.561
161 
5.118
2065 
7.327
3034 
15.67
111 
ENSG00000224081 -2.12 LINC01057 chr1 95104017 95285837 - 59.7651
8 
112.70
979 
71.806
335 
32.73
587 
50.64
0713 
30.50
0008 
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ENSG00000225383 -2.15 SFTA1P chr10 10826400 10836943 - 33.8832
36 
11.625
587 
16.437
605 
5.999
579 
6.570
4207 
16.63
6505 
ENSG00000219445 -2.15 RP11-3B12.3 chr7 124869633 124904345 - 5.30390
45 
10.288
663 
7.6753
13 
3.506
465 
4.159
0476 
2.902
5939 
ENSG00000233218 -2.25 SNX18P16 chr1 142688379 142688925 - 1.71771
82 
2.6481
433 
3.3620
58 
0.430
26203 
1.351
1974 
0.339
88443 
ENSG00000233461 -2.25 RP11-
295G20.2 
chr1 231658134 231664302 - 4.34471
65 
5.2603
03 
4.8380
613 
0.901
0945 
2.709
4634 
3.601
3868 
ENSG00000269495 -2.34 CTB-147C22.8 chr19 51453441 51466905 + 4.91188
86 
14.511
923 
12.695
248 
1.724
4989 
4.951
8948 
8.315
971 
ENSG00000257219 -2.41 RP11-54A9.1 chr12 76653619 76698911 + 3.86657
3 
2.7792
904 
2.3597
717 
0.302
85415 
0.949
48655 
1.806
0194 
ENSG00000230439 -2.41 RP11-488P3.1 chr1 94218480 94241000 - 16.7174
1 
2.3367
712 
4.8807
71 
2.343
1618 
2.641
2401 
2.188
129 
ENSG00000214110 -2.44 LDHAP4 chr9 14921335 14922332 - 6.77137
7 
6.3298
79 
5.6765
62 
2.142
0772 
2.575
1235 
3.043
416 
ENSG00000267279 -2.45 RP11-
879F14.2 
chr18 59252979 59274149 - 6.17703
3 
1.2901
783 
1.8376
158 
0.892
23325 
0.914
65175 
0.947
58815 
ENSG00000254740 -2.63 RP11-334E6.3 chr11 119243416 119252323 + 1.65935
97 
5.2611
43 
5.3788
548 
1.041
0688 
1.639
0346 
1.514
5406 
ENSG00000268621 -2.68 AC006262.5 chr19 46692423 46706340 - 2.93583
7 
5.8567
724 
3.7140
47 
1.001
9716 
2.637
1474 
1.250
5352 
ENSG00000271573 -2.69 RP11-
96C23.12 
chr10 88786941 88787234 + 1.96670
2 
9.9967
87 
7.0107
24 
0.436
6481 
2.154
825 
3.302
377 
ENSG00000257042 -2.69 RP11-
993B23.3 
chr12 28111450 28122746 + 25.1891
9 
26.207
75 
21.461
538 
4.820
6534 
9.942
112 
15.11
63 
ENSG00000255198 -2.71 SNHG9 chr16 2014960 2015510 + 5.08295
3 
5.4102
4 
2.8378
108 
1.320
2466 
1.149
7614 
2.586
8635 
ENSG00000261780 -2.74 CTD-
2354A18.1 
chr18 70992176 71017113 + 7.45266
5 
13.354
17 
8.3805
11 
2.986
0015 
4.862
3896 
2.805
7775 
ENSG00000258177 -2.75 RP11-394J1.2 chr12 96616575 96617751 - 11.3985
49 
7.2211
123 
5.6029
59 
1.443
8808 
3.685
8037 
4.163
6434 
ENSG00000255729 -2.78 AC005618.1 chr5 140699661 140700339 - 3.83701
63 
7.4735
03 
7.0763
206 
0.756
8286 
4.717
6375 
1.997
0802 
ENSG00000238266 -2.79 LINC00707 chr10 6821560 6884868 + 3.58438
56 
4.5337
21 
3.8257
384 
1.909
5888 
1.506
412 
0.787
2698 
ENSG00000239492 -2.98 FAM25HP chr10 47740330 47747200 + 15.1145
64 
31.412
348 
26.541
6 
5.972
542 
9.727
91 
8.178
021 
ENSG00000253746 -3.17 RP11-
527N22.2 
chr8 37262957 37264242 - 3.75136
5 
4.0315
757 
2.6437
647 
0.703
32074 
0.949
91237 
1.250
8819 
ENSG00000256288 -3.22 RP11-
277P12.10 
chr12 10485460 10490891 - 6.18079
3 
7.4155
67 
4.6269
43 
0.939
5672 
3.611
7387 
1.750
629 
ENSG00000242147 -4.40 RP13- chr10 5636954 5638081 - 18.6134 1.4156 3.2376 0.521 0.030 0.474
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463N16.6 9 137 003 8478 29739
3 
20192 
ENSG00000229647 -4.79 AC007879.7 chr2 208104374 208110611 + 31.3377
27 
7.7880
12 
10.499
597 
3.835
9287 
3.087
454 
1.968
523 
 
 
 
 
 
 
 
Table S2: Comparison of FAM83H-AS1 RPKM (Reads Per Kilobase Million) with other previously 
published functional LncRNAs 
 
LncRNA ENSEMBL ID Avg. RPKM GFP Avg. RPKM 16E6 Known function 
FAM83H-AS1 ENSG00000203499 5.876310667 9.9992845  
XIST ENSG00000229807 8.137879 12.21193233 miRNA sponge in cervical cancer (Zhu et al 2018) 
HOTAIR ENSG00000228630 1.817852513 1.5785181 miRNA sponge in cervical cancer (Liu et al 2018) 
NEAT1 ENSG00000245532 34.23374033 27.70111733 miRNA sponge in cervical cancer (Han et al 2018) 
TINCR ENSG00000223573 16.26229083 16.07113433 miRNA sponge in gastric cancer (Chen et al 2017) and breast cancer (Liu et al 2018) 
H19 ENSG00000130600 3.3026914 15.14256633 miRNA sponge in cervical cancer (Ou et al 2018) 
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Table S3: Primers used in this study for qRT-PCR. 
 
Primers Sequence (5'-3') 
FAM83H-AS1 FWD TCCCAATAAACAGGGCAGAC 
FAM83H-AS1 REV CAAGATCACCACACCCCTCT 
Gapdh FWD CCACTCCTCCACCTTTGAC 
Gapdh REV ACCCTGTTGCTGTAGCCA 
UBC FWD GATTTGGGTCGCAGTTCTTG 
UBC REV CCTTATCTTGGATCTTTGCCTTG 
Beta-Actin FWD AGCACAGAGCCTCGCCTTT 
Beta-Actin REV CCACGATGGAGGGGAAGAC 
U6 FWD GTGCTCGCTTCGGCAGCACATAT 
U6 REV AAAAATATGGAACGCTTCACGAA 
C. Elegans ama-1 FWD GGAGCTCGAGTGGATCTTCG 
C. Elegans ama-1 REV GCGCAGAGAGTATCCTGGAC 
HPV-16E6 FWD AATGTTTCAGGACCCACAGG 
HPV-16E6 REV ACTGTTGCTTGCAGTACACACA 
HPV-16E7 FWD ACAAGCAGAACCGGACAGAG 
HPV-16E7 REV GCCCATTAACAGGTCTTCCA 
p53 FWD TTTGGGTCTTTGAACCCTTG 
p53 REV CCACAACAAAACACCAGTGC 
p300 FWD AGCGGCCTAAACTCTCATCTC 
p300 REV CACCATTGGTTAGTCCCAATTC 
FAM83H FWD CGACAAGTGCCGTGTCAACC 
FAM83H REV ACTTCCCAGTGCGGCAGTAG 
H19 FWD AGTGGACTTGGTGACGCTGTAT 
H19 REV CTCCTGAGAGCTCATTCACTCC 
MIR205HG FWD TCATTAAAGAGAGAAATCAACTATTCA 
MIR205HG REV TAAAGCACCCAGTTCAGCAG 
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HOXC-AS5 FWD CTCCTTGGAGCAGTACACCTG 
HOXC-AS5 REV GTCCATTTGCTCTCCACTTGA 
GAS5 FWD CTTCTGGGCTCAAGTGATCCT 
GAS5 REV TTGTGCCATGAGACTCCATCAG 
LINC00963 FWD AACTGCCTTTGGAAGCAAGTAG 
LINC00963 REV ACTGCTCTAGTCCAGGAGTTCG 
SNHG15 FWD GCTGAGGTGACGGTCTCAAA 
SNHG15 REV GCCTCCCAGTTTCATGGACA 
MAFG-AS1 FWD AGGACTCGGGAGGAAGATAAAC 
MAFG-AS1 REV AACACCTTCAGCTCTCTGCTG 
RP6-65G23.3 FWD GAGATAGGAGGCCCATAATGTTTC 
RP6-65G23.3 REV CTGCAACCAGGTGGAAGTCA 
GS1-600G8.5 FWD ACTGTCCGGTTCACTGTGGG 
GS1-600G8.5 REV CGGTGCCACTGGGTCATTTT 
RP3-510D11.2 FWD CCAGACCGACGGGACAGCG 
RP3-510D11.2 REV GCTTCCCTGTCCTCCTCCTA 
RP11-479G22.8 FWD TGGGAAACTAAAACCATTTAAGC 
RP11-479G22.8 REV GCTCAGAACATGGTTTTCTCTG 
LINC01057 FWD GTGAATTCCTTGGAAGATGAGG 
LINC01057 REV TCATTCACTCAACCACTGAACC 
SFTA1P FWD CAGCATTCCAGGTGGGCTTT 
SFTA1P REV CCTTGTTTGGCTTACTCGTGC 
RP13-463N16.6 FWD TTGGAAATCACTCCTTCCACTT 
RP13-463N16.6 REV CAGAGACAATTCAACTCCCACA 
AC007879.7 FWD ACAGGGAGCCAGGACACC 
AC007879.7 REV GGAACCAGCACCAGGAACC 
 
  
 208 
 
XIII. Supplementary Methods 
 
A. Cell Culture 
 
 Primary human foreskin keratinocytes (HEKa) were cultured as described by supplier 
(EpiLife® Medium supplemented with Human Keratinocyte Growth Supplement (HKGS)). 
Primary human cervical keratinocytes (HCK) and J2-3T3 mouse fibroblast feeders were cultured 
as described by Alison McBride's laboratory (NIH, Bethesda, MD)(55). HCK were maintained in 
F-media [3:1 F12:DMEM with 5% Fetal Bovine Serum (FBS), 0.4ug/mL Hydrocortisone, 5ug/mL 
Insulin, 8.4ng/mL Cholera Toxin, 10ng/mL Epidermal Growth Factor, 24ug/mL Adenine, 
10U/mL Penicillin, 10ug/mL Streptomycin, 2mM L-Glutamine, Amphotericin B] containing 
10uM Y-27632 ROCK Inhibitor (Tocris). HCK cells were co-cultured with J2-3T3 feeder cells 
rendered mitotically inactive in 8ug/mL Mitomycin C for 3 hours; these growth-arrested feeder 
cells were replenished every 3-4 days. J2-3T3 stock cells were cultured in Feeder media 
[Dulbecco's Modified Eagles Medium (DMEM), high glucose, 10% Newborn Calf Serum, 2mM 
L-Glutamine, 10U/mL Penicillin, 10ug/mL Streptomycin, Amphotericin B]. J2-3T3 feeder cells 
are sensitive to trypsin; HCK, J2-3T3 stock, and growth-arrested J2-3T3 cells were centrifuged to 
remove the trypsin when passaged. HPV-16 positive CaSki cells were cultured in Roswell Park 
Memorial Institute (RPMI)-1640 medium containing 10% FBS, Streptomycin-Penicillin, HEPES 
Buffer, Amphotericin B. HPV-16 positive W12/20863 and W12/201402 and HPV-31b positive 
cervical (CIN-612) were co-cultured in E-media (1:1 DMEM:Ham's Nutrient Mix F12 medium 
supplemented with 5% FBS, 10mM HEPES Buffer, Penicillin-Streptomycin, Amphotericin B, 
0.02µM Triiodothyronine, 0.4µg/mL Hydrocortisone, 0.1µg/mL Cholera Toxin, 5µg/mL 
Transferrin, 180µM Adenine, 5µg/mL Insulin ) with murine 3T3 fibroblast cells (3T3M) that were 
rendered mitotically inactive with 4ug/mL Mitomycin C for at least 2 hours. HPV-negative 
cervical C33A cells, HPV-18 positive cervical (HeLa), HPV-16 positive HNSCC cell lines 
UMSCC-47 and -104, HPV negative HNSCC cell line UMSCC-1, HEK293T, and 3T3M cells 
were all cultured in DMEM supplemented with 10% FBS, Penicillin-Streptomycin, HEPES 
Buffer, and Amphotericin B. To passage stock cells, 0.25% trypsin was utilized. Growth-arrested 
J2-3T3 and 3T3M fibroblasts were removed with Versene solution and gently pipetting, prior to 
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pelleting and when otherwise desired. Cells were cultured at 37°C in a humidified 5% CO2 cell 
culture incubator. 
 
B. Generation of stable cell lines  
 
 Plasmids MSCV-N-GFP (Plasmid #37855), MSCV-N-16E6 (Plasmid #37875), and 
MSCV-N-16E7 (Plasmid #37881) were purchased from Addgene. For retroviral production, these 
plasmids were co-transfected with packaging (pCL-ECO) and envelope (pVSV-GF) plasmids into 
HEK293T cells using calcium phosphate co-precipitation. 12-16 hours later, HEK293T media was 
replaced with fresh target cell media. After 48-hour incubation, retrovirus-containing target cell 
media was harvested, filtered (0.45µm), and mixed with polybrene (4µg/mL final concentration) 
to increase infection efficiency. 24 hours before infection, co-cultured J2-3T3 fibroblasts were 
removed with Versene solution and gentle pipetting from HCK cells. HEKa and HCK cells were 
infected with recombinant retroviruses for 8 hours, virus was removed and replaced with fresh 
target cell media. Growth arrested J2-3T3 were added to infected HCK and replenished every 3 
days. Cells were allowed to recover for 24 hours prior to 72-hour puromycin selection (HEKa-
2.5µg/mL; HCK-3µg/mL).  Cells were allowed to recover and expression of exogenous HPV-16 
E6 and E7, as desired, was confirmed by RT-PCR (Fig. S1, Fig. S3). 
 
C. Generation of HPV-16 positive cervical JAMM-16 cell line 
 
 According to Buck et al. protocol described previously (56), the HPV-16 insert was cut out 
of pBR322 HPV-16 plasmid by performing a restriction digestion of two separate 25ug plasmid 
reactions in 225uL each with the restriction enzyme BamHI (NEB) according to manufacturer's 
recommended conditions (37°C for 2 hours). Digested samples were then PCR purified by 
QIAquick® PCR Purification Kit (Qiagen) resuspended in 200uL Buffer TE. Purified samples 
were then ligated under dilute conditions (9mL total volume) by adding 1X Ligase Buffer and 6uL 
of high concentration (2m U/mL) T4 DNA Ligase (NEB) and incubated at 16°C overnight. <25ug 
in 9mL ligation reactions were conducted to avoid concatemer formation. The ligated samples 
were then treated with 4.5mL of 7.5M Ammonium acetate and mixed. 35mL of 95% ethanol was 
added to each, tubes were mixed, and incubated at 4°C overnight. The next day, the samples were 
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brought back to room temperature and centrifuged at ~5,000 x g at room temperature for 1 hour. 
Pellets were washed with 70% ethanol, spun briefly, and washed again with 70% ethanol. The 
pellets were spun one last time to remove any residual ethanol, then air dried for several minutes. 
Pellets were resuspended in 100uL Buffer TE each, pellets were combined, and Nanodrop was 
used to calculate concentration retrieved. The entire product was run in 1% agarose gel for 3 hours. 
Desired band [expect to see supercoiled and relaxed circular bacterial backbone (~1.8 and ~3.2 
kb) and supercoiled and relaxed circular (nicked) HPV genome (~6.2 and >16 kb)] was cut out 
and gel extracted with QIAquick® Gel Extraction Kit (Qiagen). Before transfection of the HPV-
16 genomes, growth-arrested J2-3T3 fibroblasts were removed by Versene solution and pipetting 
from co-cultured primary normal cervical keratinocytes (HCK). HCK were plated in a 6-well plate 
on day prior to transfecting according to manufacturer's protocol for Lipofectamine LTX 
(Invitrogen). On day of transfection, HCK were at about 70% confluency. Media was replenished 
on each well. For each well, 2.8ug of re-ligated HPV-16 insert was diluted in 150uL Opti-MEM I 
Reduced Serum Media with 2.5uL PLUS Reagent, 15uL Lipofectamine LTX was diluted in Opti-
MEM I Reduced Serum Media. Diluted DNA and diluted Lipofectamine LTX/Plus complex were 
combined and incubated for 5 minutes at room temperature prior to adding to well. The transfected 
cells were passaged at least 10-15 times so HPV-16 immortalized cells could overgrowth the 
untransfected HCK cells prior to experimentation.  
 
D. RNA Extraction 
 
 Total RNA of cultured cell lines and human tissues was purified with TRIzol reagent 
(Invitrogen) and treated with Turbo DNA-free DNase (20 minutes at 37°C, Ambion) according to 
manufacturers' protocols. RNA concentration was determined with a Nanodrop 2000 
Spectrophotometer (Thermo Scientific).  
 
E. cDNA synthesis, qualitative or quantitative RT-PCR  
 
 RNA was reverse transcribed to complementary DNA (cDNA) under standard iScript 
cDNA synthesis kit (Bio-Rad) instructions in T100TM Thermal Cycler (Bio-Rad). Exogenous spike 
of C. Elegans (70ng) was added for normalization of results if GAPDH mRNA levels were altered 
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during processing (cellular fractionation). RT-PCR or qRT-PCR using SsoAdvancedTM Universal 
SYBR® Green enzyme was performed according to manufacturer's protocol (Bio-Rad) in CFX 
ConnectTM Real-Time System (Bio-Rad). The oligonucleotide primer sequences can be found in 
Supplementary Table S3. GAPDH was primarily used as housekeeping gene, however Ubiquitin 
C (UBC) or Glucuronidase Beta (GUSB) were used if GAPDH mRNA levels were altered with 
significant apoptosis (siRNA FAM83H-AS1 vs. siRNA-CTRL) and ama-1 was used for cellular 
fractionation studies.  To validate cell fractionation efficiency, U6 snRNA was used as nuclear 
control and mature mRNA beta-actin as cytoplasmic control. Qualitative RT-PCR product was 
resolved by agarose gel electrophoresis to visualize or quantitative RT-PCR (qRT-PCR) relative 
expression was calculated using the double delta CT method (relative expression = 2-∆CT; where 
∆CT=CT (Target RNA) - CT (mRNA endogenous GAPDH/UBC control or C. Elegans mRNA 
Ama-1 was exogenous spike control). Fold changes were calculated relative to control siRNA or 
the mean value of normal samples. 
 
F. Western Blot analysis  
 
 Cell lysates were boiled in sample buffer, separated by SDS-PAGE, and transferred onto 
Immobilon-Fl polyvinylidene difluoride membranes. After blocking for 1 hour with 5% milk-
TBST buffer (5% non-fat dry milk, 25mM Tris-HCl pH 8.0, 125mM NaCl, 0.5% Tween-20), the 
membranes were incubated with primary antibodies against human p53 (Cell Signaling, #9282) or 
Actin (C-11) (Santa Cruz, sc-1615) overnight at 4°C. The membranes were then washed with 
TBST, incubated with appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies 
[anti-goat IgG (Santa Cruz, sc-2020); anti-mouse IgG (Thermo Scientific)] for 1 hour at room 
temperature, washed with TBST, and the proteins were detected on the membrane using Pierce 
SuperSignal West Pico or Femto Maximum Sensitivity Substrate (Thermo Scientific) 
chemiluminescence.  
 
G. Transient transfection 
 
 The following siRNAs were used to knock down FAM83H-AS1: Lincode Human 
FAM83H-AS1 siRNA - Set of 4 (Dharmacon, RU-188909-00-0002), Lincode Human FAM83H-
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AS1 siRNA SMARTpool (Dharmacon, R-188909-00-000), Lincode Non-targeting siRNA #1 
(Dharmacon, D-001320-01-05). Two different siRNA against HPV-16E6: 5'-
GAGGUAUAUGACUUUGCUUTT-3' (Dharmacon) and 5'-
UCCAUAUGCUGUAUGUGAUTT-3' (siRNA 209, Dharmacon), two different siRNA against 
p53 (NEB, #2011S; Thermo Scientific Dharmacon®, J-003329-16), two different 
ONTARGETplus Human siRNA against p300 (Dharmacon, J-003486-11-0002; Dharmacon, J-
003486-12-0002), and CTLsiRNA (Ambion, AM16104) were used. 
 
 HCK, CaSki, and W12/201402 cells were transiently transfected using standard 
Lipofectamine® RNAiMAX protocol (siRNA FAM83H-AS1 and siRNA HPV-16E6 
#1).W12/201402 and CaSki cells were transfected with reverse transfection protocol (siRNA 
HPV-16 E6 #2 to improve transfection efficiency. For standard transfection, cells were plated at 
appropriate confluency to be about 70% confluent for transfection 24 hours post-plating. Growth-
arrested J2-3T3 fibroblasts were co-cultured with HCK, and on day of transfection removed with 
Versene solution and gently pipetting . On day of CaSki, W12/201402, and HCK standard 
transfection, media was replenished on each well. For each well, Opti-MEM I Reduced Serum 
Media was used to dilute Lipofectamine RNAiMAX (9uL per well of 6-well), as well as siRNA 
(40pmol per well of 6-well). Diluted RNAiMAX was combined with diluted siRNA, incubated 5 
minutes at room temperature and added to each well. Cells were incubated 48 hours in media 
containing siRNA prior to harvesting, unless otherwise stated.   
 
H. Cellular fractionation  
 
 Growth arrested 3T3M cells were removed by Versene solution and pipetting the day prior 
to fractionation for the W12/201402. Cellular fractionation protocol was modified from previous 
publication (57). On ice, CaSki (~70% confluent) were washed two times with cold PBS, scraped, 
pelleted, and resuspended in RSB Buffer (10-1.25mM Tris, pH 7.4; 10-1.25mM NaCl; 3-0.38mM 
MgCl2), incubated on ice for 5 minutes, centrifuged (1500rpm for 4 minutes at 4°C). RSB Buffer 
was removed and swollen pellets were resuspended in RSB-G40 Buffer [2.5-0.63mM Tris, pH 
7.4; 2.5-0.63mM NaCl; 0.75-0.19mM MgCl2; 2.5-0.63% glycerol; 0.125-0.03% NP-40; 0.125-
0.03mM DTT; 100U/mL RNasin Plus RNase Inhibitor (Promega)] in ≥ 4 times volume of pellet. 
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Cells were disrupted with Dounce homogenizer; homogenate was centrifuged (4000 rpm, 4 
minutes) to pellet nuclear fraction. The cytoplasmic fraction (supernatant) was collected. The 
pelleted nuclear fraction was resuspended in RSB-G40 Buffer, 3.3% of sodium deoxycholate and 
6.6% of Tween20 were added to the volume of RSB-G40 (10% of final volume was sodium 
deoxycholate and 10% was Tween 20), samples were tapped to mix, incubated on ice for 5 
minutes, and pelleted by centrifugation (7000rpm, 3 minutes). The supernatant was collected and 
combined with first cytoplasmic fraction, and nuclear pellet was washed two times with RSB-G40 
Buffer, and then resuspended in RSB-G40 Buffer. Fractionated cells were Turbo DNase I-treated, 
according to manufacturer's instructions (NEB), prior to RNA extraction to remove bound DNA 
and improve recovery of RNA. Total cell (second pellet), cytoplasmic, and nuclear RNA was 
extracted using TRIzol Reagent (Life Technologies) per manufacturer's instructions (Glycoblue 
was added during isopropanol precipitation step due to small amounts of RNA recovered from 
nuclear fraction) and treated with Turbo DNAfree DNase (Ambion) for 20 minutes at 37°C. qRT-
PCR analysis was performed using cDNA generated using equal concentration of RNA with 
exogenous C. elegans RNA (70ng) added for normalization.  
 
I. Cell proliferation assay 
 
 Cell proliferation was monitored using Cell Counting Kit - 8 (CCK-8) (Sigma-Aldrich). 24 
hours (CaSki) or 48 hours (201402) after transfection with FAM83H-AS1 siRNA, CaSki cells 
were detached with 0.05% trypsin and W12/201402 cells were detached with 0.25% trypsin. After 
cell detachment, trypsin was inactivated with trypsin neutralizer (CaSki) or E-media containing 
serum (201402), pelleted, resuspended in appropriate media containing serum, and plated at 
desired concentration (3E3 cells per well and of four separate 96-well plates; technical triplicates). 
In equal density per well, 3T3M fibroblasts treated with mitomycin C were added to the 
W12/201402 cells and fibroblast alone control wells were plated. At desired time (48, 72, or 96h 
post-plating), CCK-8 dye (100uL/well) was added to each well, incubated for 2 hours (CaSki) or 
3 hours (201402). Then, absorbance was read with a spectrophotometer (BioTek Synergy H1 
Hybrid Reader) (OD450) according to manufacturers' protocols. Absorbances of feeders alone were 
subtracted from W12/201402 co-cultured with feeders. Biological replicate was conducted. 
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J. Flow-cytometric analysis of cell cycle.  
 
 3T3M fibroblasts were stained with CellTraceTM Far Red Cell Proliferation Kit 
(Invitrogen) the day before plating transfected 201402 cells. 24 hours (CaSki) or 48 hours (201402) 
after transfection with FAM83H-AS1 siRNA, cells were detached with 0.05% trypsin (CaSki) or 
0.25% trypsin (201402). After cell detachment, trypsin was inactivated with trypsin neutralizer 
(CaSki) or media containing serum (201402), and cells were plated at desired concentration (4E6 
for CaSki and 2.3E6 for 201402) in 100mm dishes in media containing fetal bovine serum (FBS). 
Mitomycin C treated, far red stained 3T3M cells were added to the 201402 cells. Cells were 
allowed to attach (about 5 hours) then were washed 3 times with 1X D-PBS to remove residual 
FBS. Cells were then serum-starved for 24 hours. After incubation, cells were trypsinized with 
0.25% trypsin, suspended in serum-free media (to avoid stimulation by serum), washed with 1X 
PBS, pelleted, and resuspended in PBS (200µL). Harvested cells were then fixed by adding 70% 
cold ethanol (1.8mL) while vortexing the cells and stored at 4°C until processing. Cells in ethanol 
were pelleted, washed with PBS, centrifuged, and resuspended in room temperature 0.2% Tween 
20 in PBS (300-1,000µL, depending on pellet size). 100uL of each sample was placed in a U-
bottom 96-well plate (3 wells/technical triplicates) and incubated 15 minutes at 37°C. PBS (100uL) 
was added to each well, cells were pelleted, resuspended in 10uL of RNase A-PBS (180ug/mL 
stock), tapped gently to mix, and incubated at room temperature for 15 minutes. After incubation, 
20uL of PI-PBS (final concentration of 50µg/mL) was added to each well, pipetted to mix, and 
incubated for 15 minutes at room temperature. After incubation, the volume was brought up to 
300uL and analyzed in the dark by flow cytometry (Fortessa S10). Gates were placed around 
201402 population. Biological replicate was conducted.  
 
K. Transwell migration assay 
 
 24 hours (CaSki) or 48 hours (201402) after transfection with FAM83H-AS1 siRNA, cells 
were detached with 0.05% trypsin. After cell detachment, trypsin was inactivated with trypsin 
neutralizer, pelleted, resuspended in serum-free media, and cells were plated [1E5 (CaSki) or 
0.75E5 (201402), 200uL well, technical duplicates] in upper chambers of 24-well transwell (8mm 
pore size) with 800uL serum-free media in lower chamber. In equal density per well, 3T3M 
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fibroblasts treated with mitomycin C were added to the W12/201402 cells and fibroblast alone 
control wells were plated. Cells were then allowed to attach for ~3 hours prior to adding fetal 
bovine serum (final concentration of 20% for CaSki and 5% for W12/201402) to lower chamber. 
After 24 hours, media in upper chamber was replenished with appropriate fresh serum free media 
and lower chamber with appropriate fresh media containing with FBS chemoattractant. 48 hours 
after cells were plated, lower chamber/underside of transwell and upper chamber of transwell were 
washed with 25% D-PBS. D-PBS was removed and cells from the top of the upper chamber 
transwell membrane (non-migrated cells) were wiped away using a cotton swab. The lower 
chamber/underside of the transwell and upper chamber of transwell were washed again with 25% 
D-PBS and then the underside of the transwell (migrated cells) was fixed with 4% formaldehyde 
in 25% D-PBS in the lower chamber for 5 minutes at room temperature. The formaldehyde solution 
was removed and the lower chamber/underside of transwell and upper chamber of transwell were 
washed with 25% D-PBS. The cells on the underside of the transwell were then stained using 0.5% 
crystal violet in 20% ethanol in water. The stain was added to the lower chamber, submerging the 
transwell for 20 minutes at room temperature. The stain was removed and the lower 
chamber/underside of the transwell and upper chamber of transwell washed 3 times with 25% D-
PBS. The top of the upper chamber transwell membrane was then cleaned with a cotton swab. The 
transwells were allowed to dry overnight and then the underside of the transwell imaged with an 
Olympus MVX10 microscope. Migration was quantitated with ImageJ. Feeders alone were 
subtracted from W12/201402 co-cultured with feeders. Biological replicate was conducted.  
 
L. Flow-cytometric analysis of apoptosis 
 
 3T3M fibroblasts were stained with CellTraceTM Far Red Cell Proliferation Kit 
(Invitrogen) the day before plating transfected 201402 cells. 24 hours (CaSki) or 48 hours (201402) 
after transfection with FAM83H-AS1 siRNA, cells were detached with 0.05% trypsin (CaSki) or 
0.25% trypsin (201402). After cell detachment, trypsin was inactivated with trypsin neutralizer 
(CaSki) or media containing serum (201402), pelleted, resuspended in appropriate media 
containing serum, and cells were plated in 100mm dishes at desired concentration (1.75E6 for 
CaSki and 1.1E6 for 201402). At 24, 48, and 72h later post-plating, attached and floating cells 
were collected. On day of harvest, media containing dead cells was collected, PBS was added to 
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the plates, collected, and added to the media. Attached cells were trypsinized with 0.25% trypsin, 
cells were pelleted (2 to 5E6) at 4°C, resuspended in PBS, and 100uL of each sample was aliquoted 
into 3 wells of a 96 well plate (technical triplicates). Cells were pelleted, PBS was removed, 
Annexin V Binding Buffer (100uL; diluted with autoclaved milliQ water) was added to each tube, 
Annexin V-FITC (5uL) was added to each tube, and incubated in the dark at room temperature for 
10 minutes. After incubation, cold Binding buffer (200uL) was added to each tube, cells were 
pelleted, washed with cold Binding buffer two times, incubated on ice for 5 minutes in propidium 
iodine in Binding buffer (2ug/mL final concentration, 300uL), and analyzed by flow cytometry 
(Fortessa S10) immediately. Gates were placed around 201402 population. Biological replicate 
was conducted.  
 
M. Human cervical tissue specimen  
 
 10 human specimens were obtained from patients under the tissue collection protocol 
[Prognostic Marker (IRB0406147)] at the University of Pittsburgh. Patient samples were 
categorized as cervical intraepithelial neoplasia stage 3 (CIN3), invasive cervical cancer (CaCx), 
or non-cancerous.  
 
N. TCGA Analysis 
  
 The Cancer Genome Atlas (TCGA) (https://cancergenome.nih.gov/) contains patient 
survival and RNA sequencing data from 196 cervical squamous cell carcinoma and endocervical 
adenocarcinoma (CESC) human patient samples. TCGA-CESC reads per kilobase million 
(RPKM) data was extracted, and average RPKM for all patients combined was calculated. TCGA 
also contains RPKM data from 3 individual non-cancerous cervical samples that were averaged 
together to compare to CESC RPKM values. The Atlas of non-coding RNA in Cancer (TANRIC) 
(MD Anderson Cancer Center) (54) that utilizes TCGA-CESC dataset to characterize the 
expression profiles of long non-coding RNAs (lncRNAs) was used to extract FAM83H-AS1 
expression in each of the TCGA-CESC patient samples. Classification and Regression Trees 
(CART) analysis was used to statistically define high/low lncRNA expression groups. The cut-off 
z score value was 3 to discern between high and low expression groups. Survival curves were 
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estimated by the Kaplan-Meier method. The log-rank test was used to estimate statistical 
differences between survival curves. GraphPad software was used to make the survival plots.  
 
O. Statistics 
  
 Student's t-test was utilized to determine mean values differences between groups 
examined and significance was determined at p ≤ 0.05 (*) and p ≤ 0.01 (**). Scale bars represent 
Standard Deviations (SD).  
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PhD Candidate, West Virginia University School of Medicine 
 
Office: 1 Medical Center Dr.   (304) 581-1901 
 PO Box 9300    
Morgantown, WV 26505 
tabrownmiller@mix.wvu.edu 
 
    Home: 3092 Abbey Cove   (870) 866-3123 
     Benton, AR 72015 
     (permanent) 
Education 
West Virginia University School of Medicine, Morgantown, WV   08/2013 – 05/2020 
PhD in Biomedical Sciences – Cancer Cell Biology  
Current GPA: 3.73 
PhD conferral: 05/2020 
     
Henderson State University, Arkadelphia, AR    08/2009 – 05/2013 
Bachelor of Science in Biology  
Final GPA: 3.44 
 
Research Experience 
West Virginia University School of Medicine    08/2013 – 05/2020 
Principal Investigator: Ivan Martinez, PhD 
Project: The Importance of the Lnc-SPRY3 Family in Non-Small  
Cell Lung Cancer Therapeutic Response 
 
Henderson State University      Spring 2012 – Spring 2013 
Mentor: Martin Campbell, PhD 
Project: Nicotinic Acid Ester-Based Ionic Liquids 
 
Baylor College of Medicine       Summer 2012 
Summer Medical and Research Training (SMART) Program 
Mentor: Hoang Nguyen, PhD 
Project: Sox9 and Sox11 Inhibit Differentiation of Skin Epithelial Cells 
 
Relevant Skills 
Laboratory-based:  
RNA isolation and purification  Bacterial Cell Culture/plasmidpurification 
Mammalian cell culture   Xstrahl Xenex cell irradiation   
RT-PCR/qRT-PCR analysis    RNAi techniques     
Northern Blotting    CRISPR      
Western Blot analysis   Retro/Lentiviral transduction 
Immunoprecipitation   Guava easycyte flow cytometry 
Cloning     Cellular Fractionation 
       
Tayvia B. 
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Mouse Based:      Other:      
Cell line derived xenografts    Microsoft Office 
Xstrahl Xenex small animal irradiation  ImageJ and GraphPad Prism 
Tumor ultrasound imaging via Vevo 2100  Scientific writing/presentation 
Mentoring undergraduate/fellow 
graduate students 
 
Publications 
Barr, J.A., Hayes, K.E., Harold, A., Lovern, M., Brownmiller, T., Jagannathan, R., Lockman, P., 
Martinez, I. Long non-coding RNA FAM83H-AS1 is regulated by human papillomavirus 16 E6 
independently of p53 in cervical cancer cells. Scientific Reports, 9:3662 (2019) 
https://doi.org/10.1038/s41598-019-40094-8. 
 
Brownmiller, T., Juric, J.A., Ivey, A.D., Stevens, A.M., Hayes, K.E., Sprowls, S.A., Ammer, A.G., 
Walker, M., Wu, X., Lim, Z., Zhu, L., Bey, E.A., Hu, G., Wen, S., Ma, P.C., Martinez, I. Evidence of 
Y Chromosome LncRNAs involved in Radiation Response of Male Non-Small Cell Lung 
Cancer Cells. (undergoing revision for Cancer Research) 
 
Hayes, K.E., Barr, J.A., Harold, A., Brownmiller, T., Wilusz, J.E., Martinez, I. Discovery of Novel 
Non-Coding Circular RNAs Generated by High-Risk Human Papillomaviruses. (Manuscript in 
preparation) 
  
Honors/Awards 
Awards: 
 Graduate: 
o First Place – Poster: Basic Science, 2019 WVU Cancer Institute Annual Meeting 
o WVU Biomedical Sciences PhD Programs – Cancer Cell Biology Graduate Student 
of the Year Award 2019 
o 2019 WVU Three Minute Thesis Competition Finalist 
o WVU Office of Research and Graduate Education, Robert C. Byrd Health Sciences 
Center Doctoral Student Travel Award – Spring 2019 
o Second Place – Poster: Clinical Science, 2018 WVU Cancer Institute Annual 
Meeting  
o WVU Office of Research and Graduate Education, Robert C. Byrd Health Sciences 
Center Doctoral Student Travel Award – Spring 2018 
o Outstanding Graduate Student Award – 2016 Team Award, Mad Scientists ACS 
Relay for Life Team 
o First Place – Poster: Basic Science 2013-Group 2, 2015 Van Liere Memorial 
Convocation & HSC Research Day 
 Undergraduate: 
o Arkansas Academy of Science Undergraduate Research Award  
o Arkansas Space Grant Consortium Undergraduate Research Grant 
o Poster – American Chemical Society Excellence in Undergraduate Polymer 
Research 
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Scholarships: 
 Henderson State University Presidential Scholarship: Fall 2009 – Spring 2013 
 Arkansas Academic Challenge Scholarship: Fall 2010 – Spring 2013 
 Parkers Chapel Scholarship: Fall 2009 
 Henderson State University Match Fall: 2009 
 Hartsell Pest Control Scholarship: Fall 2009 
 Academic Honor Roll: Fall 2009 – Spring 2013 
 
Memberships 
National: 
RNA Society         2019 - Present 
American Association of University Women (AAUW)   2018 - Present 
American Association for the Advancement of Science (AAAS)   2015 – Present 
American Association for Cancer Research (AACR)   2015 – Present 
AACR Women in Cancer Research      2015 – Present 
 
West Virginia University: 
Graduate Student Organization      Fall 2013 – Present 
 President: Summer 2015 – Summer 2016 
 Vice President: Fall 2014 – Summer 2015 
Cell Biology Training Program       Fall 2014 – Present 
First Year Student Mentorship Program      Fall 2014 – Present 
  
Henderson State University: 
Biology Club         Spring 2010 – Spring 2013 
 President: Fall 2012- Spring 2013 
Chemistry Club        Spring 2011 – Spring 2013 
Tri Beta Biological Honor Society     Spring 2011 – Spring 2013 
 President: Fall 2012 – Spring 2013 
Gamma Beta Phi Academic Honor Society    Spring 2011 – Spring 2013 
American Chemical Society      Fall 2012 – Spring 2013 
 
Professional Development 
Meetings/Conferences and Abstracts: 
October 2019 - WVU Cancer Institute Annual Scientific Meeting, Morgantown, WV. Poster 
presented: “A Family of Y Chromosome LncRNAs is Involved in the Radiation Response of 
Male Non-Small Cell Lung Cancer Cells” 
 
April 2019 – NIH Symposium “RNA Biology 2019” at NCI, Bethesda, MD. Poster presented: 
“The Importance of the Lnc-SPRY3 Family in Non-small Cell Lung Cancer Therapeutic 
Response.” 
 
March 2019 – Van Liere Research Day: West Virginia University’s yearly celebration of the 
biomedical research being conducted at its Health Sciences Center campus. Flash Talk and 
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Poster presented: “The Importance of the Lnc-SPRY3 Family in Non-small Cell Lung Cancer 
Therapeutic Response.” 
 
February 2019 – Keystone Symposia, Long Noncoding RNAs: From Molecular Mechanism 
to Functional Genetics, Whistler, British Columbia, Canada. Poster Presented: “The 
Importance of the Lnc-SPRY3 Family in Non-small Cell Lung Cancer Therapeutic Response.” 
 
October 2018 – WVU Cancer Institute Annual Scientific Meeting, Morgantown, WV. Poster 
presented: “The Importance of the Lnc-SPRY3 Family in Non-small Cell Lung Cancer 
Therapeutic Response.” 
 
April 2018 – American Association for Cancer Research Annual Meeting, Chicago, IL. Poster 
presented: “The Importance of a Family of Long Non–coding RNAs from the Y Chromosome 
in Radiotherapy and Chemotherapy Response of Male Non–small Cell Lung Cancer.” 
 
April 2017 – NIH Symposium “RNA Biology 2017” at NCI, Bethesda, MD. Poster presented: 
“The Importance of the Lnc-SPRY3 Family in Non-small Cell Lung Cancer Therapeutic 
Response.” 
 
March 2017 – Van Liere Research Day: West Virginia University’s yearly celebration of the 
biomedical research being conducted at its Health Sciences Center campus. Poster 
presented: “The Importance of the Lnc-SPRY3 Family in Non-small Cell Lung Cancer 
Therapeutic Response.” 
 
June 2016 – 6th Biennial National IDeA Symposium of Biomedical Research Excellence 
(NISBRE). Poster presented: “The Importance of the PRYP4 Long Non-coding RNA family in 
Non-small Cell Lung Cancer Radiation Response.” 
 
March 2016 – Van Liere Research Day: West Virginia University’s yearly celebration of the 
biomedical research being conducted at its Health Sciences Center campus. Poster 
presented: “The Importance of the PRYP4 Long Non-coding RNA family in Non-small Cell 
Lung Cancer Radiation Response.” 
 
December 2015 – AACR Special Conference on “Non-coding RNAs and Cancer: Mechanisms 
to Medicine,” Boston, MA. 
 
October 2015 – “RNA and the New Genetics” Symposium at University of Toronto, Toronto, 
ON. 
 
March 2015 - NIH Symposium “RNA Biology 2015” at NCI, Bethesda, MD. 
 
February 2015 - Van Liere Research Day: West Virginia University’s yearly celebration of 
the biomedical research being conducted at its Health Sciences Center campus. Poster 
presented entitled “The Importance of miRNAs in the Cancer Resistant Animal Model: The 
Naked Mole-rat” 
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August 2014 – “Regulatory and Non-coding RNAs” Meeting at Cold Spring Harbor 
Laboratory, Cold Spring Harbor, NY. 
 
Other: 
September 2019 – Workshop on Long-read Sequencing, The Jackson Laboratory for 
Genomic Medicine – JAX Genomic Medicine, Farmington, CT. 
 
Spring 2019 – WVU Three Minute Thesis Competition, West Virginia University, 
Morgantown, WV. 
 
Fall 2018 – Guest lecturer for first year graduate students Cellular Methods course: “In 
Vitro Methods of Genetic Manipulation” 
 
Fall 2017 – Spring 2018: West Virginia University, Student representative to the Cancer 
Cell Biology Graduate Program faculty meetings 
 
Fall 2015 – Spring 2016: West Virginia University PhD in Biomedical Sciences admissions 
committee member 
 
June 2014 – “Setting the PACE” Writing Workshop by Laura Brady, Nathalie Singh-
Corcoran, Andrea Bebell, and James Holsinger at West Virginia University Health Sciences 
Center, Morgantown, WV. 
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